Regulation and function of Skp2 in mediating p27 degradation during adipocyte hyperplasia by Auld, Corinth Andrews & NC DOCKS at The University of North Carolina at Greensboro
 
AULD, CORINTH ANDREWS, Ph.D. Regulation and Function of Skp2 in Mediating p27 
Degradation during Adipocyte Hyperplasia. (2006) 
Directed by Dr. Ron F. Morrison. 146pp. 
 
 
 Adipocyte hyperplasia is characterized by an increase in adipocyte cell number 
and contributes significantly to the development of obesity. A key question regarding 
adipocyte hyperplasia concerns the mechanism by which preadipocytes undergo the 
transition from quiescence to proliferation. Here we examined molecular processes 
regulating the cell cycle inhibitor, p27, during adipocyte hyperplasia. Previous literature 
has shown p27 regulation by transcriptional and post-transcriptional mechanisms in 
various cell types. In neoplastic cells, the F-box protein, Skp2, can target phosphorylated 
p27 protein for degradation via the 26S proteasome. Studies presented here indicated 
cell cycle-dependent decreases in p27 occurring during early stages of adipocyte 
differentiation due to accelerated protein turnover. Further analyses revealed Cdk2-
dependent phosphorylation and polyubiquitylation of p27 during S phase progression.  
Additionally, the 26S proteasome was found to be essential for the decrease in p27 and 
subsequent cell cycle progression. It was determined that Skp2 is transiently expressed 
during preadipocyte replication and is, at least, partly responsible for increased 
degradation of p27. These are novel data suggesting the presence and role of Skp2 
during adipocyte hyperplasia. 
 It was demonstrated that expression of Skp2 is unique to preadipocyte 
proliferation and cannot be reproduced in fully differentiated, terminally growth-arrested 
adipocytes. Findings revealed transient and dramatic increases in Skp2 mRNA, 
preceding protein expression, due to promoter activation and not increased mRNA 
stability. These processes were significantly mediated by growth factor receptor 
signaling pathways involving PI3K and MAPK. Furthermore, inhibition of mTOR, a 
 
downstream target of PI3K important for translational control, produced a significant 
reduction in Skp2 protein but not mRNA. Collectively, these data suggest Skp2 
expression during adipocyte hyperplasia is regulated at multiple levels and dependent 
on kinase-driven signaling pathways. 
The sesquiterpene lactone, helenalin, is a naturally occurring compound known 
to possess anti-proliferative and anti-inflammatory properties. This may be of benefit to 
the treatment of obesity as cells within adipose tissue have the capacity to proliferate 
and secrete pro-inflammatory cytokines. Studies presented here showed that helenalin 
prevents the increase in Skp2 mRNA by completely blocking Skp2 promoter activity. 
Further studies revealed helenalin’s ability to prevent Akt phosphorylation, a key 
signaling molecule downstream of PI3K activation. Taken together, these findings 
provide valuable insight into molecular mechanisms regulating adipocyte hyperplasia.
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SIGNIFICANCE OF RESEARCH 
 
In 2002, the World Health Organization added obesity to its list of top ten 
preventable global health problems.  In America alone, more than 60 million people 
(~1/4 of the population) are obese, a number that has doubled over the past ten years.  
The United States has one of the highest percentages of overweight and obese 
individuals when compared to other nations.  In addition, almost a quarter of children in 
the U.S. are overweight or obese.  These numbers and the fact that prevalence rates are 
continuing to rise are frightening due to the multitude of adverse health conditions 
associated with obesity (e.g., heart disease, stroke, diabetes, gall bladder disease, 
endometrial, breast, prostate and colon cancers).  Hyperplastic obesity has been well-
documented in humans, rats, mice, and guinea pigs and is largely triggered by dietary 
habits.  Despite these early findings, how adipocyte proliferation occurs and is regulated 
is still unknown.  The data presented here are significant because they may one day 
lead to novel strategies for prevention and treatment of obesity, which will improve life 
expectancy, quality-of-life, and health care costs (which reached over $90 billion in 
2002).  The results of these studies also have a significant impact on cancer research.  
A main target of our mechanistic approach, the F-box protein Skp2, is used as a marker 
of prognosis for certain types of cancers (i.e., elevated levels of Skp2 indicate poor 
prognosis).  The elucidation of factors regulating Skp2 will enable the development of 
unique obesity and cancer therapies. 
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REVIEW OF LITERATURE 
Hyperplastic Obesity.  Studies on obesity and body composition have been 
conducted for over half a century.  In 1962, Zingg et al. and Enesco et al. described 
increases in fat cell number as a contributor to increases in adipose tissue (Steinberg et 
al., 1962;Enesco and Labond, 1962).  Hyperplastic obesity has been seen in rats, 
hamsters, and guinea pigs and has also been well-documented in humans (Pettersson 
et al., 1985;Hirsch and Batchelor, 1976). The accumulation of excess fat is largely 
controlled by dietary intake (i.e., caloric consumption, macronutrient profile of diet, etc.) 
and these earlier observations prompted other groups to evaluate the effect of nutritional 
status on increases in fat cell number.  In studies of both young and adult rats, diets high 
in fat and sufficient in carbohydrates caused adipocyte hyperplasia (Mandenoff et al., 
1982).  Interestingly, rats made obese via a cafeteria-fed diet for 3 weeks are able to 
lose weight gained with appropriate changes in diet (Rothwell and Stock, 1997), 
however a cafeteria-fed diet for 13 weeks results in an irreversible weight gain (Rolls et 
al., 1980).  This difference in the ability to “recover” from excessive weight gain was 
explained by a study done in 1982 by Mandenoff et al (Mandenoff et al., 1982).  They 
found that up until 8 weeks of a cafeteria-fed diet, increases in weight gain were due to 
adipocyte hypertrophy and that between 8 and 20 weeks, changes were due to 
adipocyte hyperplasia.  These studies and others demonstrate hypertrophy preceding 
hyperplasia in the development of diet-induced obesity.  One of the most devastating 
aspects of hyperplastic obesity is that unlike cell size, increases in fat cell number are 
irreversible.  Once an individual makes new fat cells, the size of these cells may change 
with weight gain or loss but the increased capacity for fat storage due to greater 
numbers is not reversible (Faust et al., 1978;Yang et al., 1990).  Two studies done in 
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1978 showed that morbid cases of obesity involve at least two times the normal number 
of fat cells and that in rats, this can be seen after only 5 months of a high-fat diet (Faust 
et al., 1978;Bosello et al., 1978). Thus, hyperplastic adipose tissue has been associated 
with the poorest prognosis (Dizdar and Alyamac, 2004). Several studies have suggested 
a cell size prerequisite in order for proliferation to occur (Marques et al., 1998), however, 
it has been shown that in human obesity, adipocyte hyperplasia can be accompanied by 
normal fat cell size (Salans et al., 1973).  This finding was coaborated by a study that 
showed a high-fat diet can induce a persistent or permanent obesity that is solely a 
result of adipocyte hyperplasia (Faust et al., 1978).  Developmental stage is not a factor 
in the development of hyperplastic obesity as it has been seen in young (Hager et al., 
1978;Lubetzki et al., 1980) and adult (Knittle and Hirsch, 1968;Hirsch and Batchelor, 
1976) animals and humans.  Interestingly, several groups have found that hibernating 
animals (i.e., dormice, woodchucks, and ground squirrels) appear to be protected from 
increases in adipocyte number (Mrosovsky et al., 1987;Young et al., 1982;Faust and 
Mrosovsky, 1987). Their weight gain is attributed to increases in adipocyte size and is 
hypothesized to be a result of some proliferation inhibitory factor or an extraordinarily 
large capacity of individual fat cells to store lipid. While hyperplastic obesity has been 
well-documented, there are very few studies examining mechanisms behind this 
increase in cell number and this tremendous gap in the knowledge base prevents 
prophylactic and treatment strategies targeting this type of obesity.  
Adipocyte Differentiation.  Cellular and molecular studies of adipogenesis have 
long been conducted using the “gold standard” model, 3T3-L1 cells.  The murine 3T3-L1 
lineage was originally isolated and identified by Howard Green (Todaro and Green, 
1963;Green and Meuth, 1974;Green and Kehinde, 1976).  These cells are fibroblast-like 
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and follow adipocyte conversion given appropriate hormonal stimulation.  Before 
stimulation, preadipocytes are grown for two days after reaching confluency to ensure 
density-induced growth arrest (i.e., day 0).  At this time, normal proliferation media (i.e., 
DMEM containing 10% calf serum) is replaced with adipogenic media consisting of 
DMEM, 10% fetal bovine serum, and MDI.  The MDI cocktail includes 3-isobutyl-1-
methylxanthine (MIX), the synthetic glucocorticoid dexamethasone, and insulin.  Each 
component has very specific and important roles in the differentiation process, examples 
of which are to follow.  MIX increases intracellular levels of cyclic AMP and leads to 
down-regulation of the transcription factor Sp1.  When expressed in preadipocytes, Sp1 
binds to the promoter of C/EBPα and blocks the C/EBP-response element, thereby 
preventing activation by C/EBPβ and C/EBPδ (Tang et al., 1999).  The glucocorticoid 
dexamethasone is able to cause greater than 50-fold increases in C/EBPδ in 3T3-L1 
adipocytes (MacDougald et al., 1994), providing a critical role during early stages of 
adipogenesis.  The importance of C/EBP proteins is discussed in more detail below.   
Insulin is used at pathophysiological concentrations known to activate the IGF1-
receptor (IGF1R).  The IGF1R to insulin receptor ratio in preadipocytes is 2:1 (Smith et 
al., 1988), thus much of the early signaling is downstream of IGF1R activation.  
Interestingly, while IGF1R expression remains unchanged throughout differentiation, the 
insulin receptor is increased 25-fold (Smith et al., 1988).  The IGF1R is essential for 
adipogenesis and plays a major role in initiating clonal expansion.  Clonal expansion is a 
very unique and brief, synchronized period of cell proliferation that occurs immediately 
after preadipocytes have been stimulated to differentiate and is required for adipocyte 
differentiation (Tang et al., 2003).  Once cells go through one to two rounds of division, 
they complete the differentiation process and become terminally growth arrested.  While 
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knowledge of distinct mechanisms regulating cell cycle control at this time is limited, the 
expression of particular cyclin-dependent kinase inhibitors has been examined.  
Morrison et al. identified changes in expression of p27Kip1, p21Cip1, and p18INK4c following 
stimulation with MDI (Morrison and Farmer, 1999).  At day 0, p27 protein is highly 
expressed and then is dramatically decreased by 18 hours following the addition of MDI.  
In contrast, p21 protein is very low at day 0 and is increased in a biphasic manner after 
stimulation.  The expression of cyclin-dependent kinase inhibitor p18 cannot be detected 
until day 3, at which time protein levels increase significantly.  Levels of both p27 and 
p18 remain high throughout the differentiation process, however, p21 returns to day 0 
levels by day 6.  Determining the mechanisms by which these cell cycle proteins are 
regulated would provide valuable information about adipocyte proliferation and 
hyperplastic obesity.   
E2F and retinoblastoma proteins play essential roles in cell cycle progression 
and are also highly regulated during adipocyte differentiation.  The retinoblastoma (Rb) 
family includes pRb, p130, and p107, all of which bind E2F proteins.  The E2F 
transcription factors bind to DNA as heterodimers with DP proteins (i.e., DP1 and 2) and 
regulate the expression of genes required for DNA replication and mitosis.  E2F4 has 
been shown to be the predominant family member present during adipocyte 
differentiation, with protein levels detectable in day 0 quiescent cells through at least 5 
days (Fajas et al., 2002).  The role E2F4 plays during adipocyte differentiation may be 
largely regulated by the retinoblastoma protein bound to it.  In growth-arrested T-cells, 
E2F4 is bound to p130.  However, when these cells reenter the cell cycle there is a 
significant change as E2F4 binds to pRb and p107 (Moberg et al., 1996).  The pattern 
seen in T-cells parallels what has been seen during adipocyte differentiation, where 
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induction of adipogenesis is accompanied by a very distinct switch in expression of p130 
and p107.  While p130 mRNA is present throughout adipocyte differentiation, protein 
levels are high on day 0, undetectable during clonal expansion, and then once again 
increased by day 3.  The kinetics of p107 are exactly opposite as protein levels are 
transiently upregulated at day 1 and extremely low before and after this time (Richon et 
al., 1997).  The very timely switch in expression of p130 and p107 surrounding this 
period of synchronized growth suggests opposing roles of these proteins during 
adipocyte differentiation.  
The entire process of adipogenic conversion involves a very concerted up- and 
down-regulation of genes.  The two major contributors to this process are the C/EBP 
family of transcription factors and the nuclear hormone receptor PPARγ. C/EBPβ and 
C/EBPδ are transiently expressed immediately following stimulation and play a critical 
role in initiating the course of differentiation.  The expression of both C/EBPβ and 
C/EBPδ proteins is first seen within 4 hours of stimulation, however, DNA-binding activity 
cannot be detected until approximately 12-14 hours after stimulation (Tang and Lane, 
1999).  When DNA-binding of C/EBPβ was blocked during clonal expansion, there was a 
marked reduction in cell cycle markers (Zhang et al., 2004).  In addition to the 
requirement for early cell cycle progression, C/EBPβ also binds to the promoters of both 
C/EBPα and PPARγ, inducing expression of these two master regulators of adipocyte 
differentiation (Christy et al., 1991;Tang et al., 2004).  The role of C/EBPδ during 
adipogenesis is thought to be through synergy with C/EBPβ leading to initial PPARγ 
promoter activity and expression (Wu et al., 1996).  This begins a positive feedback 
loop, as C/EBPα is able to bind to its own promoter as well as that of PPARγ (Tang et 
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al., 2004), and PPARγ is able to activate transcription of C/EBPα (Zuo et al., 2006).  
C/EBPα and PPARγ mRNA and protein levels are detectable by day 2 of adipocyte 
differentiation (Morrison and Farmer, 1999) and are known to be anti-mitotic suggesting 
a link between terminal growth arrest and adipocyte differentiation.  Expression of 
C/EBPα and PPARγ is essential for adipogenesis (Rosen et al., 2002) and activation of 
critical genes such as GLUT-4 (Kaestner et al., 1990;Wu et al., 1998) and the insulin 
receptor (McKeon and Pham, 1991).  
While adipose tissue was once regarded as a static, lipid storage tissue, it is now 
recognized as having very active endocrine function.  Adipose tissue is comprised of 
preadipocytes, mature adipocytes, and macrophages.  These cells work in concert to 
produce and secrete “adipokines” such as TNFα (Hotamisligil et al., 1993), IL-6 
(Mohamed-Ali et al., 1998), and C-Reactive Protein (Ouchi et al., 2003).  Release of 
these factors provides a link between obesity and inflammation associated with the 
metabolic syndrome.  As mentioned previously, obesity can manifest through increases 
in adipocyte size and number.  The lack of mechanistic research examining hyperplastic 
obesity has left many unanswered questions.  Clonal expansion provides a perfect 
model in which to study preadipocyte proliferation as synchronization allows for the 
study of specific mechanisms.  
Cell Cycle.  Cell proliferation is highly regulated in order to prevent abnormal 
growth, copies of mutated or damaged genes, etc.  There are four main sequential 
phases of the cell cycle: G1, S, G2, M. Cells are driven through this process by 
phosphorylation events initiated by the transient expression of cyclin proteins.  Cyclins 
bind to and activate cyclin-dependent kinases (cdk), which are constitutively expressed 
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throughout the cell cycle.  Figure 1.1 illustrates cell cycle phases and the cyclin/cdk 
complexes expressed during each phase.  An initial early phase is a quiescent, non-
proliferative state referred to as G0.  External mitogenic factors signal cells to exit G0 and 
enter into G1 phase.  Cells are able to fluctuate between these two phases, however 
once the G1-to-S phase restriction point is passed, environmental stimuli are no longer 
necessary and cells become fully committed to the cell cycle.  Therefore, this restriction 
point is critical to cell cycle progression and is the first major cell cycle checkpoint.  It is 
imperative that this transition be tightly controlled because it is during the following 
phase that DNA is replicated.  One of the critical events that occur during this time is 
hyperphosphorylation of Rb proteins and subsequent release of E2F.  The transcription 
factor E2F is then able to activate genes required for S phase entry and DNA replication.  
After duplicate copies of the genetic material are made, cells move out of S phase, 
through G2 and into mitosis, during which time two identical daughter cells are made.  
Two of the three major cell cycle checkpoints occur at the end of G1 and G2 phases, as 
they are preparatory phases for DNA replication and mitosis, respectively.  The third 
occurs immediately before the cell undergoes cytokinesis.  As previously mentioned, cdk 
activity is essential for cell cycle progression.  The activity of cyclin-dependent kinases is 
negatively regulated by cyclin-dependent kinase inhibitors.  These proteins inhibit cdk 
activity by preventing interactions with cyclins or blocking their ATP binding site.  There 
are two families of cyclin-dependent kinase inhibitors; INK4 and CIP/KIP, which function 
primarily to inhibit G1 and S phase progression (Fig.1.1).  The p27/Kip1 protein plays a 
pivotal role in cell cycle progression and must decrease in order for cells to pass the G1-
to-S phase restriction point.  
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Cyclin-Dependent Kinase Inhibitor, p27.  The p27 gene was first cloned in 
1994 by 3 separate groups (Polyak et al., 1994;Toyoshima and Hunter, 1994;Slingerland 
et al., 1994) and the protein crystal structure determined two years later (Russo et al., 
1996). As knowledge about this protein increased, multiple roles emerged: regulator of 
drug resistance in solid tumors (St Croix et al., 1996), promoter of apoptosis (Katayose 
et al., 1997;Levkau et al., 1998), key player in oligodendrocyte and muscle differentiation 
(Durand et al., 1997;Zabludoff et al., 1998). By far, the most widely studied and 
noteworthy function of p27 is as a cell cycle inhibitor (Toyoshima and Hunter, 1994) and 
tumor suppressor (Morosetti et al., 1995).  Once its role in cell cycle progression was 
established, a flurry of research was done examining p27 in human cancers which found 
it to be a useful prognostic tool (i.e., low levels of p27 correlate with poor prognosis or 
malignancy) for breast cancer (Porter et al., 1997;Tan et al., 1997), colorectal cancer 
(Fredersdorf et al., 1997), gastric carcinoma (Mori et al., 1997), non-small-cell lung 
carcinoma (Esposito et al., 1997), lymphoma (Sanchez-Beato et al., 1997), esophageal 
adenocarcinoma (Singh et al., 1998), prostate adenocarcinoma (Tsihlias et al., 1998), 
oral squamous cell carcinoma (Jordan et al., 1998), and malignant melanoma (Florenes 
et al., 1998).  These observations spawned many studies on the regulation of p27. 
Interestingly, when over 500 tumors of different origins were analyzed, less than 5% had 
p27 gene mutations (Spirin et al., 1996).  While p27 has been shown to be regulated at 
the level of transcription (e.g., methylation (Qian et al., 1998), FOXO family of 
transcription factors (Medema et al., 2000)), posttranscriptional modes of regulation 
have been even more extensively studied.   
Research has shown that, within different cell types, p27 protein levels and 
activity can be controlled by various mechanisms.  For example, ubiquitin/proteasome-
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dependent degradation (Pagano et al., 1995), the KPC or Kip1 Ubiquitin-Promoting 
Complex (Kamura et al., 2004), phosphorylation and cellular localization (Reynisdottir 
and Massague, 1997;Fujita et al., 2002), and proteolytic processing (Levkau et al., 
1998;Shirane et al., 1999) have all been implicated.  The importance of p27 subcellular 
localization has become increasingly apparent in recent years.  In 2001, Rodier et al. 
found that phosphorylation of p27 at Ser10 was required for nuclear export and a serine 
to alanine mutation sequestering p27 in the nucleus had no effect on interaction with the 
F-box protein Skp2 (S-phase kinase-associated protein) and subsequent ubiquitylation 
(Rodier et al., 2001).  Phosphorylation of p27 at Ser10 was later found to be essential for 
Jab1/CRM1-mediated nuclear export (Tomoda et al., 2002;Ishida et al., 2002). Several 
other groups found that following Ser10 phosphorylation and cytosolic localization, Akt 
can phosphorylate p27 on Thr157, inhibiting association of p27 with the nuclear 
localization protein, importin α, providing further assurance of retainment in the cytosol 
(Liang et al., 2002;Shin et al., 2005;Viglietto et al., 2002). It has also been shown that 
p27 can localize to the cytosol by phosphorylation at Thr198 and binding to 14-3-3 
proteins.  Two kinases have been shown to phosphorylate p27 at this residue; Akt and 
an immediate downstream target of MAPKs, p90 ribosomal protein S6 kinases (Fujita et 
al., 2002;Fujita et al., 2003).     
The importance of p27 and its regulation during cell cycle progression caused 
others to look at its expression in non-cancerous tissues. Morrison et al (Morrison and 
Farmer, 1999) first showed that p27 is highly regulated during clonal expansion of 
adipocyte differentiation. This period of obligatory proliferation and the regulated 
expression of p27 during this time provide a unique model for studying adipocyte 
hyperplasia. The importance of this is demonstrated by a study that shows p27 knockout 
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mice are obese due to adipocyte hyperplasia, resulting in a 2-fold greater number of fat 
cells when compared to wild-type counterparts (Naaz et al., 2004). These findings 
demonstrate urgency for mechanistic studies on the regulation of p27 in adipocytes. 
Both C/EBPβ and Calpain (Zhang et al., 2004;Patel and Lane, 2000) have been 
implicated in the decrease of p27 protein during clonal expansion.  While not identified 
as a direct effect, preventing nuclear localization of C/EBPβ prevents p27 degradation 
and S phase progression during early stages of 3T3-L1 differentiation (Zhang et al., 
2004).  Patel et al. (Patel and Lane, 2000) demonstrated that induced expression of the 
endogenous calpain inhibitor, calpastatin, produced increased levels of p27 during clonal 
expansion.  This has also been seen in choroidal melanoma cells where authors suggest 
the presence of a 25kDa cleaved product (Delmas et al., 2003).  Taken together, these 
data imply multiple modes of p27 regulation during preadipocyte replication. 
Ubiquitin/26S Proteasome System.  The 26S proteasome/ubiquitylation 
process begins with an E1 ubiquitin activating enzyme that binds to and activates 
ubiquitin molecules in an ATP-dependent manner. Secondly, activated ubiquitin is 
transferred to an E2 ubiquitin conjugating enzyme that brings ubiquitin in close proximity 
to the E3 ubiquitin ligase, allowing the covalent addition of ubiquitin to a lysine residue(s) 
of a specific substrate (Hershko et al., 1983;Hershko and Ciechanover, 1998).  Ubiquitin 
is a very small protein comprised of only 76 amino acids, with a mass of 8kDa.  There is 
a requirement for the targeted substrate to be covalently linked to four ubiquitin 
molecules in order for recognition by the 26S proteasome (Thrower et al., 2000).  This is 
a dynamic process within the cell as there are deubiquitylating enzymes present as well.  
As shown in Figure 1.2, Skp2-dependent ubiquitylation of p27 requires phosphorylation 
of p27 on Thr187 by Cyclin E-Cdk2 during late G1 (Carrano et al., 1999;Tsvetkov et al., 
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1999).  Akt has also been shown to cause phosphorylation on this residue in vitro using 
human embryonic kidney 293T cell extract (Fujita et al., 2002). Once phosphorylated, 
p27 can bind to Cks1 and the F-box protein Skp2, the substrate recognition portion of 
the SCFSKP2 E3 ligase (Hao et al., 2005).  Association with this ligase complex allows 
polyubiquitylation of p27, which is the target signal for rapid degradation by the 26S 
proteasome.  The SCFSkp2 E3 Ligase is composed of 5 core proteins: Skp1, Roc1, Cul1, 
Skp2, and Cks1. The expression of Skp1, Roc1, and Cul1 has been shown to be quite 
stable during cell cycle progression (Lisztwan et al., 1998).  However, Cul1 can be 
modified post-translationally by the addition of a protein, Nedd8, which has the ability to 
enhance activity of the SCFSkp2 E3 ligase. Skp2 can also be modified in a similar manner 
by the addition of a small protein, Cks1. Cks1 was first identified as a cell cycle regulator 
that interacts with cdks. Its function was not known until 2001 when Ganoth et al. 
revealed that Cks1 also binds to Skp2 and mediates Skp2-dependent p27 degradation 
(Ganoth et al., 2001).  Interestingly, in 2004 Kamura et al. (Kamura et al., 2004) 
discovered a second F-box protein important for regulating p27 protein.  The Kip1 
Ubiquitin-Promoting Complex, or KPC, was first identified in Skp2-/- mouse embryonic 
fibroblasts and found to play an important role in degrading p27 in the cytoplasm.  There 
is still much to be determined and understood regarding this novel E3 Ligase.   
The F-box Protein, Skp2.  Skp2 was first identified as a protein required for 
entry into S phase and highly expressed in transformed cells (Zhang et al., 1995). Its 
expression fluctuates throughout the cell cycle    (Lisztwan et al., 1998) and regulation 
can occur at multiple levels.  Limited studies have been done examining direct 
transcriptional regulation of Skp2.  Imaki et al. (Imaki et al., 2003) was the first to 
characterize the Skp2 promoter and determine a positive regulatory element between -
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207 and -103.  They found that GABP (i.e., GA-binding protein) binds to that region and 
knockdown of this transcription factor results in a significant decrease in Skp2 promoter 
activity and mRNA expression.  E2F1 has also been identified as a transcriptional 
regulator of Skp2 during proliferation of human fibroblasts and many tumor cell lines 
(Zhang and Wang, 2005).  Most recently, the Forkhead Box M1 (FoxM1) has been 
shown to bind to and activate the promoters of Skp2 and its accessory protein Cks1, 
resulting in increased protein expression and function (Wang et al., 2005).  Since then, 
FoxM1 has been shown to play a role in the proliferation and progression of human non-
small cell lung cancer (Kim et al., 2006). Previous findings showing Skp2 overexpression 
in non-small cell lung cancer (Osoegawa et al., 2004) suggest a functional link between 
FoxM1 and tumor growth.   
Research has shown post-translational regulation of Skp2 as well.  Cyclin A/ 
Cdk2 complexes have been shown to phosphorylate Skp2 at Ser76 (Yam et al., 1999), 
however, the function of this modification is not fully understood.  It is known that F-box 
proteins can participate in auto-ubiquitylation and studies suggest Skp2 is no exception.  
In 2000, in vitro observations revealed polyubiquitylation of Skp2 following addition of 
Cul1, Rbx1/Roc1, and Skp1 (Wirbelauer et al., 2000).  Two primary E3 Ligases 
important for regulating cell cycle progression are SCF and APC/C (anaphase-promoting 
complex/cyclosome).  Research by two separate groups demonstrate that Skp2 is a 
substrate for polyubiquitylation and subsequent degradation by the APC/CCdh1 (Bashir et 
al., 2004;Wei et al., 2004).  Thus, it is thought that the 26S proteasome plays a critical 
role in modulating Skp2 protein expression. 
Several endogenous and exogenous factors that affect the expression of Skp2 
have been identified.  The prostacyclin mimetic, cicaprost, causes G1 arrest and inhibits 
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Skp2 gene expression in smooth muscle cells (Stewart et al., 2004), although an exact 
mechanism by which this occurs is not known.  Connexin43 is important for the 
formation of gap junctions and can also suppress tumor growth.  Zhang et al. show that 
connexin43 promotes ubiquitylation and degradation of Skp2 independently of its ability 
to form gap junctions (Zhang et al., 2003c;Zhang et al., 2003b).  In fibroblasts, Skp2 
expression has been shown to be dependent on cell adhesion to the extracellular matrix 
and β1-integrin, a transmembrane receptor important for adhesion (Carrano and 
Pagano, 2001;Zhang et al., 2003a).  It is worthy to note that there is crosstalk between 
integrin and IGF1R signaling (Shen et al., 2006) and β1-integrin may be required for 
IGF1R signaling (Goel et al., 2005).  TGF-β signaling is known to inhibit cell cycle 
progression by increasing proteasome-dependent degradation of Skp2 in lung epithelial 
cells (Wang et al., 2004).  Interestingly, there is also crosstalk between TGF-β, IGF1R, 
and integrin signaling (Huang and Huang, 2005).  Another molecule involved in 
intracellular signaling that affects expression of Skp2 is PTEN.  Overexpression of PTEN 
in human glioblastoma cells results in down-regulation of Skp2, suggesting a role for the 
PI3K pathway (Mamillapalli et al., 2001).  Of particular interest to the study of 
hyperplastic obesity is the finding that the PPARγ ligand troglitazone, but not 
pioglitazone or ciglitazone, dramatically decreases Skp2 mRNA and protein expression 
in human hepatoma cells (Koga et al., 2003).  Also, treatment of mammary carcinoma 
cells with specific fatty acid synthase inhibitors (i.e., siRNA or the anti-obesity drug 
Orlistat) produced significant reductions in Skp2 protein (Knowles et al., 2004).  Finally, 
5 µM all-trans retinoic acid completely blocked Skp2 protein expression in human KCNR 
neuroblastoma cells (Nakamura et al., 2003).   
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F-box proteins function within E3 Ligases by dictating substrate recognition and 
Skp2 is known to have multiple cellular targets.  These substrates include p27 (Tsvetkov 
et al., 1999;Carrano et al., 1999;Sutterluty et al., 1999), E2F-1 (Marti et al., 1999), p130 
(Tedesco et al., 2002), CDK9 (Kiernan et al., 2001), p57 (Kamura et al., 2003), p21 
(Bornstein et al., 2003), free Cyclin E (Nakayama et al., 2000), FOXO1 (Huang et al., 
2005a), and c-myc (von der et al., 2003).  While Skp2 is known to cause rapid 
degradation of c-myc, it is interesting to note that Skp2 has also been shown to play an 
important role in c-myc-dependent gene expression.  Skp2 can complex with c-myc and 
act as a transcriptional co-factor during S phase progression (von der et al., 2003).  Due 
to the presence of ubiquitylated proteins at the promoters of Skp2/c-myc responsive 
genes, it is theorized that Skp2 promotes the degradation of repressors and/or co-
repressors.  This type of paradoxical relationship is also seen between Skp2 and E2F, 
as Skp2 causes proteasomal degradation of E2F1, but can also be a transcriptional 
target of E2F1.  These mechanisms may be explained by the cell’s need to tightly control 
DNA replication and mitosis. 
The degradation of p27 is commonly considered the main function of Skp2 due to 
the critical role this regulation plays in cell cycle progression.  Similar to p27, Skp2 
expression is used as a prognostic tool (i.e., elevated levels of Skp2 are correlated with 
poor prognosis) for certain types of cancers such as oral squamous cell carcinoma 
(Kudo et al., 2001) colorectal cancer (Shapira et al., 2005), renal cell carcinoma 
(Langner et al., 2004), epithelial ovarian cancer (Hu and Liu, 2005), diffuse large B-cell 
lymphoma (Seki et al., 2003), soft tissue sarcomas (Oliveira et al., 2003), laryngeal 
squamous cell carcinomas (Dong et al., 2003), prostate cancer (Yang et al., 2002), 
melanoma (Li et al., 2004), and non-small-cell lung cancer (Osoegawa et al., 2004). In 
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addition, Nakayama et al. found that Skp2 knockout mice are two-thirds the size of their 
wild-type littermates (Nakayama et al., 2000).  Body composition was not determined, 
however, the researchers reported that all external bodyparts (e.g., tail, ears) were 
normal which may suggest a decrease in adipose tissue contributing to the reduction in 
bodyweight.  Furthermore, because of the lack of Skp2, one might propose that a 
potential decrease in adipose tissue would be due to decreased adipocyte number.  
IGF1-Receptor Signaling.  Growth factor receptors play a primary role in 
regulating cellular responses to environmental changes.  The IGF-1 receptor (IGF1R) is 
constitutively expressed throughout adipocyte differentiation and is an essential, primary 
mediator of early signaling events following adipogenic stimulation (Smith et al., 1988).  
IGF1R signaling includes the activation of several kinase-driven cascades.  Two such 
pathways are the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-
kinase pathways (PI3K), both of which have many downstream targets involved in 
cellular proliferation.   
The MAPK pathway is initiated by autophosphorylation of the IGF1R triggered by 
binding of IGF1 or insulin.  This causes activation of MAPK kinase kinases which leads 
to the phosphorylation of MAPK proteins.  While there are three main MAPK proteins 
(i.e., ERK, p38, and JNK), ERK was the first to be identified and is the most important in 
regulating proliferation.  The MAPKs p38 and JNK are primarily involved in mediating 
stress signals.  The MAPKKK upstream of ERK is Raf.  Raf phosphorylates and 
activates the MAPKK MEK 1/2 which in turn phosphorylates ERK 1/2 (i.e., the two 
isoforms of ERK).  ERK exerts its effects on cell cycle progression in large part by 
upregulating Cyclin D1 (Lavoie et al., 1996;Weber et al., 1997), leading to critical 
downstream events such as pRb hyperphosphorylation. 
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Activation of the PI3K pathway also begins with autophosphorylation of the 
IGF1R and subsequent activation of PI3K. The two subunits (p85-regulatory and p110-
catalytic) of PI3K are able to associate with the receptor and become phosphorylated.  
PI3K can then phosphorylate the phospholipid PIP2, resulting in PIP3 within the plasma 
membrane.  The presence of PIP3 causes constitutively phosphorylated PDK1 to dock 
on the plasma membrane.  Perhaps the most widely studied downstream target of PDK1 
is Akt/PKB, a kinase that also binds PIP3 within the membrane via a PH domain allowing 
phosphorylation of Thr308 and Ser473 by PDK1 (Andjelkovic et al., 1999).  It has since 
been determined that the protein kinase mTOR is also able to target Ser473 in 
adipocytes (Hresko and Mueckler, 2005).  Once Akt is active, it phosphorylates targets 
in the cytoplasm (e.g., glycogen synthase kinase-3, GSK3-β) and nucleus (e.g., Foxo1 
transcription factor) (Cross et al., 1995;Guo et al., 1999). The PI3K pathway can be 
inhibited by the endogenous phosphatase, PTEN.  PTEN is able to remove a phosphate 
group from PIP3, thereby preventing PDK1 from docking on the plasma membrane 
(Maehama and Dixon, 1998). However, when phosphorylated on serine 380 (S380), 
PTEN is inactivated and PIP2 can be converted to PIP3 by PI3K.  The phosphorylation of 
PTEN is not dependent on external stimuli. 
 A major mode of regulating translational control within the cell is through the 
mTOR/Raptor pathway, which is downstream of PI3K.  The protein kinase mTOR is 
phosphorylated following PI3K activation, leading to the inhibition of translation repressor 
4E-BP1.  Raptor is an mTOR-binding protein that helps facilitate recognition and 
phosphorylation of 4E-BP1 (Hara et al., 2002;Nojima et al., 2003).  This initiates a 
cascade of events, beginning with the release of eIF4E, that promotes cap-dependent 
translation.  The protein p70S6K is also downstream of mTOR and once activated, can 
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increase expression of proteins important for translational machinery (Burnett et al., 
1998).  Thus, mTOR exerts its effects on translational control by multiple mechanisms.  
It appears that mTOR plays a significant role in regulating adipogenesis as treatment of 
3T3-L1 preadipocytes with the potent mTOR inhibitor rapamycin results in marked 
reductions in clonal expansion and C/EBPα (Yeh et al., 1995); expression of PPARγ and 
other adipogenic markers such as adipsin and aP2 (Cho et al., 2004); and insulin 
signaling, which was also seen in human adipocytes (Tremblay et al., 2005).  
NFκB.  NFκB is a downstream target of several signaling cascades (e.g., PI3K) 
and is known to regulate cell cycle progression (Kane et al., 1999). The NFκB family of 
transcription factors is composed of five proteins: RelA/p65, Rel B, c-Rel, p105/p50, and 
p100/p52.  These proteins bind in homo- and heterodimers, with p65:p50 and p50:p50 
being the most predominant forms found.  NFκB dimers can have positive or negative 
effects on transcription depending on the combination (Chen and Greene, 2004).  
RelA/p65, Rel B, and c-Rel have transactivation domains and can upregulate the 
expression of many anti-apoptotic genes. Homodimers of p50 and p52 can also bind 
DNA but act to repress transcription.  The IκB family of proteins can bind and inhibit 
these dimers by preventing nuclear localization and interaction with DNA.  Research has 
shown that these inhibitory subunits can be removed by phosphorylation (initiated by 
Akt), polyubiquitylation and degradation by the 26S proteasome or sequestration by 
PI3K.  In addition, p105 and p100 are members of the IκB family.  Cleavage of these 
proteins by the 26S proteasome results in the formation of active NFκB proteins p50 and 
p52, respectively (Palombella et al., 1994). 
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 RelA/p65 has warranted much attention due to its role in regulating such 
processes as proliferation, apoptosis, and inflammation.  A great deal of research has 
been done to determine downstream targets of NFκB.  The use of chemical inhibitors 
has become very popular, as several naturally occurring compounds have been 
identified.  The most direct method of blocking p65 activity is by preventing DNA-binding.  
The sesquiterpene lactone, helenalin, is known to do this through alkylation of p65. 
Helenalin.  Helenalin is a biologically active compound that has long been used 
for external healing purposes.  It was originally identified as one of the sesquiterpene 
lactones found in the yellow flower of arnica Montana L, belonging to the 
Compositae/Asteraceae family of flowering plants.  Arnica has been used for the 
treatment of poor circulation, reduced immune function, and inflammatory conditions 
such as bruises, sprains, and rheumatic pain.  Although The European Scientific 
Cooperative on Phytotherapy (ESCOP) approved the use of this flowering plant for 
external treatments, there are detrimental side effects associated with its use, including 
stomach discomfort, organ damage dermatitis, liver and kidney damage, and even 
death.  Helenalin is just one of several sesquiterpene lactones found in this plant known 
to exhibit anti-inflammatory and analgesic effects.  It has been used in molecular biology 
research as a potent inhibitor of NFκB p65 DNA-binding activity through direct alkylation 
of p65 (Lyss et al., 1998).  Many biologically active compounds have multiple targets 
within the cell and emerging data imply this is also true for helenalin.  In 2005, Huang et 
al. revealed helenalin’s ability to alkylate telomerase (Huang et al., 2005b), an important 
enzyme in the progression of neoplastic growth.  Helenalin’s function as a potent 
alkylating agent suggests the possibility of additional targets within the cell.   
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 Helenalin’s anti-tumor properties have also been well-documented since the 
1970’s.  In 1977, Lee et al. (Lee et al., 1977) describe helenalin’s ability to inhibit nuclear 
DNA polymerase activity and increase cyclic AMP levels within Ehrlich ascites, 
observations consistent with a reversal of tumor growth.  Interestingly, helenalin was 
also able to decrease HMG-CoA reductase activity and hypercholesteremic state.  
Helenalin’s effect on proliferation and cholesterol synthesis makes it an interesting 




Chapter II: It has been shown that p27 protein decreases during early stages of 
adipocyte differentiation (i.e., clonal expansion).  The F-box protein, Skp2, can target 
p27 for rapid degradation by the 26S proteasome in many types of cancer, thus leading 
to increased proliferation.  In Chapter II, we demonstrate that the change in p27 
expression during preadipocyte replication is due to a decrease in protein half-life.  
Subsequently, we show a transient upregulation of Skp2 during this time and examine 
Skp2’s role in the decrease in p27. 
 
Chapter III: We are the first to show Skp2 expression during adipogenesis.  Determining 
how Skp2 is regulated in adipocytes is expected to provide valuable information for the 
study of hyperplastic obesity and the regulation of cell cycle in other cell/tissue types.  
We show that insulin is the primary component of the differentiation cocktail that causes 




Chapter IV: The sesquiterpene lactone, helenalin, is known to exhibit anti-inflammatory 
and anti-proliferative properties.  However, its effect on adipogenesis and adipocyte 
hyperplasia has not yet been explored.  Helenalin’s primary function within the cell has 
long been thought to be inhibition of p65 DNA-binding by direct alkylation.  In Chapter IV, 
we examine the effect of helenalin on Skp2 expression during early stages of 
adipogenesis.  An effect on Akt signaling is also revealed. 
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Figure 1.1. Mammalian Cell Cycle Model.  Cell cycle progression is mediated 
by the sequential activation of cyclin-dependent kinases (cdks).  Cdks 
(rectangles) are positively regulated by association with cyclin proteins (ovals) 
and negatively regulated by two classes of cyclin dependent kinase inhibitors 
(octagons).  Cell cycle phases are illustrated as part of the pie chart, with a red 
“R” denoting the restriction point. 
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Figure 1.2.  Model of SCFSkp2 E3 Ligase dependent degradation of p27.
Phosphorylated p27 (Thr187) is bound by Skp2, Cks1, and the SCF E3 Ligase 





Andjelkovic,M., S.M.Maira, P.Cron, P.J.Parker, and B.A.Hemmings. 1999. Domain 
swapping used to investigate the mechanism of protein kinase B regulation by 3-
phosphoinositide-dependent protein kinase 1 and Ser473 kinase. Mol. Cell Biol. 19: 
5061-5072. 
Bashir,T., N.V.Dorrello, V.Amador, D.Guardavaccaro, and M.Pagano. 2004. Control of 
the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 428: 
190-193. 
Bornstein,G., J.Bloom, D.Sitry-Shevah, K.Nakayama, M.Pagano, and A.Hershko. 2003. 
Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. 
Chem. 278: 25752-25757. 
Bosello,O., F.Armellini, R.Ostuzzi, G.Bissoli, and L.A.Scuro. 1978. Behavior of adipose 
tissue cellularity in gross obesity. Minerva Med. 69: 3831-3833. 
Burnett,P.E., R.K.Barrow, N.A.Cohen, S.H.Snyder, and D.M.Sabatini. 1998. RAFT1 
phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. 
Acad. Sci. U. S. A 95: 1432-1437. 
Carrano,A.C., E.Eytan, A.Hershko, and M.Pagano. 1999. SKP2 is required for ubiquitin-
mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1: 193-199. 
Carrano,A.C. and M.Pagano. 2001. Role of the F-box protein Skp2 in adhesion-
dependent cell cycle progression. J. Cell Biol. 153: 1381-1390. 
Chen,L.F. and W.C.Greene. 2004. Shaping the nuclear action of NF-kappaB. Nat. Rev. 
Mol. Cell Biol. 5: 392-401. 
Cho,H.J., J.Park, H.W.Lee, Y.S.Lee, and J.B.Kim. 2004. Regulation of adipocyte 
differentiation and insulin action with rapamycin. Biochem. Biophys. Res. Commun. 321: 
942-948. 
Christy,R.J., K.H.Kaestner, D.E.Geiman, and M.D.Lane. 1991. CCAAT/enhancer binding 
protein gene promoter: binding of nuclear factors during differentiation of 3T3-L1 
preadipocytes. Proc. Natl. Acad. Sci. U. S. A 88: 2593-2597. 
Cross,D.A., D.R.Alessi, P.Cohen, M.Andjelkovich, and B.A.Hemmings. 1995. Inhibition 
of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-
789.
25 
Delmas,C., N.Aragou, S.Poussard, P.Cottin, J.M.Darbon, and S.Manenti. 2003. MAP 
kinase-dependent degradation of p27Kip1 by calpains in choroidal melanoma cells. 
Requirement of p27Kip1 nuclear export. J. Biol. Chem. 278: 12443-12451.Dizdar,O. and 
E.Alyamac. 2004. Obesity: an endocrine tumor? Med. Hypotheses 63: 790-792. 
Dong,Y., L.Sui, Y.Watanabe, K.Sugimoto, and M.Tokuda. 2003. S-phase kinase-
associated protein 2 expression in laryngeal squamous cell carcinomas and its 
prognostic implications. Oncol. Rep. 10: 321-325. 
Durand,B., F.B.Gao, and M.Raff. 1997. Accumulation of the cyclin-dependent kinase 
inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J. 16: 306-
317. 
Enesco,M. and C.P.Labond. 1962. Increase in cell number as a factor in the growth of 
the organ and tissue of the young male rat. J. Embryol. Exp. Morphol. 10: 530-562. 
Esposito,V., A.Baldi, A.De Luca, A.M.Groger, M.Loda, G.G.Giordano, M.Caputi, F.Baldi, 
M.Pagano, and A.Giordano. 1997. Prognostic role of the cyclin-dependent kinase 
inhibitor p27 in non-small cell lung cancer. Cancer Res. 57: 3381-3385. 
Fajas,L., R.L.Landsberg, Y.Huss-Garcia, C.Sardet, J.A.Lees, and J.Auwerx. 2002. E2Fs 
regulate adipocyte differentiation. Dev. Cell 3: 39-49. 
Faust,I.M., P.R.Johnson, J.S.Stern, and J.Hirsch. 1978. Diet-induced adipocyte number 
increase in adult rats: a new model of obesity. Am. J. Physiol 235: E279-E286. 
Faust,I.M. and N.Mrosovsky. 1987. Resistance to adipocyte hyperplasia in ground 
squirrels given high-fat diets. Am. J. Physiol 253: R576-R579. 
Florenes,V.A., G.M.Maelandsmo, R.S.Kerbel, J.M.Slingerland, J.M.Nesland, and 
R.Holm. 1998. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant 
melanoma: inverse correlation with disease-free survival. Am. J. Pathol. 153: 305-312. 
Fredersdorf,S., J.Burns, A.M.Milne, G.Packham, L.Fallis, C.E.Gillett, J.A.Royds, 
D.Peston, P.A.Hall, A.M.Hanby, D.M.Barnes, S.Shousha, M.J.O'Hare, and X.Lu. 1997. 
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: 
inverse correlation between the expression of p27(kip1) and degree of malignancy in 
human breast and colorectal cancers. Proc. Natl. Acad. Sci. U. S. A 94: 6380-6385. 
Fujita,N., S.Sato, K.Katayama, and T.Tsuruo. 2002. Akt-dependent phosphorylation of 
p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 277: 
28706-28713. 
Fujita,N., S.Sato, and T.Tsuruo. 2003. Phosphorylation of p27Kip1 at threonine 198 by 
p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic 
localization. J. Biol. Chem. 278: 49254-49260. 
26 
Ganoth,D., G.Bornstein, T.K.Ko, B.Larsen, M.Tyers, M.Pagano, and A.Hershko. 2001. 
The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated 
ubiquitinylation of p27. Nat. Cell Biol. 3: 321-324. 
Goel,H.L., M.Breen, J.Zhang, I.Das, S.znavoorian-Cheshire, N.M.Greenberg, 
A.Elgavish, and L.R.Languino. 2005. beta1A integrin expression is required for type 1 
insulin-like growth factor receptor mitogenic and transforming activities and localization 
to focal contacts. Cancer Res. 65: 6692-6700. 
Green,H. and O.Kehinde. 1976. Spontaneous heritable changes leading to increased 
adipose conversion in 3T3 cells. Cell 7: 105-113. 
Green,H. and M.Meuth. 1974. An established pre-adipose cell line and its differentiation 
in culture. Cell 3: 127-133. 
Guo,S., G.Rena, S.Cichy, X.He, P.Cohen, and T.Unterman. 1999. Phosphorylation of 
serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of 
insulin on insulin-like growth factor-binding protein-1 promoter activity through a 
conserved insulin response sequence. J. Biol. Chem. 274: 17184-17192. 
Hager,A., L.Sjorstrom, B.Arvidsson, P.Bjorntorp, and U.Smith. 1978. Adipose tissue 
cellularity in obese school girls before and after dietary treatment. Am. J. Clin. Nutr. 31: 
68-75. 
Hao,B., N.Zheng, B.A.Schulman, G.Wu, J.J.Miller, M.Pagano, and N.P.Pavletich. 2005. 
Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) 
ubiquitin ligase. Mol. Cell 20: 9-19. 
Hara,K., Y.Maruki, X.Long, K.Yoshino, N.Oshiro, S.Hidayat, C.Tokunaga, J.Avruch, and 
K.Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates 
TOR action. Cell 110: 177-189. 
Hershko,A. and A.Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67: 
425-479. 
Hershko,A., H.Heller, S.Elias, and A.Ciechanover. 1983. Components of ubiquitin-
protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. 
Biol. Chem. 258: 8206-8214. 
Hirsch,J. and B.Batchelor. 1976. Adipose tissue cellularity in human obesity. Clin. 
Endocrinol. Metab 5: 299-311. 
Hotamisligil,G.S., N.S.Shargill, and B.M.Spiegelman. 1993. Adipose expression of tumor 
necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91. 
Hresko,R.C. and M.Mueckler. 2005. mTOR.RICTOR is the Ser473 kinase for Akt/protein 
kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280: 40406-40416. 
27 
Hu,Y.Q. and Y.J.Liu. 2005. Expressions of Cx43 and Skp2 in epithelial ovarian tumor 
and their clinical significances. Ai. Zheng. 24: 104-109. 
Huang,H., K.M.Regan, F.Wang, D.Wang, D.I.Smith, J.M.van Deursen, and D.J.Tindall. 
2005a. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated 
degradation. Proc. Natl. Acad. Sci. U. S. A 102: 1649-1654. 
Huang,P.R., Y.M.Yeh, and T.C.Wang. 2005b. Potent inhibition of human telomerase by 
helenalin. Cancer Lett. 227: 169-174. 
Huang,S.S. and J.S.Huang. 2005. TGF-beta control of cell proliferation. J. Cell Biochem. 
96: 447-462. 
Imaki,H., K.Nakayama, S.Delehouzee, H.Handa, M.Kitagawa, T.Kamura, and 
K.I.Nakayama. 2003. Cell cycle-dependent regulation of the Skp2 promoter by GA-
binding protein. Cancer Res. 63: 4607-4613. 
Ishida,N., T.Hara, T.Kamura, M.Yoshida, K.Nakayama, and K.I.Nakayama. 2002. 
Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear 
export. J. Biol. Chem. 277: 14355-14358. 
Jordan,R.C., G.Bradley, and J.Slingerland. 1998. Reduced levels of the cell-cycle 
inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am. J. Pathol. 
152: 585-590. 
Kaestner,K.H., R.J.Christy, and M.D.Lane. 1990. Mouse insulin-responsive glucose 
transporter gene: characterization of the gene and trans-activation by the 
CCAAT/enhancer binding protein. Proc. Natl. Acad. Sci. U. S. A 87: 251-255. 
Kamura,T., T.Hara, S.Kotoshiba, M.Yada, N.Ishida, H.Imaki, S.Hatakeyama, 
K.Nakayama, and K.I.Nakayama. 2003. Degradation of p57Kip2 mediated by SCFSkp2-
dependent ubiquitylation. Proc. Natl. Acad. Sci. U. S. A 100: 10231-10236. 
Kamura,T., T.Hara, M.Matsumoto, N.Ishida, F.Okumura, S.Hatakeyama, M.Yoshida, 
K.Nakayama, and K.I.Nakayama. 2004. Cytoplasmic ubiquitin ligase KPC regulates 
proteolysis of p27(Kip1) at G1 phase. Nat. Cell Biol. 6: 1229-1235. 
Kane,L.P., V.S.Shapiro, D.Stokoe, and A.Weiss. 1999. Induction of NF-kappaB by the 
Akt/PKB kinase. Curr. Biol. 9: 601-604. 
Katayose,Y., M.Kim, A.N.Rakkar, Z.Li, K.H.Cowan, and P.Seth. 1997. Promoting 
apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. 
Cancer Res. 57: 5441-5445. 
Kiernan,R.E., S.Emiliani, K.Nakayama, A.Castro, J.C.Labbe, T.Lorca, K.K.Nakayama, 
and M.Benkirane. 2001. Interaction between cyclin T1 and SCF(SKP2) targets CDK9 for 
ubiquitination and degradation by the proteasome. Mol. Cell Biol. 21: 7956-7970. 
28 
Kim,I.M., T.Ackerson, S.Ramakrishna, M.Tretiakova, I.C.Wang, T.V.Kalin, M.L.Major, 
G.A.Gusarova, H.M.Yoder, R.H.Costa, and V.V.Kalinichenko. 2006. The Forkhead Box 
m1 Transcription Factor Stimulates the Proliferation of Tumor Cells during Development 
of Lung Cancer. Cancer Res. 66: 2153-2161. 
Knittle,J.L. and J.Hirsch. 1968. Effect of early nutrition on the development of rat 
epididymal fat pads: cellularity and metabolism. J. Clin. Invest 47: 2091-2098. 
Knowles,L.M., F.Axelrod, C.D.Browne, and J.W.Smith. 2004. A Fatty Acid Synthase 
Blockade Induces Tumor Cell-cycle Arrest by Down-regulating Skp2. J. Biol. Chem. 279: 
30540-30545. 
Koga,H., M.Harada, M.Ohtsubo, S.Shishido, H.Kumemura, S.Hanada, E.Taniguchi, 
K.Yamashita, R.Kumashiro, T.Ueno, and M.Sata. 2003. Troglitazone induces p27Kip1-
associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. 
Hepatology 37: 1086-1096. 
Kudo,Y., S.Kitajima, S.Sato, M.Miyauchi, I.Ogawa, and T.Takata. 2001. High expression 
of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor 
prognosis in oral squamous cell carcinomas. Cancer Res. 61: 7044-7047. 
Langner,C., R.von Wasielewski, M.Ratschek, P.Rehak, and R.Zigeuner. 2004. Biological 
significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis 
of primary and metastatic tumour tissues using a tissue microarray technique. Virchows 
Arch. 445: 631-636. 
Lavoie,J.N., G.L'Allemain, A.Brunet, R.Muller, and J.Pouyssegur. 1996. Cyclin D1 
expression is regulated positively by the p42/p44MAPK and negatively by the 
p38/HOGMAPK pathway. J. Biol. Chem. 271: 20608-20616. 
Lee,K.H., I.H.Hall, E.C.Mar, C.O.Starnes, S.A.ElGebaly, T.G.Waddell, R.I.HADGRAFT, 
C.G.Ruffner, and I.Weidner. 1977. Sesquiterpene antitumor agents: inhibitors of cellular 
metabolism. Science 196: 533-536. 
Levkau,B., H.Koyama, E.W.Raines, B.E.Clurman, B.Herren, K.Orth, J.M.Roberts, and 
R.Ross. 1998. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in 
endothelial cells through activation of Cdk2: role of a caspase cascade. Mol. Cell 1: 553-
563. 
Li,Q., M.Murphy, J.Ross, C.Sheehan, and J.A.Carlson. 2004. Skp2 and p27kip1 
expression in melanocytic nevi and melanoma: an inverse relationship. J. Cutan. Pathol. 
31: 633-642. 
Liang,J., J.Zubovitz, T.Petrocelli, R.Kotchetkov, M.K.Connor, K.Han, J.H.Lee, S.Ciarallo, 
C.Catzavelos, R.Beniston, E.Franssen, and J.M.Slingerland. 2002. PKB/Akt 
phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 
arrest. Nat. Med. 8: 1153-1160. 
29 
Lisztwan,J., A.Marti, H.Sutterluty, M.Gstaiger, C.Wirbelauer, and W.Krek. 1998. 
Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box 
protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of 
the CDC34-SCF pathway. EMBO J. 17: 368-383. 
Lubetzki,J., C.Roussel, A.Mosse, J.Duprey, A.Warnet, and D.Bargy. 1980. Morphology 
of adipose tissue. Study in 102 obese subjects in reference to some clinical and 
biological criteria (author's transl). Pathol. Biol. (Paris) 28: 17-24. 
Lyss,G., A.Knorre, T.J.Schmidt, H.L.Pahl, and I.Merfort. 1998. The anti-inflammatory 
sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly 
targeting p65. J. Biol. Chem. 273: 33508-33516. 
MacDougald,O.A., P.Cornelius, F.T.Lin, S.S.Chen, and M.D.Lane. 1994. Glucocorticoids 
reciprocally regulate expression of the CCAAT/enhancer-binding protein alpha and delta 
genes in 3T3-L1 adipocytes and white adipose tissue. J. Biol. Chem. 269: 19041-19047. 
Maehama,T. and J.E.Dixon. 1998. The tumor suppressor, PTEN/MMAC1, 
dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. 
J. Biol. Chem. 273: 13375-13378. 
Mamillapalli,R., N.Gavrilova, V.T.Mihaylova, L.M.Tsvetkov, H.Wu, H.Zhang, and H.Sun. 
2001. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor 
p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. 11: 263-267. 
Mandenoff,A., T.Lenoir, and M.Apfelbaum. 1982. Tardy occurrence of adipocyte 
hyperplasia in cafeteria-fed rat. Am. J. Physiol 242: R349-R351. 
Marques,B.G., D.B.Hausman, and R.J.Martin. 1998. Association of fat cell size and 
paracrine growth factors in development of hyperplastic obesity. Am. J. Physiol 275: 
R1898-R1908. 
Marti,A., C.Wirbelauer, M.Scheffner, and W.Krek. 1999. Interaction between ubiquitin-
protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat. 
Cell Biol. 1: 14-19. 
McKeon,C. and T.Pham. 1991. Transactivation of the human insulin receptor gene by 
the CAAT/enhancer binding protein. Biochem. Biophys. Res. Commun. 174: 721-728. 
Medema,R.H., G.J.Kops, J.L.Bos, and B.M.Burgering. 2000. AFX-like Forkhead 
transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. 
Nature 404: 782-787. 
Moberg,K., M.A.Starz, and J.A.Lees. 1996. E2F-4 switches from p130 to p107 and pRB 
in response to cell cycle reentry. Mol. Cell Biol. 16: 1436-1449. 
Mohamed-Ali,V., J.H.Pinkney, and S.W.Coppack. 1998. Adipose tissue as an endocrine 
and paracrine organ. Int. J. Obes. Relat Metab Disord. 22: 1145-1158. 
30 
Mori,M., K.Mimori, T.Shiraishi, S.Tanaka, H.Ueo, K.Sugimachi, and T.Akiyoshi. 1997. 
p27 expression and gastric carcinoma. Nat. Med. 3: 593. 
 
Morosetti,R., N.Kawamata, A.F.Gombart, C.W.Miller, Y.Hatta, T.Hirama, J.W.Said, 
M.Tomonaga, and H.P.Koeffler. 1995. Alterations of the p27KIP1 gene in non-Hodgkin's 
lymphomas and adult T-cell leukemia/lymphoma. Blood 86: 1924-1930. 
Morrison,R.F. and S.R.Farmer. 1999. Role of PPARgamma in regulating a cascade 
expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), 
during adipogenesis. J. Biol. Chem. 274: 17088-17097. 
Mrosovsky,N., P.Nash, and I.M.Faust. 1987. Protection against fat cell hyperplasia in a 
hibernator, Glis glis. Am. J. Physiol 253: R580-R586. 
Naaz,A., D.R.Holsberger, G.A.Iwamoto, A.Nelson, H.Kiyokawa, and P.S.Cooke. 2004. 
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity. 
FASEB J. 18: 1925-1927. 
Nakamura,M., T.Matsuo, J.Stauffer, L.Neckers, and C.J.Thiele. 2003. Retinoic acid 
decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 
phosphorylation and an N-myc-independent decrease in Skp2. Cell Death. Differ. 10: 
230-239. 
Nakayama,K., H.Nagahama, Y.A.Minamishima, M.Matsumoto, I.Nakamichi, K.Kitagawa, 
M.Shirane, R.Tsunematsu, T.Tsukiyama, N.Ishida, M.Kitagawa, K.Nakayama, and 
S.Hatakeyama. 2000. Targeted disruption of Skp2 results in accumulation of cyclin E 
and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 19: 2069-2081. 
Nojima,H., C.Tokunaga, S.Eguchi, N.Oshiro, S.Hidayat, K.Yoshino, K.Hara, N.Tanaka, 
J.Avruch, and K.Yonezawa. 2003. The mammalian target of rapamycin (mTOR) partner, 
raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR 
signaling (TOS) motif. J. Biol. Chem. 278: 15461-15464. 
Oliveira,A.M., S.H.Okuno, A.G.Nascimento, and R.V.Lloyd. 2003. Skp2 protein 
expression in soft tissue sarcomas. J. Clin. Oncol. 21: 722-727. 
Osoegawa,A., I.Yoshino, S.Tanaka, K.Sugio, T.Kameyama, M.Yamaguchi, and 
Y.Maehara. 2004. Regulation of p27 by S-phase kinase-associated protein 2 is 
associated with aggressiveness in non-small-cell lung cancer. J. Clin. Oncol. 22: 4165-
4173. 
Ouchi,N., S.Kihara, T.Funahashi, T.Nakamura, M.Nishida, M.Kumada, Y.Okamoto, 
K.Ohashi, H.Nagaretani, K.Kishida, H.Nishizawa, N.Maeda, H.Kobayashi, H.Hiraoka, 
and Y.Matsuzawa. 2003. Reciprocal association of C-reactive protein with adiponectin in 
blood stream and adipose tissue. Circulation 107: 671-674. 
31 
Pagano,M., S.W.Tam, A.M.Theodoras, P.Beer-Romero, G.Del Sal, V.Chau, P.R.Yew, 
G.F.Draetta, and M.Rolfe. 1995. Role of the ubiquitin-proteasome pathway in regulating 
abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685. 
Palombella,V.J., O.J.Rando, A.L.Goldberg, and T.Maniatis. 1994. The ubiquitin-
proteasome pathway is required for processing the NF-kappa B1 precursor protein and 
the activation of NF-kappa B. Cell 78: 773-785. 
Patel,Y.M. and M.D.Lane. 2000. Mitotic clonal expansion during preadipocyte 
differentiation: calpain-mediated turnover of p27. J. Biol. Chem. 275: 17653-17660. 
Pettersson,P., R.Van, M.Karlsson, and P.Bjorntorp. 1985. Adipocyte precursor cells in 
obese and nonobese humans. Metabolism 34: 808-812. 
Polyak,K., M.H.Lee, H.Erdjument-Bromage, A.Koff, J.M.Roberts, P.Tempst, and 
J.Massague. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a 
potential mediator of extracellular antimitogenic signals. Cell 78: 59-66. 
Porter,P.L., K.E.Malone, P.J.Heagerty, G.M.Alexander, L.A.Gatti, E.J.Firpo, J.R.Daling, 
and J.M.Roberts. 1997. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone 
and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3: 
222-225. 
Qian,X., L.Jin, E.Kulig, and R.V.Lloyd. 1998. DNA methylation regulates p27kip1 
expression in rodent pituitary cell lines. Am. J. Pathol. 153: 1475-1482. 
Reynisdottir,I. and J.Massague. 1997. The subcellular locations of p15(Ink4b) and 
p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 11: 
492-503. 
Richon,V.M., R.E.Lyle, and R.E.McGehee, Jr. 1997. Regulation and expression of 
retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte differentiation. J. Biol. 
Chem. 272: 10117-10124. 
Rodier,G., A.Montagnoli, L.Di Marcotullio, P.Coulombe, G.F.Draetta, M.Pagano, and 
S.Meloche. 2001. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 
and is not a prerequisite for its proteolysis. EMBO J. 20: 6672-6682. 
Rolls,B.J., E.A.Rowe, and R.C.Turner. 1980. Persistent obesity in rats following a period 
of consumption of a mixed, high energy diet. J. Physiol 298: 415-427. 
Rosen,E.D., C.H.Hsu, X.Wang, S.Sakai, M.W.Freeman, F.J.Gonzalez, and 
B.M.Spiegelman. 2002. C/EBPalpha induces adipogenesis through PPARgamma: a 
unified pathway. Genes Dev. 16: 22-26. 
Rothwell,N.J. and M.J.Stock. 1997. A role for brown adipose tissue in diet-induced 
thermogenesis. Obes. Res. 5: 650-656. 
32 
Russo,A.A., P.D.Jeffrey, A.K.Patten, J.Massague, and N.P.Pavletich. 1996. Crystal 
structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 
complex. Nature 382: 325-331. 
Salans,L.B., S.W.Cushman, and R.E.Weismann. 1973. Studies of human adipose 
tissue. Adipose cell size and number in nonobese and obese patients. J. Clin. Invest 52: 
929-941. 
Sanchez-Beato,M., A.I.Saez, J.C.Martinez-Montero, M.M.Sol, L.Sanchez-Verde, 
R.Villuendas, G.Troncone, and M.A.Piris. 1997. Cyclin-dependent kinase inhibitor 
p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the 
proliferative index. Am. J. Pathol. 151: 151-160. 
Seki,R., T.Okamura, H.Koga, K.Yakushiji, M.Hashiguchi, K.Yoshimoto, H.Ogata, 
R.Imamura, Y.Nakashima, M.Kage, T.Ueno, and M.Sata. 2003. Prognostic significance 
of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am. J. Hematol. 
73: 230-235. 
Shapira,M., O.Ben Izhak, S.Linn, B.Futerman, I.Minkov, and D.D.Hershko. 2005. The 
prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal 
carcinoma. Cancer 103: 1336-1346. 
Shen,M.R., Y.M.Hsu, K.F.Hsu, Y.F.Chen, M.J.Tang, and C.Y.Chou. 2006. Insulin-like 
growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and 
proliferation which is modulated by {alpha}v{beta}3 integrin signaling. Carcinogenesis. 
Shin,I., J.Rotty, F.Y.Wu, and C.L.Arteaga. 2005. Phosphorylation of p27Kip1 at Thr-157 
interferes with its association with importin alpha during G1 and prevents nuclear re-
entry. J. Biol. Chem. 280: 6055-6063. 
Shirane,M., Y.Harumiya, N.Ishida, A.Hirai, C.Miyamoto, S.Hatakeyama, K.Nakayama, 
and M.Kitagawa. 1999. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-
mediated degradation and proteolytic processing. J. Biol. Chem. 274: 13886-13893. 
Singh,S.P., J.Lipman, H.Goldman, F.H.Ellis, Jr., L.Aizenman, M.G.Cangi, S.Signoretti, 
D.S.Chiaur, M.Pagano, and M.Loda. 1998. Loss or altered subcellular localization of p27 
in Barrett's associated adenocarcinoma. Cancer Res. 58: 1730-1735. 
Slingerland,J.M., L.Hengst, C.H.Pan, D.Alexander, M.R.Stampfer, and S.I.Reed. 1994. A 
novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested 
epithelial cells. Mol. Cell Biol. 14: 3683-3694. 
Smith,P.J., L.S.Wise, R.Berkowitz, C.Wan, and C.S.Rubin. 1988. Insulin-like growth 
factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J. Biol. 
Chem. 263: 9402-9408. 
Spirin,K.S., J.F.Simpson, S.Takeuchi, N.Kawamata, C.W.Miller, and H.P.Koeffler. 1996. 
p27/Kip1 mutation found in breast cancer. Cancer Res. 56: 2400-2404. 
33 
St Croix,B., V.A.Florenes, J.W.Rak, M.Flanagan, N.Bhattacharya, J.M.Slingerland, and 
R.S.Kerbel. 1996. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance 
of tumor cells to anticancer agents. Nat. Med. 2: 1204-1210. 
Steinberg,M.D., W.Zingg, and A.Angel. 1962. Studies of the number and volume of fat 
cells in adipose tissue. J. Pediatr. 61: 299-300. 
Stewart,S.A., D.Kothapalli, Y.Yung, and R.K.Assoian. 2004. Antimitogenesis Linked to 
Regulation of Skp2 Gene Expression. J. Biol. Chem. 279: 29109-29113. 
Sutterluty,H., E.Chatelain, A.Marti, C.Wirbelauer, M.Senften, U.Muller, and W.Krek. 
1999. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. 
Nat. Cell Biol. 1: 207-214. 
Tan,P., B.Cady, M.Wanner, P.Worland, B.Cukor, C.Magi-Galluzzi, P.Lavin, G.Draetta, 
M.Pagano, and M.Loda. 1997. The cell cycle inhibitor p27 is an independent prognostic 
marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 57: 1259-1263. 
Tang,Q.Q., M.S.Jiang, and M.D.Lane. 1999. Repressive effect of Sp1 on the 
C/EBPalpha gene promoter: role in adipocyte differentiation. Mol. Cell Biol. 19: 4855-
4865. 
Tang,Q.Q. and M.D.Lane. 1999. Activation and centromeric localization of 
CCAAT/enhancer-binding proteins during the mitotic clonal expansion of adipocyte 
differentiation. Genes Dev. 13: 2231-2241. 
Tang,Q.Q., T.C.Otto, and M.D.Lane. 2003. Mitotic clonal expansion: a synchronous 
process required for adipogenesis. Proc. Natl. Acad. Sci. U. S. A 100: 44-49. 
Tang,Q.Q., J.W.Zhang, and L.M.Daniel. 2004. Sequential gene promoter interactions of 
C/EBPbeta, C/EBPalpha, and PPARgamma during adipogenesis. Biochem. Biophys. 
Res. Commun. 319: 235-239. 
Tedesco,D., J.Lukas, and S.I.Reed. 2002. The pRb-related protein p130 is regulated by 
phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). 
Genes Dev. 16: 2946-2957. 
Thrower,J.S., L.Hoffman, M.Rechsteiner, and C.M.Pickart. 2000. Recognition of the 
polyubiquitin proteolytic signal. EMBO J. 19: 94-102. 
Todaro,G.J. and H.Green. 1963. Quantitative studies of the growth of mouse embryo 
cells in culture and their development into established lines. J. Cell Biol. 17: 299-313. 
Tomoda,K., Y.Kubota, Y.Arata, S.Mori, M.Maeda, T.Tanaka, M.Yoshida, N.Yoneda-
Kato, and J.Y.Kato. 2002. The cytoplasmic shuttling and subsequent degradation of 
p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J. Biol. Chem. 
277: 2302-2310. 
34 
Toyoshima,H. and T.Hunter. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase 
activity, is related to p21. Cell 78: 67-74. 
Tremblay,F., A.Gagnon, A.Veilleux, A.Sorisky, and A.Marette. 2005. Activation of the 
mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and 
glucose transport in 3T3-L1 and human adipocytes. Endocrinology 146: 1328-1337. 
Tsihlias,J., L.R.Kapusta, G.DeBoer, I.Morava-Protzner, I.Zbieranowski, N.Bhattacharya, 
G.C.Catzavelos, L.H.Klotz, and J.M.Slingerland. 1998. Loss of cyclin-dependent kinase 
inhibitor p27Kip1 is a novel prognostic factor in localized human prostate 
adenocarcinoma. Cancer Res. 58: 542-548. 
Tsvetkov,L.M., K.H.Yeh, S.J.Lee, H.Sun, and H.Zhang. 1999. p27(Kip1) ubiquitination 
and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 
in p27. Curr. Biol. 9: 661-664. 
Viglietto,G., M.L.Motti, P.Bruni, R.M.Melillo, A.D'Alessio, D.Califano, F.Vinci, 
G.Chiappetta, P.Tsichlis, A.Bellacosa, A.Fusco, and M.Santoro. 2002. Cytoplasmic 
relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by 
PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8: 1136-1144. 
von der,L.N., S.Johansson, S.Wu, F.Bahram, A.Castell, C.Cetinkaya, P.Hydbring, 
I.Weidung, K.Nakayama, K.I.Nakayama, O.Soderberg, T.K.Kerppola, and L.G.Larsson. 
2003. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts 
as a cofactor for c-Myc-regulated transcription. Mol. Cell 11: 1189-1200. 
Wang,I.C., Y.J.Chen, D.Hughes, V.Petrovic, M.L.Major, H.J.Park, Y.Tan, T.Ackerson, 
and R.H.Costa. 2005. Forkhead box M1 regulates the transcriptional network of genes 
essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin 
ligase. Mol. Cell Biol. 25: 10875-10894. 
Wang,W., D.Ungermannova, J.Jin, J.W.Harper, and X.Liu. 2004. Negative regulation of 
SCFSkp2 ubiquitin ligase by TGF-beta signaling. Oncogene 23: 1064-1075. 
Weber,J.D., D.M.Raben, P.J.Phillips, and J.J.Baldassare. 1997. Sustained activation of 
extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression 
of cyclin D1 in G1 phase. Biochem. J. 326 ( Pt 1): 61-68. 
Wei,W., N.G.Ayad, Y.Wan, G.J.Zhang, M.W.Kirschner, and W.G.Kaelin, Jr. 2004. 
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-
promoting complex. Nature 428: 194-198. 
Wirbelauer,C., H.Sutterluty, M.Blondel, M.Gstaiger, M.Peter, F.Reymond, and W.Krek. 
2000. The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin 
ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in 
quiescent fibroblasts. EMBO J. 19: 5362-5375. 
35 
Wu,Z., N.L.Bucher, and S.R.Farmer. 1996. Induction of peroxisome proliferator-activated 
receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by 
C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol. Cell Biol. 16: 4128-4136. 
Wu,Z., Y.Xie, R.F.Morrison, N.L.Bucher, and S.R.Farmer. 1998. PPARgamma induces 
the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during 
the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest 101: 22-32. 
Yam,C.H., R.W.Ng, W.Y.Siu, A.W.Lau, and R.Y.Poon. 1999. Regulation of cyclin A-
Cdk2 by SCF component Skp1 and F-box protein Skp2. Mol. Cell Biol. 19: 635-645. 
Yang,G., G.Ayala, A.De Marzo, W.Tian, A.Frolov, T.M.Wheeler, T.C.Thompson, and 
J.W.Harper. 2002. Elevated Skp2 protein expression in human prostate cancer: 
association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with 
reduced recurrence-free survival. Clin. Cancer Res. 8: 3419-3426. 
Yang,M.U., E.Presta, and P.Bjorntorp. 1990. Refeeding after fasting in rats: effects of 
duration of starvation and refeeding on food efficiency in diet-induced obesity. Am. J. 
Clin. Nutr. 51: 970-978. 
Yeh,W.C., B.E.Bierer, and S.L.McKnight. 1995. Rapamycin inhibits clonal expansion and 
adipogenic differentiation of 3T3-L1 cells. Proc. Natl. Acad. Sci. U. S. A 92: 11086-
11090. 
Young,R.A., L.B.Salans, and E.A.Sims. 1982. Adipose tissue cellularity in woodchucks: 
effects of season and captivity at an early age. J. Lipid Res. 23: 887-892. 
Zabludoff,S.D., M.Csete, R.Wagner, X.Yu, and B.J.Wold. 1998. p27Kip1 is expressed 
transiently in developing myotomes and enhances myogenesis. Cell Growth Differ. 9: 1-
11. 
Zhang,H., R.Kobayashi, K.Galaktionov, and D.Beach. 1995. p19Skp1 and p45Skp2 are 
essential elements of the cyclin A-CDK2 S phase kinase. Cell 82: 915-925. 
Zhang,H., I.Ozaki, T.Mizuta, T.Yoshimura, S.Matsuhashi, A.Hisatomi, J.Tadano, 
T.Sakai, and K.Yamamoto. 2003a. Mechanism of beta 1-integrin-mediated hepatoma 
cell growth involves p27 and S-phase kinase-associated protein 2. Hepatology 38: 305-
313. 
Zhang,J.W., Q.Q.Tang, C.Vinson, and M.D.Lane. 2004. Dominant-negative C/EBP 
disrupts mitotic clonal expansion and differentiation of 3T3-L1 preadipocytes. Proc. Natl. 
Acad. Sci. U. S. A 101: 43-47. 
Zhang,L. and C.Wang. 2005. F-box protein Skp2: a novel transcriptional target of E2F. 
Oncogene. 
Zhang,Y.W., M.Kaneda, and I.Morita. 2003b. The gap junction-independent tumor-
suppressing effect of connexin 43. J. Biol. Chem. 278: 44852-44856. 
36 
Zhang,Y.W., K.Nakayama, K.Nakayama, and I.Morita. 2003c. A novel route for connexin 
43 to inhibit cell proliferation: negative regulation of S-phase kinase-associated protein 
(Skp 2). Cancer Res. 63: 1623-1630. 
Zuo,Y., L.Qiang, and S.R.Farmer. 2006. Activation of C/EBPalpha expression by 
C/EBPbeta during adipogenesis requires a PPARgamma-associated repression of 




SKP2-MEDIATED p27(KIP1) DEGRADATION DURING S/G2 PHASE  





 Determining mechanisms responsible for preadipocyte replication is vital to 
understanding the etiology of hyperplastic obesity. Here we demonstrate that protein 
accumulation of the cyclin dependent kinase inhibitor, p27(Kip1), decreased modestly in 
mid-G1, precipitously near the G1/S transition, and maximally during G2 phase 
progression of 3T3-L1 preadipocyte clonal expansion. The dramatic changes in p27 
protein accumulation resulted from post-transcriptional mechanisms involving elevated 
protein degradation. Specific proteasome inhibitors, epoxomicin and lactacystin, 
completely abolished p27 degradation and S phase progression resulting in G1 arrest. It 
is further demonstrated that p27 was phosphorylated on threonine 187 during S phase 
progression by Cdk2 and that phosphorylated p27 was polyubiquitylated and degraded. 
Data are also presented demonstrating increased protein accumulation of the F-box, 
Skp2, and accessory protein, Cks1, which peaked during G2 phase coordinate with the 
maximal decrease in p27 protein levels. A direct role for Skp2 in p27 degradation was 
demonstrated with Skp2 specific RNA interference. It is also demonstrated that while 
specific inhibition of Cdk2 activity with Roscovitine completely blocked S phase 
progression and p27 (Thr187) phosphorylation and ubiquitylation, the loss of Cdk2 
activity only partially prevented p27 degradation. Consistent with this observation, 
complete Skp2 knockdown did not completely prevent p27 degradation, suggesting that 
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other proteasome-dependent mechanisms contributed to p27 degradation during cell 
cycle progression. We also demonstrate that Skp2 knockdown had no effect on S phase 
progression suggesting that Skp2-mediated p27 degradation was not essential for G1/S 
transition as quiescent preadipocytes reenter the cell cycle. Finally, evidence is 
presented suggesting that increased p27 inhibitory activity resulting from elevated p27 
protein in the absence of Skp2 may have been neutralized by sequestration of p27 
protein by Cyclin D1/Cdk4 complexes. Considering the kinetics of Cdk2 activation, p27 
(Thr187) phosphorylation, and Skp2 and Cks1 protein accumulation, we propose that 
p27 phosphorylation and ubiquitylation by the SCFSkp2 E3 ligase is mechanistically 




 Obesity develops through an expansion of adipose tissue mass resulting from 
enlargement of adipocyte size (hypertrophy) and cell number (hyperplasia). As mature 
adipocytes are terminally differentiated and resistant to cell division, adipocyte 
hyperplasia generally refers to proliferation and subsequent differentiation of adipocyte 
precursor cells or ‘preadipocytes’ (Hausman et al., 2001). Preadipocyte replication is 
accelerated at birth and puberty then slows to provide a constant ratio of preadipocytes 
to adipocytes in adulthood as long as body weight remains constant. Adipocyte 
hyperplasia, however, plays a critical role in the onset of obesity throughout all stages of 
childhood development and in adults under morbid conditions. Despite evidence 
indicating that the most severe forms of obesity with the poorest prognosis of treatment 
are associated adipocyte hyperplasia (Hirsch et al., 1989;Bjorntorp et al., 1982;Bonnet, 
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1981;Hausman et al., 2001), mechanisms regulating preadipocyte proliferation remain 
largely unknown.  
 A key question with regard to adipocyte hyperplasia concerns the mechanism by 
which preadipocytes undergo the transition from quiescence to proliferation. The 
decision of mammalian cells to replicate involves the convergence of mitogen-dependent 
signaling pathways on a series of cyclin-dependent kinases (Cdks) that function to 
mediate orderly cell cycle progression. Cells become mitogen-independent near the 
G1/S phase transition following activation of Cdk2, subsequent phosphorylation of the 
retinoblastoma protein, and initiation of E2F transcriptional activity promoting S phase 
gene expression. As progression beyond this restriction point is independent of mitogen 
availability, activation of Cdk2 activity during late G1 and S phase represents a pivotal 
and decisive point of autonomous cell cycle control.  
 Numerous lines of evidence have established the removal of p27 (Kip1) inhibitory 
activity as rate limiting for Cdk2 activation. Elevated p27 protein resulting from serum 
deprivation, density arrest, and terminal differentiation ensures cell cycle arrest in G1 
phase and subsequent entry into the G0 state of quiescence. Under growth promoting 
conditions, p27 protein levels decrease modestly during mid-G1 and precipitously near 
the G1/S phase transition. Ectopic p27 expression unequivocally inhibits Cdk2 activity 
resulting in cell cycle arrest in G1 (Polyak et al., 1994;Toyoshima and Hunter, 1994). 
Conversely, reduction of p27 protein increases the number of cells that enter S phase 
(Coats et al., 1996). Moreover, p27 gene ablation yields larger than normal mice with 
marked organomegaly as well as increased adipocyte number relative to wildtype mice 
(Naaz et al., 2004). Gene ablation of both p27 and p21(Cip1), another member of the 
Cip/Kip family of cyclin dependent kinase inhibitors (CKIs), results in a phenotype of 
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severe obesity, metabolic abnormalities, and more than a 5-fold increase in adipocyte 
number (Naaz et al., 2004).  
 While much attention has focused on regulation of p27 activity through changes 
in protein accumulation by post-transcriptional mechanisms involving protein 
degradation, the complexity of this process was underscored by recent reports 
suggesting that p27 protein proteolysis is regulated by distinct mechanisms during 
different phases of the cell cycle. During S and G2 phases, the process of targeted 
degradation begins with Cdk2 phosphorylation of p27 (Sheaff et al., 1997;Vlach et al., 
1997) on a threonine residue (Thr187) that promotes binding of nuclear SCFSkp2 
(Skp1/Cul1/Rbx1/F-Box Protein; the superscript denotes the F-box protein) E3 ligase. 
Upon assembly, this complex mediates covalent modification of a polyubiquitin chain 
that targets p27 for degradation by the 26S proteasome (Carrano et al., 1999;Sutterluty 
et al., 1999;Tsvetkov et al., 1999). During G1 phase progression, proteasome-dependent 
p27 degradation appears to involve the cytosolic ubiquitin E3 ligase, KPC (Kip1 
Ubiquitination-Promoting Complex). In addition to being localized to a different 
compartment, KPC mediates ubiquitylation of p27 independent of Thr187 
phosphorylation and Skp2 interaction (Kamura et al., 2004). Other p27 degradation 
mechanisms have also been described including proteolytic processing (Shirane et al., 
1999) and degradation by non-lysosomal calpains (Delmas et al., 2003;Patel and Lane, 
2000) and caspase-dependent pathways (Levkau et al., 1998;Loubat et al., 1999;Eymin 
et al., 1999). In addition, p27 levels can be regulated by transcriptional (Kops et al., 
2002) and translational (Hengst and Reed, 1996) mechanisms. Furthermore, p27 activity 
can be modulated through sequestration by Cyclin D-Cdk4/6 complexes (Perez-Roger et 
al., 1999).  
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 Considering the pivotal role p27 plays in cell cycle progression and the diversity 
of cell-type and condition-specific mechanisms regulating its inhibitory activity, we 
explored phase specific mechanisms regulating p27 protein accumulation during cell 
cycle progression of murine 3T3-L1 preadipocytes as a model of adipocyte hyperplasia. 
When grown to a state of density arrest, these quiescent preadipocytes synchronously 
reenter the cell cycle for 1-2 rounds of cell proliferation following exposure to a hormonal 
cocktail of methylisobutylxanthine, dexamethasone, and insulin (MDI). This period of cell 
cycle progression, referred to as ‘mitotic clonal expansion’, is a prerequisite for 
differentiation of this cell line and precedes the irreversible growth arrest that 
characterizes terminal differentiation. In this report, we demonstrate that p27 protein 
levels decrease during G1-S-G2 phase transitions of 3T3-L1 mitotic clonal expansion by 
elevated protein degradation mechanisms involving the 26S proteasome. In addition, 
data presented here document p27 phosphorylated on Thr187 by Cdk2 during S phase 
is targeted for ubiquitylation. Moreover, we demonstrate that preadipocyte replication is 
characterized by increased Skp2 and Cks1 protein levels with maximal accumulation 
occurring concomitantly with decreased p27 levels during S and G2 phases of mitotic 
clonal expansion. Finally, using RNA interference for Skp2, we demonstrate a role for 
the SCFSkp2 E3 ligase in mediating p27 turnover during S and G2 phases of the cell 
cycle.  
 
MATERIALS AND METHODS 
 Materials - Dulbecco's Modified Eagle's Medium (DMEM) was purchased from 
Cellgro by Mediatech.  Bovine Serum, Fetal Bovine Serum (FBS), and Trypsin-EDTA 
were from Invitrogen Corporation. Propidium Iodide and RNase A was purchased from 
42 
Sigma.  Chemical inhibitors were purchased from the following: Epoxomicin, Lactacystin 
(Boston Biochem), Cyclohexamide (Sigma), Roscovitine (Calbiochem), LY294002 
(Promega), Leptomycin B (Sigma), PP1 (New England Biolabs).  Enhanced 
chemiluminescence (ECL) reagents were from PerkinElmer Life Sciences.   
 
 Cell Culture and Differentiation - Murine 3T3-L1 preadipocytes were propagated 
in growth medium containing DMEM supplemented with 10% calf bovine serum as 
described previously (Morrison and Farmer, 1999).  By standard differentiation protocol, 
preadipocytes were propagated in growth medium until reaching a state of density arrest 
at 2 days post-confluence. Growth medium was replaced at density arrest with 
differentiation medium comprised of DMEM supplemented with 10% fetal bovine serum 
(FBS), 0.5 mM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, and 1.7 µM insulin 
(MDI).  The term "post-MDI" refers to the time elapsed since the addition of MDI to the 
culture medium. At 2 days post-MDI, medium was changed to DMEM supplemented with 
10% FBS and 0.4 µM insulin. From 4 days post-MDI until harvest, maintenance medium 
containing DMEM supplemented only with 10% FBS was changed every 48 hrs.  
Throughout the study, "time 0" refers to density arrested cells immediately before 
chemical induction of differentiation with the addition of MDI to the culture medium. 
Experiments described herein were conducted within the period of differentiation 
spanning from density arrest (0 hr) through 32 hrs post-MDI. All experiments were 
repeated three to five times to validate results and ensure reliability. 
 
 Flow Cytometry - Cell cycle progression was assessed by flow cytometry. Briefly, 
cell monolayers were washed with phosphate-buffered saline (PBS), trypsinized, and 
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detached cells diluted in ice cold PBS to produce a single cell suspension. Cells were 
gently pelleted by centrifugation (300 x g, 5 min). Following centrifugation, PBS was 
decanted and cells were fixed and permeabilized by drop-wise addition of 70% ethanol 
at -20°C while vortexing. Fixed cells were incubated on ice for 30 minutes or stored at     
-20˚C for no more than one week before processing. Fixed cells were washed 2x with 
PBS and incubated in the dark for 30 minutes with 1ml propidium iodide staining solution 
containing 50 µg/ml propidium iodide (PI) and 100 µg/ml RNase A in PBS.  DNA 
fluorescence was measured with a FACS Calibur Flow Cytometer (Becton Dickinson) 
equipped with a 488-nm argon laser. Width (FL2W) and area (FL2A) of PI fluorescence 
was recorded for at least 10,000 counts. DNA histograms were extracted from FL2W-
FL2A dot plots after gating to eliminate aggregates. The percentage of cells in each 
phase of the cell cycle was analyzed using ModFit software (Verity). 
 
 Immunoblotting - Cell monolayers were washed with PBS and scraped into ice 
cold lysis buffer containing 1.0 M Tris, pH 7.4, 150 mM NaCl, 1% Triton X, 0.5% Nonidet 
P-40, 1 mM EDTA, 1 mM EGTA, and 10 mM N-ethylmaleimide (NEM). Lysis buffer was 
freshly supplemented with phosphatase inhibitors; 20mM β-glycerophosphate, 10mM 
NaFl, and 2 µM sodium vanadate, as well as protease inhibitors; 0.3  µM aprotonin, 21 
µM leupeptin, E-64, 1 µM pepstatin, 50 µM phenanthroline, 0.5 µM phenylmethylsulfonyl 
fluoride. Cell lysates were clarified by centrifugation (13,000 x g, 10 min, 4°C) and 
protein concentration was determined by BCA assay (Pierce). Lysates were 
resuspended in loading buffer containing 0.25 M Tris, pH 6.8, 4% SDS, 10% glycerol, 
10% dithiotreitol, 0.01% bromophenol blue, heated for 5 mins at 80°C, and placed on 
ice. Lysates were resolved on SDS-PAGE gels and transferred to polyvinylidene fluoride 
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membranes (Millipore).  Following transfer, membranes were blocked with 4% milk and 
probed with indicated primary antibodies overnight at 4°C and horseradish peroxidase-
conjugated secondary antibodies for 1 hr at room temperature. Immunoblots were 
developed with ECL and visualized by autoradiography CL-XPosure film (Pierce).  
 
 Immunoprecipitation – Cell monolayers were washed with PBS and scraped into 
ice cold precipitation buffer containing 10mM Tris pH 7.4, 150mM NaCl, 1% Triton X, 
0.5% NP40, 1mM EDTA, 1mM EGTA, 10mM NEM. Phosphatase/protease inhibitors 
were freshly added as discussed above. Cell lysates were clarified by centrifugation 
(13,000 x g, 10 min, 4°C) and protein concentration was determined by BCA assay 
(Pierce). Lysates (500 µg) were incubated with primary antibody for 3 hr at 4°C with 
rotation. Protein G Magnetic Beads (New England Biolabs) were added to each sample 
and incubated for an additional 1 hr at 4°C. Immune complexes were collected by brief 
centrifugation (13,000 x g, 2 min, 4°C) and washed 3x with ice cold precipitation buffer. 
Complexes were resuspended in loading buffer, resolved on SDS-PAGE gels, and 
immunoblotted as discussed above. 
 
 RNA Isolation and Analysis - Total RNA was extracted using the RNeasy Mini Kit 
(QIAGEN) according to manufacturer’s instructions.  Total RNA (1µg) was subjected to 
Reverse-Transcriptase Polymerase Chain Reaction using One-Step RT-PCR kit 
(QIAGEN) according to manufacturer’s instruction.  Briefly, RT-PCR reactions were 
carried out in the presence of the supplied buffer, dNTPs (400 µM), enzyme mix (reverse 
transcriptases and DNA polymerase), and RNase inhibitor (10 U).  Gene specific primers 
were used at a final concentration of 0.6 µM and designed as follows: p27(Kip1) forward, 
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5΄-CGCTTTTGTTCGGTTTTGTT-3΄; p27 reverse, 5΄-TTCGGAGCTGTTTACGTCTG-3΄ 
(product size = 690 bp). QuantamRNA Classic and Classic II 18S primer/competimers 
(Ambion) were used in the reactions as internal standards at a final concentration of 0.6 
µM according to manufacturer’s instruction. 
 
 RNA interference (RNAi) - SMARTpools of short interfering RNAs (siRNAs) for 
non-targeting sequences and Skp2 specific sequences (Dharmacon) were transfected 
using electroporation (Amaxa).  Briefly, 80% confluent monolayers were trypsinized and 
2.5 x 106 cells resuspended in Nucleofector V solution (Amaxa) supplemented with 
siRNA oligos according to manufacturer’s instructions. Cells were electroporated using 
program T20, transferred to pre-warmed growth medium and incubated at 37°C for no 
more than 10 minutes. Cells were than replated at a confluent density and fresh 
proliferation media replaced 24 hours post-transfection. Optimization with pmaxGFP 




 Changes in p27 protein abundance relative to cell cycle phase transitions. 
While it is generally accepted that Cdk2 driven G1/S phase transition is dependent on 
obligatory suppression of p27 activity, numerous phase-specific mechanisms regarding 
p27 inhibition have recently been described. To determine how p27 is regulated relative 
to cell cycle progression of replicating preadipocytes, we first determined the kinetics of 
phase transition with flow cytometric DNA analysis. Preadipocytes were propagated until 
reaching saturation density and maintained in growth medium containing 10% calf serum 
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until 2 days post-confluence. Density-arrested preadipocytes were stimulated to re-enter 
the cell cycle by switching to differentiation medium containing 10% FBS supplemented 
with MDI. Cells were harvested over time following exposure to MDI, stained with 
propidium iodide, and analyzed for DNA content. As illustrated in Figure 2.1A, all 
histograms displayed two DNA peaks in the 2n and 4n range representing G0/G1 and 
G2/M cell populations, respectively. No significant apoptotic or polyploidy cells were 
noted. DNA histograms were analyzed with ModFit software (Becton Dickinson) to 
determine the distribution of cells in each phase of the cell cycle. As graphically 
illustrated in Figure 2.1B, 88% of density-arrested preadipocytes presented with 
G0/G1DNA content prior to stimulation (0hr post-MDI), with remaining 12% partitioned 
equally between S and G2/M phases. Following exposure to MDI, cells progressively 
moved through G1/S and S/G2 phase transitions at 15 hrs and 19 hrs, respectively. Peak 
S (64%) and G2/M (54%) phases were observed at 17 hrs and 21 hrs, respectively. 
Within 32 hrs following MDI treatment, 82% of the cell population again exhibited G0/G1 
phase DNA content demonstrating the synchronous completion of one cell cycle. These 
estimations of the kinetics of phase transition of 3T3-L1 preadipocytes during clonal 
expansion are consistent with those obtained over time following subconfluent replating 
of density-arrested NIH3T3 fibroblasts (Shirane et al., 1999). 
 To analyze cell cycle protein abundance with respect to phase transition, total 
soluble protein was harvested under identical conditions employed in Figure 2.1A, 
resolved with SDS-Page, and immunoblotted with various anti-cyclin and p27 antibodies. 
The first lane of Figure 2.1C, representing the protein profile of proliferating 
preadipocytes (PPA) at ~70% confluence, illustrates that Cyclin D1 was the only protein 
examined showing modest accumulation under asynchronous, subconfluent growth 
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conditions. As cells reached two days post-confluence (0 hr), a divergent profile was 
observed with minimal and maximal accumulation of cyclin proteins and p27, 
respectively, providing further evidence that this condition represented a G0/G1 state of 
density-induced growth arrest. Following MDI stimulation, Cyclin D1 rapidly 
accumulated, peaked during mid-G1 and progressively decreased during S and G2/M 
phases. The onset of Cyclin A and Cyclin B1 accumulation marked the transition through 
S and G2 phases, respectively, with both declining abruptly during late G2/M phase. The 
abundant accumulation of p27 protein observed during density arrest progressively 
declined throughout the cell cycle with 72% and 55% of maximal levels remaining at 12 
hrs (mid-G1 phase) and 16 hrs (G1/S transition) post-MDI, respectively.  Peak decline in 
p27 protein abundance, however, was not observed until 22 hrs post-MDI coordinate 
with G2/M phase progression with 35% of maximal abundance remaining. Comparing 
peak accumulation in cyclin protein levels following MDI stimulation with subconfluent 
proliferating preadipocytes (PPA) clearly illustrates the synchrony in which these density-
arrested preadipocytes reentered and progressed through the cell cycle. Collectively, 
these data demonstrate that synchronous cell cycle progression correlates with a 
marked decline in p27 protein accumulation that began in mid-G1 and peaked during 
G2/M with a 65% decrease in p27 relative to maximal levels observed during density 
arrest. 
 Increased rate of p27 protein degradation. To determine the mechanism by 
which p27 protein abundance decreased during clonal expansion, total soluble protein 
and RNA were harvested at 0 hr and 20 hr post-MDI and subjected to immunoblotting 
and RT-PCR analysis of p27 protein and mRNA, respectively. As an internal control, 
18S ribosomal RNA was determined concurrently in the same PCR reaction using 
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competimer technology. Densitometric analysis of representative findings depicted in 
Figure 2.2A is illustrated in Figure 2.2B. Stimulation of density-arrested 3T3-L1 
preadipocytes with MDI resulted in a decrease in p27 protein accumulation to 35% of 
maximal abundance by 20 hrs with no change in mRNA demonstrating the involvement 
of a posttranscriptional event. To further categorize the mechanism, density-arrested 
cells were cultured with and without MDI for 18 hrs. At that point, protein synthesis was 
blocked with 30 µM cycloheximide. Total soluble protein was harvested over time and 
immunoblotted for p27 to examine the rate of protein decay. As shown in Figure 2.2C, 
MDI stimulation resulted in a 2-fold increase in p27 protein turnover (t1/2) with 6.42 hrs 
and 3.25 hrs representing the half life of p27 during density arrest (G0/G1) and G2/M 
phase, respectively. Estimations of p27 protein stability are consistent with other reports 
(Beniston and Campo, 2003). These data collectively demonstrate that the change in 
p27 protein abundance during cell cycle progression of replicating preadipocytes 
involves posttranscriptional events that include mechanisms mediating changes in 
protein degradation.  
 Proteasome-dependent p27 degradation. Multiple mechanisms involving p27 
degradation during cell cycle progression have been described including proteolytic 
processing, as well as calpain and proteasome mediated degradation. To determine 
what role the proteasome plays in regulating p27 degradation during preadipocyte clonal 
expansion, we tested the effects of two potent, highly selective, irreversible, cell 
permeable, and structurally distinct proteasome inhibitors, epoxomicin and lactacystin. 
Both compounds inhibit all three major proteolytic activities of the 20S catalytic core of 
the 26S proteasome: chymotrypsin-like, trypsin-like, and peptidyl-glutamyl peptide 
hydrolyzing (PGPH) activity (Meng et al., 1999;Kim et al., 1999;Fenteany et al., 1995). 
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Unlike many proteasome inhibitors, however, both epoxomicin and lactacystin do not 
inhibit other common proteases such as trypsin, chymotrypsin, papain, cathespin B, and 
calpain at concentrations up to 50 µM for epoxomicin (Sin et al., 1999) and 100 µM for 
lactacystin (Fenteany et al., 1995). The observation that the inhibitory concentration of 
epoxomicin was 25 times less than that for lactacystin (IC50 of 80 nM and 2 µM, 
respectively) is consistent with other reports demonstrating that epoxomicin is a more 
potent inhibitor of chymotrypsin-like activity than lactacystin (Meng et al., 1999).  As 
proteasome proteolytic activity is known to play a permissive role in G1-to-S phase 
progression, we first tested the effects of either inhibitor on S phase progression 
following MDI stimulation of density-arrested preadipocytes. As illustrated in Figure 2.3A, 
epoxomicin (1µM) or lactacystin (10µM), supplemented with MDI, completely abolished 
S phase progression 20hrs following MDI stimulation with greater than 91% of the cells 
not exiting the G0/G1 phase of the cell cycle. Cell morphology (not shown) and DNA 
histograms presented no evidence of apoptosis or cellular stress during this limited 
exposure of either inhibitor.  
 We subsequently tested both epoxomicin and lactacystin for their ability to 
suppress p27 degradation during preadipocyte replication. Density-arrested 
preadipocytes were stimulated with MDI in the absence or presence of either 
proteasome inhibitor over a range of concentrations given concomitantly with MDI. As 
shown in Figure 2.3B, both epoxomicin and lactacystin potently inhibited the degradation 
of p27 in a concentration dependent fashion. The effect was selective for degradation as 
a constitutively expressed protein, Skp1, was completely unaffected. Densitometric 
values of accumulated p27 resulting from each inhibitor were normalized to the level of 
p27 abundance at 20hrs post-MDI in the absence of inhibitor and logarithmically plotted 
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against inhibitor concentration (Figure 2.3C). The 50% inhibitory concentration (IC50) 
was estimated at 80 nM for epoxomicin and 2 µM for lactacystin. Maximal suppression of 
p27 degradation by epoxomicin and lactacystin was estimated at 0.3 µM and 10 µM, 
respectively. 
 Ubiquitylation of p27 during Preadipocyte Replication.  A polyubiquitin chain 
formed through isopeptide bonds involving the ε-amino group of internal lysine residues 
of four or more ubiquitin molecules and a protein substrate selectively targets the 
substrate to the 26S proteasome for degradation. As the decay in p27 protein is a 
function of cell cycle progression, proteasome specific inhibitors, such as epoxomicin 
and lactacystin, could prevent polyubiquitylated p27 degradation directly by blocking the 
catalytic activity of the 20S core or indirectly by blocking ‘phase-specific’ signaling 
necessary for ubiquitin ligase activity and/or other ubiquitin-unrelated proteolytic 
processes (e.g., calpain) directed toward p27. To determine a specific role for p27 
ubiquitylation during preadipocyte replication, we examined the relative abundance and 
kinetics of accumulated unmodified p27 as well as ubiquitylated p27 (p27-Ub) following 
proteasome blockade during the course of cell cycle progression. As ubiquitin-modified 
proteins are difficult to detect due to rapid removal of the ubiquitin chain by endogenous 
de-ubiquitylating isopeptidases (Figure 2.4A), the isopeptidase inhibitor N-
ethylmaleimide (NEM) was included in the lysis buffer of all samples to minimize p27 de-
ubiquitylation during cell lysis. 
 Density-arrested preadipocytes were treated with medium containing MDI 
supplemented with and without 1 µM epoxomicin. Cell lysates were harvested at 
designated times post-MDI and immunoblotted for p27 and Skp1 (Figure 2.4B). In the 
absence of epoxomicin, p27 protein abundance decreased to 75%, 55%, and 35% of 
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unstimulated levels by 12 hrs (mid-G1), 16hrs (G1-to-S phase transition), and 20hrs 
(G2/M phase) post-MDI, respectively. When comparing unstimulated (0hr) protein 
abundance with that observed for any time point post-MDI, it is clearly evident that 
epoxomicin completely abolished the decline in p27 protein abundance during all phases 
of cell cycle progression. Inhibition of p27 decay as early as 8 hrs post-MDI also 
demonstrates sensitivity to proteasomal blockade at a point during mid-G1 significantly 
preceding G1-to-S phase transition. Of additional interest, epoxomicin treatment not only 
prevented the decay in p27 protein, it also resulted in an increase in unmodified p27 
protein accumulation above unstimulated levels (0hr) that plateaued by 12 hrs post-MDI 
and remained constant throughout 20 hrs of epoxomicin treatment. Finally, it is important 
to note that epoxomicin had no effect on Skp1 protein accumulation demonstrating the 
selectivity of proteasomal blockade toward p27 degradation. 
 Using the same experimental paradigm as described in Figure 2.4B, the kinetics 
and pattern of p27 ubiquitylation was examined by extended exposure of direct 
immunoblotting analysis of p27. As illustrated in Figure 2.4C, we consistently observed 
four or more p27 immunoreactive bands that migrated slower than unmodified p27 
following epoxomicin treatment. These distinct bands (labeled with reverse text) likely 
represent ubiquitin modified p27 for the following reasons. Firstly, the intensity of the 
bands significantly and continuously increased with time following epoxomicin treatment 
of MDI-stimulated cells. Secondly, the mass of each band is consistent with the 
consecutive addition of 8 kDa ubiquitin moieties to unmodified p27 (i.e., 35, 43, 51, 59, 
and 67 kDa). Thirdly, these slower migrating bands were less evident in the absence of 
NEM in the lysis buffer (not shown). Fourthly, the in vivo ubiquitylation pattern reported 
here is consistent with numerous reports of in vitro p27 ubiquitylation under defined 
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conditions reported elsewhere.  With these assumptions, ubiquitin-modified p27 was 
minimally visible by 8 hrs of MDI stimulation in the presence of proteasomal blockade 
and continued to increase unequivocally with each 4 hrs of epoxomicin exposure. Cell 
cycle progression in the absence of epoxomicin resulted in slight, but marked increased 
accumulation of ubiquitylated p27 protein by 20-24 hrs post-MDI. These data 
demonstrate that ubiquitylation is among the proteasome-dependent mechanisms 
regulating p27 degradation during preadipocyte replication. 
 Reciprocal accumulation of Skp2/Cks1 with p27 degradation. Skp2-
dependent, as well as independent, mechanisms involving p27 ubiquitylation and 
proteasomal degradation have been described. To explore a role for Skp2 in p27 
ubiquitylation during preadipocyte replication, we examined the protein abundance 
profile of various members of the SCF E3 ligase complex in the context of p27 protein 
levels and cell cycle phase transition. Total soluble protein was harvested over time 
following MDI stimulation of density-arrested preadipocytes and immunoblotted as 
illustrated in Figure 2.5. Under conditions of density arrest exhibiting abundant levels of 
p27 (i.e., 0 hr), we did not observe any appreciable accumulation of Skp2 or Cks1. Both 
proteins, however, accumulated concomitant with cell cycle progression. Skp2 protein 
was first evident during mid-G1 and peaked in abundance at 22 hrs-post MDI during the 
S-G2/M phase transition. Accumulation of Cks1 was delayed to early S phase and 
peaked along with Skp2 during early G2/M phase progression. In contrast to these 
variable components, Skp1 exhibited no variability in abundance throughout the cell 
cycle. Similarly, no variability was noted in protein abundance of the other known 
members of the SCF complex, Cul1 and Roc1 (data not shown). In the context of p27 
levels, Skp2 and Cks1 kinetically accumulated in a reciprocal manner with the increase 
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in p27 protein degradation. The highest abundance of Skp2 and Cks1 were observed 
with the lowest levels of p27 during G2/M, 22 hrs post-MDI. These data strongly support 
the notion that Skp2 and Cks1 play a mechanistic role in p27 degradation. Furthermore, 
the precise timing of Skp2 and Cks1 accumulation is expected to play a permissive role 
in specific phase transition through temporal changes in p27 degradation. 
 Cdk2-dependent phosphorylation of p27 on residue Thr187.  To further 
explore a role for the SCFSkp2 E3 ligase in p27 degradation, we examined the 
phosphorylation state of p27 on residue Thr187 which is known to be a prerequisite for 
p27 recognition by Skp2/Cks1. Total soluble protein was harvested at 0 hr and 18 hrs 
following MDI treatment and subjected to immunoprecipitation (IP) with a 
phosphospecific p27(T187) antibody. Comparing lanes 1 and 2 of Figure 2.6A illustrates 
that the abundance of p-p27(T187) was elevated during S-to-G2/M phase transition (18 
hrs post-MDI) relative to density-arrest (0 hr post-MDI). This pattern of accumulation was 
also observed with input protein (lanes 3 and 4), but to a lesser extent, demonstrating 
the effectiveness of the IP in concentrating the relative magnitude of protein 
accumulation. Input protein also showed a faster migrating p27 immunoreactive band 
with relative mass consistent with hypophosphorylated p27, suggesting minimal cross 
reactivity between Thr187 phosphorylated and non-phosphorylated forms of this protein. 
The observation that the faster migrating band decreased during S-to-G2/M phase 
transition adds further support to the premise that this immunoreactive band represents 
the declining pool of p27 observed during cell cycle progression. These data are 
consistent with the notion that a phase-specific increase in p-p27(T187) leads to p27 
ubiquitylation and subsequent degradation, decreasing total p27 during phase transition.  
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 To confirm p27 phosphorylation, p-p27(T187) immunoprecipitates, harvested 18 
hrs post-MDI, were treated prior to electrophoresis with or without Protein Phosphatase 
1 (PP1) which displays selective phosphatase activity towards phosphoserine/threonine 
residues.  Based on our working model that p-p27(T187) is a substrate for SCF E3 
ligase activity, we also explored the premise that p-p27(T187) immunoreactive 
immunoprecipitates would migrate as successively slower bands with relative mass 
consistent with p27 ubiquitylation. As shown in Figure 2.6B, PP1 treatment dramatically 
decreased the abundance of multiple phosphorylated p27 reactive species that migrated 
slower in the gel as polyubiquitylated p27 (compare lanes 1 and 2). The effect of PP1 
was most pronounced on reactive species with relative mass equivalent to p-p27(Ub0), 
p-27(Ub1), and p-p27(Ub4) as illustrated.  
 We further explored the identity of the kinase responsible for phase-specific p27 
phosphorylation. Density arrested preadipocytes were stimulated with and without MDI 
supplemented with specific inhibitors Roscovitine to block Cdk2 activity or LY294002 to 
block phosphatidylinositol 3-kinase (PI3K) and the downstream kinase Akt/PKB. Total 
soluble protein was harvested at 18 hrs following stimulation and immunoprecipitated for 
p-p27(T187). As depicted in Figure 2.6C, Roscovitine dramatically attenuated the level 
of all immunoreactive p-p27 immunoprecipitates (compare lane 1 and 2) as well as all 
immunoreactive species observed with input protein (compare lanes 4 and 5). In 
contrast, LY294002 had minimal effect on p-p27(T187) accumulation. These data 
strongly suggest that Cdk2 activity is responsible for p27 phosphorylation on residue 
Thr187 leading to ubiquitylation and degradation.  
 Inhibition of Cdk2 activity partially rescues p27 degradation. Proteasome-
dependent degradation of p27 is known to occur through Thr187-dependent as well as 
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Thr187-independent mechanisms. To determine the contribution of Cdk2 in proteasome-
mediated p27 degradation, density-arrested preadipocytes were stimulated with MDI 
supplemented with and without the specific inhibitors epoxomicin to block proteasome 
activity or roscovitine to block Cdk2 activity. Total soluble protein was harvested at 0 hr 
and 20 hrs post-MDI and immunoblotted for p27, Skp1 and Cyclin A as illustrated in 
Figure 2.7A. Consistent with other data presented in this report, p27 accumulation during 
G2/M phase represented ~35% of that observed during density arrest. The dramatic 
increase in Cyclin A protein, which is known to accumulate acutely during S/G2 phase, 
confirmed cell cycle progression with MDI stimulation. In the context of cell cycle 
progression, inhibition of proteasome catalytic activity with epoxomicin completely 
abolished the decrease in p27 as well as the increase in Cyclin A at 20 hrs post-MDI. 
While blocking Cdk2 activity with Roscovitine had similar effects on Cyclin A 
accumulation, the rescue of p27 degradation was incomplete with approximately 65% 
accumulation relative to density arrest (0 hr). Consistent with ablation of Cyclin A 
accumulation, both inhibitors equally prevented S phase progression and established 
G0/G1 arrest. No G1 subpopulation of apoptotic cells were noted with either inhibitor. 
These data demonstrate that while Cdk2 activity is essential for S phase progression, it 
accounts for only part of proteasome-dependent p27 degradation. 
 Phase-specific Skp2 protein accumulation partially accounts for p27 
degradation. To determine the contribution of Skp2 in p27 degradation, RNA 
interference (RNAi) was employed to knockdown Skp2 accumulation during cell cycle 
progression. Subconfluent preadipocytes were harvested and electroporated with two 
independent, sequence-distinct pools containing four short interfering RNAs (siRNAs) 
designed to specifically suppress murine Skp2 gene expression. To detect any off-target 
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effects caused by transfection, cells were also electroporated with a ‘mock’ pool of non-
functional, non-targeting siRNAs. Following siRNA transfer, cells from both groups were 
replated at near confluency and stimulated with MDI at 2 days post-confluence (i.e., 
density arrest). As illustrated in Figure 2.8A, both Skp2 siRNA pools completely 
abolished Skp2 protein accumulation at 20 hrs post-MDI. The extent of the knockdown 
was not unexpected as these studies involved preventing protein accumulation versus 
knocking down the level of a constitutively expressed protein. Mock siRNA had no effect 
on Skp2 accumulation at 20 hrs post-MDI when compared to non-transfected cells (not 
shown). Both populations of siRNAs for Skp2 equally and partially rescued p27 
accumulation to 61% (RNAi-1) and 59% (RNAi-2) of p27 levels observed at density 
arrest (0hr). Interestingly, this level of p27 rescue was nearly identical to the 65% rescue 
observed when Cdk2 activity and phospho-Thr187 dependent p27 ubiquitylation were 
blocked with Roscovitine (Figure 2.7A). Specificity was suggested as siRNA for Skp2 
had no effect on Skp1 protein levels. 
 Considering the marked rescue of p27 degradation during S phase progression 
under conditions of Skp2 knockdown, we next determined the effect of Skp2 RNAi on 
phase transition. As illustrated in Figure 2.8A, we observed the expected accumulation 
of Cyclins D1, A, and B1 at 20 hrs post-MDI. Unexpectedly, however, Skp2 knockdown 
and resulting partial rescue of p27 degradation had no effect on protein accumulation of 
each cyclin suggesting that G1-to-S phase transition was not obstructed.  Under identical 
conditions, RNAi for Skp2 and non-targeting sequences (mock) presented with identical 
overlapping DNA histograms representing S-G2/M phase progression at 20 hrs post-MDI 
(Figure 2.8B), suggesting that Skp2-mediated p27 degradation is not required for G1-to-
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S phase transition. Population doubling after one cell cycle was also similar between 
Skp2 and Mock siRNA treated cells (not shown). 
 Elevated interaction with between p27 and Cyclin D1/Cdk4 following Skp2 
RNAi.  We also observed that Skp2 knockdown modestly increased protein 
accumulation (~25%) of Cyclin D1 and Cdk4 relative to non-targeting siRNA (mock) 
treated cells at 20 hrs post-MDI (Figure 2.8A). As Cyclin D1/Cdk4 can bind and 
neutralize p27 inhibitory activity (Sherr and Roberts, 1999), we explored the possibility of 
increased protein-protein interaction between Cyclin D1/Cdk4 and p27. Skp2 and non-
targeting siRNA pools were introduced into preadipocytes as described above. Lysates, 
collected from cells at 0 hr (density arrest) and 20 hrs post-MDI (S-G2/M), were 
immunoprecipitated for p27 (polyclonal Ab) and immunoblotted for p27 (monoclonal Ab), 
Cdk2, Cyclin D1, and Cdk4 (Figure 2.9A). Similar p27 protein patterns were detected 
with p27 immunoprecipitates relative to input protein validating the IP procedure. 
Relative to density arrest (0hr), S/G2 phase transition correlated with a 62% and 33% 
decrease in p27 protein with mock (compare lanes 3 vs 2) and Skp2 (compare lanes 4 
vs 2) siRNAs, respectively.   
 For quantitation of protein-protein interaction, densitometric data of Cdk2, Cyclin 
D1, and Cdk4 were normalized to the level of immunoprecipitated p27 protein for each 
condition. These values were subsequently normalized to mock RNAi at 0 hr post-MDI 
and the results depicted in Figure 2.9B. Thus, values greater and lesser than one 
represent respective changes in p27 protein interaction relative to density arrest. The 
level of Cdk2-p27 protein interaction decreased by 24% and 19%, respectively, with 
mock versus Skp2 knockdown. This decrease in Cdk2-p27 protein interaction was 
consistent with expected elevated Cdk2 activity during this phase of the cell cycle (Gu et 
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al., 1992). Nearly identical Cdk2-p27 protein interaction between mock and Skp2 
knockdown was also consistent with the observation that Skp2 knockdown produced no 
impediment to phase transition.  
 In contrast to the decrease in p27-Cdk2 interaction during S/G2 phase transition, 
p27-Cyclin D1 and p27-Cdk4 protein interaction increased by 297% and 188%, 
respectively, with non-targeting RNAi. Under conditions of Skp2 knockdown, p27 
interaction with Cyclin D1 and Cdk4 increased equivalently to 427% and 424%, 
respectively, relative to density arrest. These data support the premise that elevated p27 
protein resulting from Skp2 knockdown was sequestered through elevated p27 
interactions with Cyclin D1/Cdk4 during S/G2 phase. These selective protein-protein 
interactions, presumably, suppressed the expected inhibition of Cdk2 activity associated 
with elevated p27 protein levels during S/G2 transition under Skp2 knockdown 
conditions.  
 It was also noted that elevated protein-protein interactions resulting from Skp2 
knockdown were not simply a function of elevated input protein. Under mock conditions, 
cell cycle progression at 20 hrs post-MDI correlated with a 45%, 43%, and 22% increase 
in Cdk2, Cyclin D1, and Cdk4 protein accumulation (input protein), respectively. Skp2 
knockdown modestly increased S/G2 accumulation for Cdk2, Cyclin D1, and Cdk4 to 
61%, 64%, and 52%, respectively. Even considering the decrease in p27 protein during 
S/G2, it is unlikely that differences in protein levels would account for a greater than 






 The observation that removal of p27 inhibitory activity is rate limiting for Cdk2 
activation and that p27 proteins levels decrease during clonal expansion of density-
arrested preadipocytes raises three important questions: 1) Does decreased p27 protein 
accumulation result from elevated protein turnover involving a proteasome-dependent 
mechanism(s)? 2) Is p27 phosphorylation by Cdk2 involved in p27 ubiquitylation by the 
SCFSkp2 E3 ligase during S and G2 phases? and 3) Is Skp2-mediated p27 degradation 
essential for G1/S phase transition? While previous reports have demonstrated that p27 
protein levels decrease during 3T3-L1 preadipocyte clonal expansion (Morrison and 
Farmer, 1999;Patel and Lane, 2000;Tang et al., 2003;Zhang et al., 2004), only one study 
has reported that p27 is regulated by a calpain-dependent, proteasome-independent 
mechanism (Patel and Lane, 2000). In the current study we elaborated on mechanisms 
regulating p27 degradation by distinct mechanisms at different points in the cell cycle 
and determine the necessity for proteasome-mediated proteolysis for proliferation of 
preadipocytes during adipocyte hyperplasia.  
 To address the hypothesis that phase-specific mechanisms modulate p27 activity 
during cell cycle progression, we initially characterized the kinetics of protein fluctuation 
in precise reference to the timing of phase transitions. p27 protein levels decreased 
modestly in mid-G1, decreasing further near the G1/S phase transition, and maximally 
during G2 phase. The early onset and extended period of p27 suppression as well as 
variant rates of protein fluctuation during specific points of the cell cycle strongly suggest 
the possibility that phase-specific mechanisms are likely involved as discussed below. 
The observation that p27 protein levels dramatically decreased over the course of 
G1/S/G2 phase transitions in the absence of any change in mRNA accumulation 
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demonstrates that transcriptional mechanisms, as well as any process involving p27 
mRNA stability, are not involved during activation of preadipocyte cell cycle progression. 
We and others have determined that proliferative signals of the mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways synergistically 
mediate 3T3-L1 clonal expansion. A major target of PI3K signaling, Akt/PKB has been 
shown to directly phosphorylate and inactivate a family of Forkhead transcription factors 
consisting of Foxo4, Foxo1, and Foxo3a (Kops et al., 2002;Brunet et al., 1999;Rena et 
al., 1999). Others have further demonstrated that all three Forkhead family members 
inhibit cell cycle progression at the G1/S transition, at least in part by controlling p27 
gene expression (Medema et al., 2000;Nakamura et al., 2000;Brunet et al., 2001). In 
previous work, which focused on PPARγ mediated changes in p21 and p18 gene 
expression, it was reported that p27 mRNA levels decrease within two days of 3T3-L1 
preadipocyte differentiation  (Morrison and Farmer, 1999). While it is possible, even 
probable, that PI3K activation leads to a decrease in p27 mRNA at a subsequent point of 
differentiation (e.g., second cell cycle of clonal expansion), data presented here 
demonstrate that transcriptional mechanisms mediating changes in p27 gene expression 
are not involved in the initial G1/S phase transition as preadipocytes undergo the 
transition from quiescence to proliferation. 
 In the absence of mRNA fluctuations, changes in p27 protein levels are regulated 
by translational mechanisms and/or processes mediating p27 degradation. We 
demonstrate in this report that cell cycle progression is marked by a 2-fold increase in 
the rate of p27 turnover during S/G2 phase transition. While these data clearly 
demonstrate a role for regulated p27 proteolysis (e.g., calpain, proteasome, caspases), 
they do not rule out mechanisms involving translational control. Other studies have 
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reported that p27 protein levels decrease during cell cycle progression, in part through 
decreased p27 translation (Hengst and Reed, 1996). During the course of this 
investigation, we determined that rapamycin, a specific chemical inhibitor of the mTOR 
pathway, resulted in a modest increase in p27 protein levels during G1/S phase transition 
(not shown). While this observation suggests a potential for p27 translational control, a 
direct mechanism was not determined. As we also found that Skp2 protein is sensitive to 
rapamycin treatment, it is plausible that mTOR blockade could lead to increased p27 
protein accumulation, indirectly, through decreased p27 protein degradation.  This level 
of regulation is often overlooked as a contributor to p27 regulation, therefore, further 
studies are needed to elucidate the role of translational control in p27 degradation during 
preadipocyte replication. 
 To address the question of whether p27 degradation is proteasome-dependent, 
we utilized two structurally distinct proteasome inhibitors, epoxomicin and lactacystin. 
The 26S proteasome complex is composed of a 20S catalytic core flanked by two outer 
19S regulatory domains. The 20S core is a cylindrical-shaped complex made up of 28 
subunits organized into four rings where the outer two rings contain seven different 
alpha subunits and the inner two rings contain seven different beta subunits. Epoxomicin 
covalently binds four of the beta subunits and potently inhibits the chymotrypsin-like 
activity of the proteasome without inhibiting any other tested protease (i.e., calpain, 
cathepsins, papain, trypsin, and chymotrypsin) at concentrations up to 50 µM (Meng et 
al., 1999). Lactacystin also binds covalently to a beta subunit of the 20S core and 
selectively inhibits all three proteasomal activities at different rates. Unlike epoxomicin, 
however, lactacystin also inhibits cathepsin A and tripeptidyl peptidase II, but without 
effect on other serine proteases (trypsin and chymotrypsin) and cysteine proteases 
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(calpain I, calpain II, papain, and cathepsin B) (Fenteany et al., 1994;Fenteany and 
Schreiber, 1998). Although widely used to study proteasome function, other non-specific 
inhibitors, such as peptide aldehydes (i.e., MG115 and MG132) and N-acetyl-L-leucyl-L-
leucyl-L-norleucinal (ALLN), also inhibit lysosomal (e.g., cathepsins) and calcium-
activated proteases (e.g., calpains).  
 In this report, epoxomicin and lactacystin completely abolished the decrease in 
p27 protein associated with cell cycle progression with absolutely no effect on 
accumulation of the constitutively expressed protein, Skp1, strongly suggesting that the 
decrease in p27 protein was the result of increased degradation by the proteasome. 
While other studies using non-specific inhibitors have reached the same conclusion, 
these are the first data demonstrating proteasome specificity through the effect of 
epoxomicin on p27 degradation. As the decrease in p27 involves signaling events 
associated with cell cycle progression, it is conceivable that proteasome inhibitors could 
prevent the decrease in p27, indirectly, by inhibiting cell cycle events (e.g., Cdk2 activity) 
that signal the timely destruction of p27. To address this, we also present data 
demonstrating that epoxomicin treatment throughout G1 phase increased ubiquitylated 
p27. The data provide direct evidence that p27 is polyubiquitylated during cell cycle 
progression of replicating preadipocytes. In the presence of epoxomicin, ubiquitylated 
p27 is not degraded by the proteasome.  
 Data are also presented clearly demonstrating that both epoxomicin and 
lactacystin unequivocally block S phase progression of clonal expansion resulting in G1 
phase arrest. While these data are consistent with other reports demonstrating that 
proteasome inhibitors effectively block cell proliferation, little is known concerning the 
mechanism of proteasome inhibitor mediated cell cycle arrest. From data presented in 
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this report, it could be speculated that preventing the decline in p27 protein levels in the 
presence of epoxomicin would prohibit Cdk2 activation during late G1 phase, thereby 
inhibiting G1/S phase transition. While elevated p27 protein levels are hypothesized to 
play a role, blocking the proteasome involves other cell cycle related events. For 
example, we have also determined that both epoxomicin and lactacystin treatment lead 
to a dramatic and sustained increase in p21 protein accumulation during mid-G1 phase 
providing an additional mechanism supporting G1 arrest resulting from proteasome 
blockade. In contrast to the data presented here, others have reported that while 
lactacystin (10 µM) was an effective inhibitor of subconfluent preadipocyte proliferation, 
this proteasome inhibitor had no effect 3T3-L1 clonal expansion (Patel and Lane, 2000). 
While ALLN, which blocks calpain and proteasome activities, effectively suppressed 
clonal expansion, no other specific proteasome inhibitor was used. The reason for the 
discrepancy between their findings and ours is unknown. 
 To address a phase-specific mechanism linking proteasome activity with p27 
degradation, we present data demonstrating that 1) p27 protein is phosphorylated on 
Thr187 during S/G2 phase, 2) phosphorylated p27 (Thr187) is polyubiquitylated, and 3) 
p27 phosphorylation is dependent on Cdk2 activity. Other studies have established that 
p27 can be phosphorylated on residue Thr187 by Cdk2, presumably when the amount of 
Cyclin E/A-Cdk2 complexes exceed the amount of available p27, triggering p27 
degradation (Sheaff et al., 1997;Vlach et al., 1997;Muller et al., 1997;Malek et al., 2001). 
This pathway of p27 degradation is regulated in a phase specific manner as Cdk2 
activation does not occur until late G1 phase, with maximal activity through S and G2. 
While activation of the PI3K/AKT pathway in early G1 is essential for preadipocyte 
proliferation, data presented here suggest that this kinase is not responsible for p27 
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phosphorylation at Thr187. These are important observations as Akt has been shown to 
phosphorylate p27 at Thr187, Ser10, Thr198, and Thr157 (Fujita et al., 2002;Shin et al., 
2002). 
 Our finding that phosphorylated p27 (Thr187) is also ubiquitylated during clonal 
expansion is consistent with recent studies establishing a role for Skp2 in ubiquitylation 
of p27 (Carrano et al., 1999;Sutterluty et al., 1999;Tsvetkov et al., 1999). The SCFSkp2 
E3 ligase is a multiprotein complex whereby Roc1 and Skp1 interact with Cul1 through 
its C-terminus and N-terminus, respectively. Roc1 further recruits an E2 ubiquitin 
conjugating enzyme and Skp1 interacts with the F-box protein, Skp2. Unlike other 
SCFSkp2 substrates, interaction of Skp2 with p27 is dependent on p27 recognition by 
Cks1 which harbors the phosphorylated Thr187 binding site (Hao et al., 2005). Once 
assembled, this complex effectively positions p27 in the proper orientation for 
successive rounds of E2-mediated ubiquitin conjugation. In this report, we also 
demonstrate for the first time that maximal protein accumulation for Skp2 and Cks1 is 
restricted to S and G2 phases of mitotic clonal expansion.  
 Considering the kinetics of 1) Cdk2 activation, 2) p27 (Thr187) phosphorylation, 
and 3) Skp2 and Cks1 protein accumulation, we propose that p27 phosphorylation and 
ubiquitylation by the SCFSkp2 E3 ligase is mechanistically responsible, in part for phase-
specific p27 degradation during S and G2 phase progression. While data presented in 
this report provide direct evidence confirming a role for Skp2 in p27 degradation through 
selective RNAi, several lines of evidence suggests that Skp2-mediated p27 
ubiquitylation is only partially responsible for proteasome-mediated p27 degradation 
during preadipocyte replication. First, we demonstrate that specific proteasome 
inhibitors, such as epoxomicin and lactacystin, completely abolish any decrease in p27 
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protein levels during cell cycle progression. Specific blockade of Cdk2 activity with 
Roscovitine partially prevented p27 degradation. If proteasome-mediated p27 
degradation was completely dependent on p27 phosphorylation by Cdk2, it would be 
expected that Roscovitine should completely prevent p27 degradation. Our observation 
that Skp2 knockdown partially prevented the decline in p27 supports the same premise 
that other proteasome-dependent mechanisms are also involved. Second, p27 protein 
levels began to decline during mid-G1 at a point preceding Cdk2 activation and maximal 
accumulation of Skp2 and Cks1 protein.  
 Results from recent studies suggest that the SCFSkp2 pathway plays a role in 
proteasome-mediated p27 degradation during cell cycle progression by maintaining p27 
protein at low levels during S and G2 phases, but not for the decline in p27 protein that 
has been postulated as a prerequisite for G1/S transition. Using a genetic knockin model 
replacing endogenous p27 with mutant p27(T187A) that cannot be phosphorylated, it 
was observed that both wildtype p27 as well as mutant p27 declined during G1/S phase 
transition (Malek et al., 2001). In contrast to wildtype p27, p27(T187A) protein re-
accumulated as cells completed G1 and entered S phase suggesting that 
phosphorylation of p27 at Thr187 and subsequent ubiquitylation by SCFSkp2 E3 ligase 
activity functions to maintain p27 at low levels during S and G2 phase transition. 
 To address the final question of whether Skp2-mediated p27 degradation is 
required for G1/S phase as quiescent preadipocytes reenter the cell cycle, data 
presented here clearly demonstrate that while Skp2 RNAi markedly increased p27 
protein accumulation, the near complete knockdown of Skp2 had absolutely no effect on 
S phase progression during synchronous cell cycle progression of preadipocyte mitotic 
clonal expansion. These observations are supported by other reports demonstrating that 
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Skp2 RNAi did not alter the length of the cell cycle nor the proportion of cells in S phase 
(Duan et al., 2001). Furthermore, other reports have demonstrated that lymphocytes 
from wildtype and Skp2 knockout animals have identical phase distribution profiles for up 
to three days after which cells accumulate in G1 suggesting that elevated p27 protein 
resulting from the absence of Skp2 leads to G1 arrest during subsequent cell cycles 
(Hara et al., 2001).   
 While no direct role for Skp2 has been demonstrated in Cyclin D1 ubiquitylation 
(Carrano et al., 1999;Nakayama et al., 2000;Ganiatsas et al., 2001), Skp2 deficient cells 
have been reported to have modest elevation in levels of Cyclin D1 (Nakayama et al., 
2000). In this report, we also present initial evidence suggesting that the inhibitory action 
of p27 resulting from elevated p27 protein in the absence of Skp2 may be neutralized 
through sequestration by Cyclin D1/Cdk4 complexes. The amount of Cdk2 associated 
with p27 decreased during S phase and was nearly identical when comparing the 
presence or absence of Skp2 knockdown. Conversely, the amount of Cyclin D1 and 
Cdk4 associated with p27 dramatically increased during S phase progression under 
conditions of Skp2 knockdown, suggesting the possibility that Cdk2 activation is shielded 
from elevated p27 inhibitory activity through sequestration of p27 into Cyclin D1/Cdk4 
complexes. 
In summary, the data presented here support a model for different mechanisms 
regulating p27 protein degradation at different points in the cell cycle. While p27 
degradation throughout cell cycle progression is proteasome-dependent, mechanisms 
eliminating p27 during late G1 for Cdk2 activation and G1/S transition appear to be 
independent of Skp2-mediated p27 degradation during S and G2 phase progression. 
These data provide valuable insight into mechanisms mediating the transition of 
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preadipocytes from quiescence to proliferation during adipocyte hyperplasia and the 
onset of hyperplastic obesity. 
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Figure 2.1. Changes in p27 protein accumulation relative to cell cycle 
phase transition. A. Density-arrested preadipocytes were harvested over time 
following exposure to MDI and stained with propidium iodide for DNA 
histograms generated with flow cytometric analysis. B. Cell cycle phase 
distribution was determined through mod-Fit analysis of DNA histograms and 
plotted over time following MDI exposure. Dotted lines through phase 
intersections approximate the kinetics of phase transitions. C. Total soluble 
protein was harvested at each time point following MDI exposure, separated by 
SDS-Page, and immunoblotted with designated antibodies. Protein from 




Figure 2.2. Posttranscriptional regulation of p27 during preadipocyte 
proliferation. A. Total soluble protein and RNA were harvested at 0 hr and 20 
hr post-MDI and subjected immunoblotting and RT-PCR analysis of p27 protein 
and mRNA, respectively. B. Densitometric analysis of protein and RNA 
abundance at 0 hr and 20 hr post-MDI with p27 mRNA normalized to 18S 
mRNA. C. Density-arrested preadipocytes were cultured with and without MDI 
for 18 hrs. At that point, total soluble protein was harvested over time following 
treatment with 30 µM cycloheximide (CHX) and immunoblotted for p27. Linear 
regression of protein remaining over time post-CHX was used for estimation of 
protein half life (T1/2). 
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Figure 2.3. Proteasome-dependent inhibition of p27 degradation and S 
phase progression. A. Cells were harvested at 0 hr and 20 hr post-MDI 
treatment supplemented with or without Epoxomicin (Epox) or Lactacystin 
(Lact). Nuclei were stained and DNA histograms generated with flow cytometry. 
B. Density-arrested preadipocytes were stimulated with MDI for 18 hrs in the 
presence of increasing proteasome inhibitor concentration. Total cell lysates 
were harvested and immunoblotted for p27 and Skp2. C. Densitometric of p27 
immunoblots were normalized to no treatment levels and plotted 
logarithmetically against proteasome inhibitor concentrations. Approximate IC50
values are illustrated. 
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Figure 2.4. Ubiquitin-dependent p27 degradation. A. Diagram of processes 
regulating the accumulation of ubiquitylated p27 protein. All cell lysates were 
harvested in the presence of N-ethylmaleimide (NEM) to block de-ubiquitylating 
isopeptidase activity. B. Cell lysates were harvested from density-arrested 
preadipocytes at times indicated following MDI stimulation in the presence and 
absence of 1 µM epoxomicin (Epox) and immunoblotted as illustrated. C. 
Pattern of p27 ubiquitylation was examined by extended exposure of direct 
immunoblotting analysis of p27. Numbers on the right represent the mobility of 




Figure 2.5. Maximal Skp2/Cks1 protein levels during S/G2 phase 
progression. A. Total cell lysates were harvested from density-arrested 
preadipocytes at 0hr and 18hr post-MDI treatment, and immunoblotted for as 




Figure 2.6. Ubiquitylated p27 phosphorylated on Thr187 by Cdk2. A. Total cell 
lysates were harvested from density-arrested preadipocytes at 0hr and 18hr post-MDI 
and immunoprecipitated (IP) with a polyclonal phosphospecific p27(T187) antibody. 
Immunoprecipitates were separated by SDS-Page electrophoresis and 
immunoblotted with a monoclonal p27 antibody. B. 18 hr post-MDI cell lysates were 
immunoprecipitated for phospho-p27(T187), treated with and without protein 
phosphatase-1 (PP1), and immunoblotted for p27. C. Total cell lysates from density-
arrested preadipocytes, treated with MDI for 18 hrs in the presence or absence of 
25µM Roscovitine (Rosco) or 10µM LY294002 (LY), were immunoprecipitated for 
phospho-p27(T187) and immunoblotted for p27. Input data were generated by 
immunoblotting 10% of protein used for immunoprecipitation. Asterisks denote IgG 




Figure 2.7. Cdk2 inhibition partially prevents p27 degradation. A. Total cell 
lysates, harvested from density-arrested preadipocytes at 0hr and 20hr post-
MDI supplemented with and without 1µM Epoxomicin (Epox) or 25µM 
Roscovitine (Rosco), were separated by SDS-Page electrophoresis and 




Figure 2.8. RNAi Skp2 knockdown partially prevents p27 degradation. A. 
Cells were transfected with non-targeting siRNA (Mock) and two different pools 
of siRNA for Skp2. Total cell lysates were harvested from density-arrested 
preadipocytes transfected with siRNA at 0hr and 20hr post-MDI, separated by 
SDS-Page electrophoresis and immunoblotted as illustrated. B. DNA 




Figure 2.9. Increased p27 interaction with Cyclin D1/Cdk4 following Skp2 
knockdown. A. Cells were transfected with non-targeting siRNA (Mock; M) or 
Skp2 siRNA (S). Total cell lysates, harvested at 0hr and 20 hr post-MDI, were 
immunoprecipitated (IP) for p27 and immunoblotted (IB) as illustrated. Input 
data were generated by immunoblotting 10% of protein used for 
immunoprecipitation. B. Densitometric data representing Cdk2, Cyclin D1, and 
Cdk4 were normalized to protein levels of p27 IP for each condition and to the 
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HORMONAL INDUCTION OF ADIPOGENESIS INDUCES SKP2 EXPRESSION 





Hyperplastic obesity is particularly devastating because increased lipid 
accumulation is accompanied by increased adipocyte number, the latter of which is 
largely irreversible.  Cellular mechanisms regulating the proliferation of these cells are 
poorly understood.  The Ubiquitin-Proteasome System (UPS) has been shown to play an 
important role in adipocyte differentiation and we have shown previously its importance 
in regulating the cell-cycle inhibitor p27 during clonal expansion.  This is mediated by the 
F-box protein, Skp2, of which nothing is known about its regulation during adipogenesis.  
Here, we describe the transient expression of Skp2 protein in 3T3-L1 preadipocytes 
during the early stages of adipocyte differentiation, a pattern that cannot be reproduced 
in fully mature adipocytes.  Dramatic changes in mRNA are also present at this time and 
we show this to be due to increased promoter activity.  Our studies further show that 
immediately following the addition of adipogenic media, both the PI3K and MAPK 
pathways increase Skp2 promoter activity.  We have determined the responsive 
element(s) to be immediately upstream of the gene.  In addition, our data suggests the 
possibility of translational control, downstream of PI3K.  These are the first studies 
describing the regulation of the mammalian cell cycle protein Skp2 in 3T3-L1 cells, a 




Obesity is a devastating condition due to its widespread occurrence in all 
populations regardless of race, age, gender, or socioeconomic status, and its negative 
effects on life expectancy and quality-of-life due to comorbidities such as heart disease, 
stroke, diabetes, and cancer.  Early studies demonstrated that adipocyte hyperplasia is 
largely responsible for childhood (Hager et al., 1978), morbid (Pettersson et al., 1985), 
and diet-induced obesity (Mandenoff et al., 1982).  A majority of the research-to-date 
has been focused on adipocyte hypertrophy, which has left many unanswered questions 
regarding adipocyte hyperplasia.  There are two phases of hyperplastic obesity; the 
proliferation of preadipocytes and subsequent differentiation to form mature lipid-filled 
adipocytes.  While much work has explored the process of adipocyte differentiation, little 
is known about the mechanisms regulating preadipocyte replication.   
The F-box protein, Skp2 or S-phase kinase-associated protein, has been shown 
to promote cell cycle progression in neoplastic cells, in large part, by targeting the cyclin-
dependent kinase inhibitor p27 for degradation.  Skp2 is the substrate recognition 
component of a larger complex, the SCFSkp2 E3 Ligase, that targets specific proteins for 
polyubiquitylation and subsequent degradation by the 26S proteasome.  Skp2 binds to 
the core of the E3 Ligase complex via its F-box motif, a region composed of 
approximately 40 amino acids common among all F-box proteins.  Its peptide structure is 
further characterized by a region containing leucine-rich repeats (LRR).  It is within this 
LRR region that Skp2 (as part of the SCFSkp2 E3 Ligase) binds Cks1 and p27, bringing 
the substrate, p27, in close proximity to ubiquitin-conjugating enzymes (Hao et al., 
2005).  In 1999, Morrison and Farmer first identified a decrease in p27 protein 
expression during early adipocyte differentiation while characterizing the switch between 
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proliferation and differentiation.  Recently, Naaz et al. (Naaz et al., 2004) found that p27 
knockout mice had 80% heavier fat pads than wildtype controls due to an increase in 
adipocyte number, not size (i.e., p27 KO animals had two times the number of fat cells).  
We are the first to show that Skp2 is transiently expressed during an early phase of 
adipocyte differentiation and that this increase plays a major role in regulating p27 
(Chapter II).  While much research has been devoted to the regulation of p27, less is 
known about how Skp2 is regulated.  Determining mechanisms controlling Skp2 
expression may provide important insight into the regulation of hyperplastic obesity.    
Signal transduction pathways have been shown to play an important role in 
initiating cell cycle progression.  Phosphatidylinositol-3 kinases (PI3Ks) exert their 
effects on proliferation through targets such as E2F (Brennan et al., 2002), NFκB (Shah 
et al., 2001), Forkhead transcription factors (Brunet et al., 1999;Kops et al., 2002), and 
mTOR (Gao et al., 2003).  These effects can occur through PI3K directly or indirectly by 
its downstream targets, PDK1 and PKB/Akt.  Activation of Akt also augments this 
process as it can lead to increased expression of the insulin-like growth factor 1 receptor 
(IGF1R) (Tanno et al., 2001).  This is of particular interest as the IGF1R is a 
predominant cell-surface growth factor receptor expressed during early adipocyte 
differentiation.  A second pivotal pathway is regulated by mitogen-activated protein 
kinases (MAPKs).  The activation of this pathway leads to increased Cyclin D1 
expression, Rb hyperphosphorylation, and subsequent downstream events (e.g., 
increases in Cyclin E/A – Cdk2 complexes) (Lavoie et al., 1996).  The IGF1R is known to 
activate both pathways and is required for differentiation of 3T3-L1 preadipocytes (Smith 
et al., 1988).  In this study we show significant regulation of Skp2 and its accessory 
protein Cks1 by insulin, at a concentration known to bind and activate the IGF1R.  The 
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addition of the mitogenic cocktail MDI (methylisobutylxanthine, dexamethasone, and 
insulin) is the conventional way to induce adipocyte differentiation in these cells.  Early 
stages of adipogenesis include a brief period of one to two rounds of synchronous cell 
division, which is obligatory for further differentiation as critical chromatin remodeling 
occurs and adipogenic precursor proteins are expressed.   
The objective of this study was to identify the mechanism by which Skp2 
expression is increased during adipocyte hyperplasia.  We sought to determine the 
kinetics of Skp2 expression throughout adipocyte differentiation and identify the 
upstream events leading to its expression.  In addition, we determined the level at which 
Skp2 regulation occurs.  Our findings revealed that Skp2 promoter activity is increased 
in response to PI3K and MAPK activation during preadipocyte proliferation.  In addition, 
Skp2 protein, but not mRNA, is responsive to Rapamycin, suggesting possible 
translational control.  These data provide the first study of Skp2 regulation in adipocytes 
and provide a link between this cell cycle protein, early signaling events, and adipocyte 
hyperplasia. 
 
MATERIALS AND METHODS 
 Materials - Dulbecco's Modified Eagle's Medium (DMEM) was purchased from 
Cellgro by Mediatech.  Bovine Serum, Fetal Bovine Serum (FBS), and Trypsin-EDTA 
were from Invitrogen Corporation. Propidium Iodide and RNase A was purchased from 
Sigma.  Chemical inhibitors were purchased from the following: LY294002 and U1026 
(Promega); Actinomycin D (Sigma); Rapamycin (Calbiochem). Antibodies used for 
western blot analysis were as follows: Skp2 (Zymed); Cks1, Skp1, Cyclin A, Cul1, and 
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C/EBPα (Santa Cruz Biotechnology). Enhanced chemiluminescence (ECL) reagents 
were from PerkinElmer Life Sciences.  
 
    Cell Culture and Differentiation - Murine 3T3-L1 preadipocytes were propagated 
in growth medium containing DMEM supplemented with 10% calf bovine serum as 
described previously (Morrison and Farmer, 1999).  By standard differentiation protocol, 
preadipocytes were propagated in growth medium until reaching a state of density arrest 
at 2 days post-confluence. Growth medium was replaced at density arrest with 
differentiation medium comprised of DMEM supplemented with 10% fetal bovine serum 
(FBS), 0.5 mM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, and 1.7 µM insulin 
(MDI).  The term "post-MDI" refers to the time elapsed since the addition of MDI to the 
culture medium. At 2 days post-MDI, medium was changed to DMEM supplemented with 
10% FBS and 0.4 µM insulin. From 4 days post-MDI until harvest, maintenance medium 
containing DMEM supplemented only with 10% FBS was changed every 48 hrs.  
Throughout the study, "time 0" refers to density arrested cells immediately before 
chemical induction of differentiation with the addition of MDI to the culture medium. All 
experiments were repeated three to five times to validate results and ensure reliability. 
 
 Flow Cytometry - Cell cycle progression was assessed by flow cytometry. Briefly, 
cell monolayers were washed with phosphate-buffered saline (PBS), trypsinized, and 
detached cells diluted in ice cold PBS to produce a single cell suspension. Cells were 
gently pelleted by centrifugation (300 x g, 5 min). Following centrifugation, PBS was 
decanted and cells were fixed and permeabilized by drop-wise addition of 70% ethanol 
at -20°C while vortexing. Fixed cells were incubated on ice for 30 minutes or stored at     
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-20˚C for no more than one week before processing. Fixed cells were washed 2x with 
PBS and incubated in the dark for 30 minutes with 1ml propidium iodide staining solution 
containing 50 µg/ml propidium iodide (PI) and 100 µg/ml RNase A in PBS.  DNA 
fluorescence was measured with a FACS Calibur Flow Cytometer (Becton Dickinson) 
equipped with a 488-nm argon laser. Width (FL2W) and area (FL2A) of PI fluorescence 
was recorded for at least 10,000 counts. DNA histograms were extracted from FL2W-
FL2A dot plots after gating to eliminate aggregates.  
 
 Immunoblotting - Cell monolayers were washed with PBS and scraped into ice 
cold lysis buffer containing 1.0 M Tris, pH 7.4, 150 mM NaCl, 1% Triton X, 0.5% Nonidet 
P-40, 1 mM EDTA, 1 mM EGTA, and 10 mM N-ethylmaleimide (NEM). Lysis buffer was 
freshly supplemented with phosphatase inhibitors; 20 mM β-glycerophosphate, 10 mM 
NaF, and 2 µM sodium vanadate, as well as protease inhibitors; 0.3  µM aprotonin, 21 
µM leupeptin, E-64, 1 µM pepstatin, 50 µM phenanthroline, 0.5 µM phenylmethylsulfonyl 
fluoride. Cell lysates were clarified by centrifugation (13,000 x g, 10 min, 4°C) and 
protein concentration was determined by BCA assay (Pierce). Lysates were 
resuspended in loading buffer containing 0.25 M Tris, pH 6.8, 4% SDS, 10% glycerol, 
10% dithiotreitol, 0.01% bromophenol blue, heated for 5 mins at 80°C, and placed on 
ice. Lysates were resolved on SDS-PAGE gels and transferred to polyvinylidene fluoride 
membranes (Millipore).  Following transfer, membranes were blocked with 4% milk and 
probed with indicated primary antibodies overnight at 4°C and horseradish peroxidase-
conjugated secondary antibodies for 1 hr at room temperature. Immunoblots were 
developed with ECL and visualized by autoradiography CL-XPosure film (Pierce). 
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 RNA Isolation and Analysis - Total RNA was extracted using the RNeasy Mini Kit 
(QIAGEN) according to manufacturer’s instructions.  Total RNA (1µg) was subjected to 
Reverse-Transcriptase Polymerase Chain Reaction using One-Step RT-PCR kit 
(QIAGEN) according to manufacturer’s instruction.  Briefly, RT-PCR reactions were 
carried out in the presence of the supplied buffer, dNTPs (400 µM), enzyme mix (reverse 
transcriptases and DNA polymerase), and RNase inhibitor (10 U).  Gene specific primers 
were used at a final concentration of 0.6 µM and designed as follows: Skp2 forward, 5΄-
GGCAAAGGGAGTGACAAAGA-3΄; Skp2 reverse, 5΄-TCAAAGCACCAGGAGAGATT-3΄ 
(product size = 590 bp); Cks1 forward, 5΄-TGTCTGAATCTGAATGGAGG-3΄; Cks1 
reverse, 5΄-TGCTTCTGCCAAATGACTAA-3΄ (product size = 381 bp). QuantamRNA 
Classic and Classic II 18S primer/competimers (Ambion) were used in the reactions as 
internal standards at a final concentration of 0.6 µM.   
 
 Plasmids – Promega’s pGL3-basic vector was used to create mouse Skp2-pGL3 
constructs for luciferase assays.  Primers flanking the region of -2404 to +74 (2478bp) 
were used to amplify the murine Skp2 promoter from 3T3-L1 preadipocyte genomic 
DNA.  Positive DNA fragments were gel purified. Vector and isolated genomic DNA were 
double-digested with Kpn I and Bgl II. The resulting DNA fragment was subcloned into 
the pGL3-basic vector. Nucleotide sequencing was conducted by SeqWright DNA 
Technology Services. This entire process was repeated twice to ensure reliability of 
results. Restriction digest reactions were done to make deletion constructs from this “full 
length” promoter (2.4kb) as follows: 2.2kb (-2248 to +74) insert using Kpn I and BbvC I; 
1.5kb (-1573 to +74) using Kpn I and EcoR I; 1.0kb (-1073 to +74) using Kpn I and Nsi I; 
0.4kb (-0.454 to +74) using Kpn I and Mlu I.  5’ and 3’ overhangs were flushed using T4 
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DNA Polymerase (Promega), resulting DNA fragments gel-purified, and blunt-end 
ligations were carried out using T4 DNA ligase (Promega). All vectors were transformed 
into JM109 competent cells (Promega) and screened for positive ligations using 
ampicillin-containing LB agar plates. DNA was isolated using the endotoxin-free Wizard 
PureFection Plasmid DNA Purification System (Promega). Restriction digests were 
performed to confirm positive clones. 
 
 Luciferase Reporter Assays – 3T3-L1 preadipocytes (2.0 x 106 cells) were 
transiently transfected with 5 µg of firefly reporter plasmid and 20.0 ng renilla-SV40 
plasmid using Amaxa’s Nucleofector (program T20), then incubated with pre-warmed 
proliferation media for no more than 10 minutes at 37°C.  Cells were subsequently 
replated at a confluent density, fresh media replaced 24 hours post-transfection, and 
further cultured as indicated. Firefly and renilla luciferase were measured using the Dual-




We have previously determined an upregulation of Skp2 protein and subsequent 
role in the regulation of p27 protein during clonal expansion.  To examine Skp2 
expression throughout the entire process of adipocyte differentiation, 3T3-L1 
preadipocytes were stimulated with the differentiation cocktail, MDI, and protein 
abundance was determined by immunoblotting.  As shown in Figure 3.1, Skp2 is not 
expressed at day 0, when cells are density-arrested.  However, by 24 hours post-MDI, 
Skp2 protein expression increases transiently, returning to day 0 levels as the cells 
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begin to express adipogenic markers (e.g., C/EBPα) and become fully mature 
adipocytes.  As well, other proteins essential for the function of the SCFSkp2 E3 Ligase 
are expressed during the same time.  Skp1 and Cul1 are ubiquitously expressed 
throughout adipocyte differentiation, consistent with previous literature that suggests 
these components are not regulated at the level of protein expression.  Interestingly, the 
expression pattern of Cks1 follows that of Skp2 precisely.  This is extremely important as 
Cks1 has been shown to be required for Skp2-dependent degradation of p27 (Ganoth et 
al., 2001;Hao et al., 2005).  During clonal expansion, an early stage of adipocyte 
differentiation, density-arrested preadipocytes synchronously reenter the cell cycle.  This 
is demonstrated by the differential expression of Skp2 in proliferating preadipocytes 
(PPA), which are subconfluent and progressing through different stages of the cell cycle, 
and day 1 cells which have been arrested in G0 by contact inhibition and driven back into 
the cell cycle very synchronously.  These data show regulated expression of Skp2 and 
Cks1 during early stages of adipocyte differentiation. 
To determine whether the upregulation of Skp2 protein is purely a result of 
adding the stimulation cocktail to these cells (i.e., a chemical effect) or if it is a 
phenomenon unique to cell cycle and clonal expansion, mature adipocytes were 
stimulated with MDI.  As shown in Figure 3.2, Skp2 protein is transiently expressed 
during clonal expansion, 22 hours after the initial stimulation, but cannot be upregulated 
by administering the same chemical cocktail once the cells have fully differentiated 
(indicated by C/EBPα expression), and the same is true for its accessory protein Cks1.  
Thus, the mechanism(s) responsible for increased expression of Skp2, and its required 
accessory protein, are limited to preadipocyte proliferation.   
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There is limited information about the regulation of Skp2 in malignant cells and 
nothing is known about how it is regulated in adipocytes.  To determine whether 
changes in Skp2 protein are accompanied by changes in mRNA during preadipocyte 
proliferation, 3T3-L1 cells were stimulated with MDI and samples harvested at indicated 
times post-stimulation.  As shown in Figure 3.3, Skp2 protein increases slightly by 12 
hours post-MDI and is highly expressed by 20 hours.  This change in protein is preceded 
by a dramatic increase in Skp2 mRNA.  Skp2 mRNA is extremely low at day 0 but is 
significantly increased by 12 hours following stimulation.  The kinetics of Skp2 mRNA 
throughout differentiation match exactly that of Skp2 protein, as mRNA is increased at 
12 and 20 hours during cell cycle progression and back down to basal levels during 
terminal differentiation (i.e., days 2 and 4).  This suggests regulation at the level of 
transcription and/or mRNA stability but does not rule out further regulation by way of 
translational or post-translational control. 
To identify the events leading to Skp2 expression, the effects of individual 
components of the stimulation cocktail were evaluated.  Density-arrested 3T3-L1 
preadipocytes were stimulated with MDI, individual components, or varying combinations 
of two components.  Levels of Skp2 expression in the presence of these chemicals were 
compared to that of growth arrested cells (i.e., unstimulated condition – first lane in 
Figure 3.4).  These studies revealed that while there is a synergistic effect of MDI 
together, insulin is the primary component responsible for Skp2 protein expression, as 
well as Cks1 and cell cycle progression, as shown by Cyclin A expression.  Again, Skp1 
is constitutively expressed, serving as a loading control.  Protein levels were also 
examined from cells that received a media change with either calf serum (proliferation 
media) or fetal bovine serum (part of the differentiation media) 20 hours prior to 
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harvesting.  This was done to determine whether the increase in Skp2 protein could be 
due to the replenishment of depleted growth factors via a media change with calf serum 
or a result of additional mitogens present in fetal bovine serum alone.  We found no 
increase in Skp2 protein with either condition.  Taken together, these data suggest that 
Skp2 induction is primarily mediated by insulin. 
Insulin is known to play a role in cell cycle progression by activating different 
signaling cascades.  Two such pathways are the PI3K and MAPK pathways which have 
been shown to activate downstream targets (e.g., c-myc, E2F, Cyclin D1) important for 
cell cycle progression.  These kinase-driven pathways can work independently and/or 
synergistically, as there is crosstalk between the two cascades.  To determine whether 
either pathway plays a role in regulating Skp2 expression during preadipocyte 
proliferation, cells were treated with the PI3K inhibitor LY294002, MAPK inhibitor U0126, 
or both.  As shown in Figure 3.5A, inhibition of either pathway for 20 hours post-
stimulation prevents maximal expression of Skp2 mRNA.  While there is an additive 
effect of blocking both pathways, LY294002 has the greatest effect when comparing 
inhibition of either pathway alone.  Cks1 mRNA is also significantly affected by 
LY294002 but only negligibly affected by U0126.  However, there is a greater effect on 
Cks1 mRNA when both inhibitors are used simultaneously than with LY294002 alone.  
We examined protein levels for these same conditions (Figure 3.5B) and found that 
Skp2 protein followed the same pattern seen in mRNA, and to a slightly greater extent.  
Cks1 protein expression was negatively affected by LY294002 and also decreased in 
the presence of U0126.  The two inhibitors in combination caused no further decrease 
than what was seen with LY294002 alone.  To determine whether blocking these 
pathways also had an effect on cell cycle progression, we examined Cyclin A protein 
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expression, a marker of S phase, and found that both inhibitors decreased Cyclin A and 
did so synergistically, with LY294002 having the most potent effect alone.  These data 
were further validated using flow cytometry.  Figure 3.5C shows G1 arrest in the 
presence of LY294002 and/or U0126.  These findings indicate that PI3K and, to a lesser 
extent, MAPK signaling is required for the increase in Skp2 mRNA and protein levels 
during clonal expansion. 
Because PI3K plays the primary role in regulating Skp2 and Cks1, we examined 
the phosphorylation status of critical kinases involved in this pathway to determine the 
time at which activation of downstream targets occurs.  As shown in Figure 3.6, PDK1 is 
constitutively phosphorylated on Ser241 before and immediately following stimulation 
with slightly less phosphorylation at 20 hours.  This pattern is consistent with previous 
findings that show serine-phosphorylated PDK1 present in unstimulated and IGF-1 
stimulated 293 cells (Casamayor et al., 1999).  While phosphorylation of PDK1 at S241 
is necessary for activation, it is not sufficient.  Activation requires association between 
PDK1 and PIP3 in the plasma membrane, created by active PI3K.  We show here that 
the primary downstream target of PDK1, Akt, is transiently phosphorylated at residues 
Ser473 and Thr308 beginning at 15-30 minutes post-stimulation, continuing through at 
least 8 hours.  Phosphorylation of Akt is a strong indicator of activity, therefore, we 
examined the phosphorylation status of two of its targets, Foxo1 and GSK3β.  Foxo1 is a 
transcription factor whose activity is blocked by cytosolic translocation upon 
phosphorylation by Akt at Ser256.  Consistent with the kinetics of Akt phosphorylation, 
Foxo1 is phosphorylated at Ser256 30 minutes after stimulation through at least 8 hours 
and is no longer phosphorylated at this residue by 20 hours post-stimulation.  
Interestingly, the kinase GSK3β can also phosphorylate Foxo1 at this same residue, 
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however, cannot do so when phosphorylated at Ser9, as this inhibits GSK3β kinase 
activity.  In Figure 3.6, we show constitutive phosphorylation of GSK3β at S9 before and 
immediately following the addition of MDI.  Taken together, phosphorylation of GSK3β 
and Foxo1, simultaneously, suggests that Akt is active and is the kinase responsible for 
Foxo1 phosphorylation.  The tumor suppressor PTEN inhibits this signaling cascade by 
reverting PIP3 within the plasma membrane to PIP2, hence blocking PDK1 and Akt 
activation, however, when phosphorylated at Ser380 is inactive.  We found PTEN to be 
constitutively phosphorylated, further support of PI3K pathway activation.   
We have shown increased levels of Skp2 mRNA in preadipocytes at 12 hours 
post-stimulation.  To determine the kinetics of this increase in Skp2 mRNA, 3T3-L1 cells 
were stimulated and RNA collected every 2 hours until 12 hours post-MDI and then 
again at 34 hours, a time at which Skp2 mRNA should be low.  Figure 3.7A shows that 
by 4 hours after stimulation with MDI, Skp2 mRNA begins to increase.  There is a 
continual increase through 12 hours and then a dramatic decrease by 34 hours. This 
early increase in Skp2 mRNA is preceded by Akt phosphorylation, as it peaks at 1 hour 
(Figure 3.6.). 
We have demonstrated the importance of the PI3K and MAPK pathways in the 
increase in Skp2 mRNA, and protein, but to determine how these signaling cascades 
regulate Skp2 mRNA in preadipocytes, we examined mRNA stability and promoter 
activity.  To ascertain potential changes in Skp2 mRNA half-life, 3T3-L1 cells stimulated 
with FBS/MDI or maintained in FBS alone were treated with Actinomycin D (an inhibitor 
of mRNA synthesis) and mRNA harvested over a period of 5 hours beginning at 12 
hours post-MDI.  As illustrated in Figure 3.7B, no change in Skp2 mRNA stability during 
clonal expansion was observed.  Because these data ruled out regulation at the level of 
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mRNA stability, we examined Skp2 promoter activity.  To do this, 2.4kb upstream of the 
coding region of the Skp2 gene was cloned into a pGL3-basic luciferase reporter vector.  
Cells were transfected using Amaxa’s Nucleofector and stimulated with MDI alone or 
MDI plus the pathway inhibitors to determine whether there is an increase in Skp2 
promoter activity during preadipocyte replication and if so, whether the PI3K and MAPK 
pathways play a role in that increase.  As shown in Figure 3.8, there is a greater than 2.5 
fold increase in Skp2 promoter activity by 12 hours during clonal expansion as compared 
to activity at day 0.  These data are identical to the kinetics of mRNA suggesting that the 
increase in Skp2 mRNA and protein is largely due to an increase in promoter activity.  In 
the presence of LY294002, Skp2 promoter activity is inhibited by 35% and with U0126, 
activity is down by 20%.  These inhibitors in combination had an additive effect, that is, 
Skp2 promoter activity was reduced by almost 50%.  These findings show substantial 
regulation of Skp2 promoter activity by the PI3K and MAPK pathways, leading to an 
increase in Skp2 protein expression that promotes preadipocyte proliferation by 
contributing to p27 degradation. 
 After finding the Skp2 promoter to be responsive to MDI and inhibition of the 
PI3K and MAPK pathways, we determined in which region(s) these response elements 
were contained.  To do this, restriction enzymes were used to make deletion constructs 
of the original 2.4kb promoter/pGL3 vector.  The resulting promoter lengths were 2.4, 
2.2, 1.5, 1.0, and 0.4kb (Figure 3.9A).  As shown in Figure 3.9B, all constructs produce 
essentially the same amount of luciferase activity at day 0, however, the 0.476kb 
promoter is significantly less than 1.095kb.  By 12 hours after stimulation with MDI, 
activity of all constructs increases by 100% with the 1.0kb having an even greater 
activity when compared to day 0.  The patterns of expression for all constructs in the 
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presence of LY294002 and U0126 follow Skp2 mRNA kinetics precisely, that is 
LY294002 produces a significant decrease in luciferase activity and U0126 has a lesser 
effect.  When these data were normalized to compare the amount of change from day 0, 
we observed no difference between constructs (Figure 3.9C).  Taken together, these 
results indicate the presence of PI3K and MAPK responsive element(s) within the first 
476bp of the Skp2 promoter. 
When examining the effect of LY294002 and U0126 on Skp2 mRNA and protein, 
it was apparent that while the pattern was the same, the magnitude of change was 
slightly greater when looking at protein expression.  This observation suggested Skp2 
protein might also be regulated in addition to the increase in promoter activity.  The PI3K 
pathway plays a major role in regulating translational control by activating the protein 
kinase mTOR.  This activation can occur through any of the three major kinases (i.e., 
PI3K, PDK1, and Akt).  To assess whether this pathway plays a role in Skp2 protein 
expression, cells were stimulated with MDI and treated with the specific mTOR inhibitor, 
Rapamycin.  Skp2 mRNA and protein were collected.  As shown in Figure 3.10, 
Rapamycin has no effect on Skp2 mRNA (panel A) but has a dramatic effect on protein 
(panel B) at 20 hours post-stimulation.  These findings suggest the possibility that mTOR 
regulates the rate at which Skp2 protein is translated.  Further studies are needed to 






The study of adipocyte hyperplasia has received little attention as great strides 
have been made in understanding late stages of adipocyte differentiation and 
hypertrophic obesity.  Skp2 is overexpressed in many cancers and can be used as a 
prognostic tool when characterizing tumor stage (Kudo et al., 2001;Shapira et al., 
2005;Langner et al., 2004;Hu and Liu, 2005;Seki et al., 2003;Oliveira et al., 2003;Dong 
et al., 2003;Yang et al., 2002;Li et al., 2004;Osoegawa et al., 2004).  This regulation has 
been shown to be due to increases in transcription (Imaki et al., 2003;Zhang and Wang, 
2005a) and posttranslational modification, via phosphorylation (Yam et al., 1999), 
ubiquitylation (Wei et al., 2004;Bashir et al., 2004) and possibly auto-ubiquitylation 
(Wirbelauer et al., 2000;Zhang et al., 2003) .  In neoplastic cells, Skp2 has been shown 
to be upregulated by PI3K (Mamillapalli et al., 2001;Andreu et al., 2005) and Notch1 
(Sarmento et al., 2005) signaling, and negatively regulated by TGFβ (Wang et al., 2004).  
To date, nothing is known about Skp2 regulation in adipose tissue.  We show here that 
Skp2 is expressed transiently during preadipocyte proliferation in 3T3-L1 cells, primarily 
due to increases in transcription with the minimal promoter located within 500bp 
upstream of the Skp2 gene.  These findings are consistent with a previous 
characterization of the Skp2 promoter in mouse embryonic fibroblasts (Imaki et al., 
2003).  Our promoter deletion studies revealed that this region includes an element 
which is responsive to PI3K and MAPK inhibition.  While the presence of two distinct 
response elements within this region may exist, these pathways are known to overlap 
and a common element(s) is quite probable.   
We have shown Skp2 mRNA begins to increase 4 hours after induction of 
adipocyte differentiation.  This suggests a very early transcriptional event responsible for 
Skp2 promoter activity.  In 2003, Imaki et.al. identified the GA-binding protein (GABP) as 
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an essential transcription factor for Skp2 promoter activity (Imaki et al., 2003).  While 
GABP has been shown to play a role in mitochondrial thermogenesis in brown adipose 
tissue (Villena et al., 1998), its role in white adipose tissue proliferation and 
differentiation has yet to be determined.  More recently, E2F1 has been shown to be a 
transcriptional regulator of Skp2 in human fibroblasts and tumor cell lines (Zhang and 
Wang, 2005b).  We have identified two E2F consensus sequences within the 3T3-L1 
murine Skp2 gene.  The E2F proteins are expressed differentially throughout the cell 
cycle, with E2F-4 being the predominant form present in almost all phases of the cell 
cycle.  It will be interesting to see whether E2F also plays a role in regulating Skp2 
promoter activity during preadipocyte proliferation and identify the E2F protein(s) 
responsible for this action.  The activity of E2F is primarily regulated by phosphorylation 
of the retinoblastoma protein (pRb), which increases late during G1.  Skp2 mRNA begins 
to increase at 4 hours following the addition of MDI, suggesting a regulation much earlier 
than pRb hyperphosphorylation.  E2F-4 is a likely candidate for regulating Skp2 gene 
expression at this early time because it is known to be active during G0-G1 and its 
activity regulated by subcellular localization (Moberg et al., 1996;Verona et al., 1997) 
and its association with p130 and p107 (Moberg et al., 1996), two proteins that undergo 
a critical switch in expression during early stages of adipogenesis.  It is also possible 
that E2F1 binds to the Skp2 promoter, during mid to late G1 phase, and augments 
expression rather than initiating promoter activity. It is crucial to understand how Skp2 is 
regulated during preadipocyte proliferation because of the impact on hyperplastic 
obesity.  In addition to the paper by Naaz et al. showing increased adiposity and 
adipocyte number in p27 knockout mice (Naaz et al., 2004), Nakayama et al. showed 
that Skp2 knockout mice were two-thirds smaller than wildtype animals (Nakayama et 
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al., 2000).  While body composition was not measured, the change in body size could be 
largely due to changes in adipose tissue due to the fact that they report no changes in 
external bodypart sizes.    
The function of Skp2 as the substrate recognition portion of the SCFSkp2 E3 
Ligase is dependent on expression of and interaction with the accessory protein, Cks1 
(Spruck et al., 2001;Ganoth et al., 2001).  We have shown that Cks1 is expressed in a 
coordinate manner with Skp2 and is also induced by insulin stimulation.  Additionally, 
Cks1 protein cannot be increased during differentiation.  This seems logical as the cell 
has completed the differentiation process and has likely put mechanisms in place to 
block any induction of cell cycle.  While Cks1 is upregulated during clonal expansion, 
this increase is not as dramatic as what is seen with Skp2.  Furthermore, Cks1 mRNA is 
regulated by PI3K alone and is not affected by the addition of U0126.  However, mRNA 
levels are further decreased in the presence of both inhibitors suggesting synergy 
between the two signaling cascades.  In contrast, Cks1 protein is regulated 
independently by both the PI3K and MAPK pathways.  The regulation of Cks1 is 
important as it lends further insight into the activity of Skp2 and the SCFSkp2 E3 Ligase 
during the differentiation process.  It appears that while some proteins (e.g., C/EBPβ, as 
discussed later) are expressed for some time before becoming active, this is not the 
case for Skp2.  That is, Skp2 plays an important and targeted role in proliferation during 
early adipocyte differentiation and is expressed only during this time.  Additionally, Skp1 
and Cul1, required components of the E3 ligase, are constitutively expressed during 
differentiation.  These core proteins can form E3 Ligase complexes with other F-box 
proteins (e.g., β-TrCP and Cyclin F) (Latres et al., 1999;Bai et al., 1996), a notable fact 
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as the importance of the 26S proteasome during adipocyte differentiation has become 
increasingly apparent in recent years.       
 Of particular interest is the effect of Rapamycin, potent inhibitor of mTOR, on 
Skp2 protein at 20 hours post-stimulation.  Recently, mTOR was identified as a kinase 
responsible for Akt phosphorylation at Ser473, therefore contributing to Akt activation 
(Hresko and Mueckler, 2005;Sarbassov et al., 2005).  However, we have shown 
decreased Skp2 mRNA and protein levels with the potent PI3K inhibitor LY294002 at 20 
hours following stimulation, whereas inhibition of mTOR only had an effect on protein at 
this same time.  This suggests that there is a redundant pathway involved in the 
presence of Rapamycin.  Specifically, PDK1, once thought to only phosphorylate Akt at 
Thr308, has been shown to also target Ser473 (Balendran et al., 1999).  Therefore, if 
phosphorylation of Akt at Ser473 by PDK1 occurs in preadipocytes, when mTOR is 
blocked (i.e., with Rapamycin) complete phosphorylation of Akt is not also blocked.  This 
would indicate that there is a PI3K-dependent pathway, likely requiring Akt activation, 
leading to Skp2 promoter activation.  In addition, there may be mTOR-dependent 
translational control of Skp2 during preadipocyte proliferation as well.  4E-BP1, one of 
the downstream targets of mTOR and a repressor of mRNA translation, has been shown 
to be phosphorylated transiently within 1 hour following insulin stimulation in 3T3-L1 
preadipocytes allowing for increased translational control via this pathway.  In addition, 
by day 4 of adipocyte differentiation, the time in which Skp2 levels decrease terminally, 
total 4E-BP1 protein expression increases dramatically (El Chaar et al., 2004), 
suggesting decreased translational control by this pathway.  Moreover, we have shown 
maximal Skp2 mRNA expression by 10 hours following stimulation, however protein 
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levels do not peak until approximately 20 hours, further evidence of post-transcriptional 
control in addition to increased promoter activity.   
Proliferation and differentiation are mutually exclusive processes and the link 
between the two during adipocyte differentiation is not fully understood.  The 
differentiation process is highly regulated by the C/EBP family of transcription factors.  
C/EBPβ is expressed during early stages and leads to upregulation of the two master 
adipogenic proteins, C/EBPα and PPARγ.  We have identified three putative C/EBPβ 
binding sites in the Skp2 promoter, however, while it has been shown to be essential for 
clonal expansion (Tang et al., 2005;Zhang et al., 2004), C/EBPβ DNA-binding activity is 
not present until 12 hours after stimulation with MDI (Tang and Lane, 1999), 8 hours 
after Skp2 mRNA begins to increase.  In addition, C/EBPβ has been shown to be 
downstream of PI3K and MAPK signaling following PDGF stimulation (Tullai et al., 
2004).  Further studies are needed to determine an effect of C/EBPβ on Skp2 
expression during preadipocyte proliferation.  Interestingly, Skp2 expression cannot be 
induced during terminal adipocyte differentiation.  We hypothesize that the presence of 
some adipogenic factor is required for the decrease in Skp2 because when re-
introducing the stimulation media at d9, Skp2 expression is not affected and it is known 
that PI3K/Akt signaling is intact at this time (e.g., Glut4 trafficking).  PPARγ has been 
shown to be anti-mitotic (Altiok et al., 1997) and, therefore, could potentially play a role 
in maintaining low levels of Skp2 during adipocyte differentiation.  Interestingly, we have 
identified a potential PPAR/RXR binding site within the Skp2 promoter.  The PPARγ 
ligand, troglitazone, but not other ligands, has been shown to decrease Skp2 protein 
expression in human hepatoma cells (Koga et al., 2003).  The mechanism behind this 
may give insight into the regulation of low levels of Skp2 during late stages of 
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differentiation and terminal growth arrest.  In conclusion, this is the first report of 
regulated Skp2 promoter activity during adipocyte differentiation and preadipocyte 
proliferation.  These and future studies will provide valuable information into the 





Figure 3.1.  Expression of Skp2 and SCFSkp2 proteins through the course 
of adipocyte differentiation.  3T3-L1 preadipocytes were stimulated with MDI 
and whole cell lysates were collected every 2hr beginning at 8hr post-MDI. 
Unstimulated (d0) and subconfluent proliferating preadipocytes (PPA) samples 
were also harvested.  One hundred micrograms of protein was used to detect 




Figure 3.2.  Skp2 dependence on cell cycle progression and subsequent 
inhibition during differentiation.  3T3-L1 preadipocytes were stimulated with 
MDI and differentiated for nine days, at which time the full adipogenic media 
(FBS/MDI) was administered to the cells and whole cell lysates were collected 
every two hours, beginning at 14hr following re-stimulation. 
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Figure 3.3. Skp2 protein expression during early stages of adipocyte 
differentiation is preceded by dramatic changes in mRNA. 3T3-L1 
preadipocytes were stimulated with MDI and whole cell lysates and total RNA 
were harvested at 12hr, 20hr, 2 days, and 4 days after the addition of the 
differentiation cocktail.  An unstimulated d0 sample was also collected.  One 
hundred micrograms of protein was examined using western blot analysis. 
RNA was isolated and analyzed using RT-PCR. 
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Figure 3.4. Insulin is required for maximal induction of Skp2, its accessory 
protein Cks1, and cell cycle progression.  Cultured preadipocytes were 
stimulated with MDI, individual components, or combinations of these three 
components for 20hr.  In addition, other cells had either: no media change, 
change to fresh calf serum (CS), or fetal bovine serum (FBS).  Whole cell 





Figure 3.5. The PI3K and MAPK pathways play an important role in the 
increased abundance of Skp2 mRNA and protein.  Cultured preadipocytes 
were stimulated with MDI in the presence of 10µM LY294002, 10µM U0126, or 
the two inhibitors combined.  An unstimulated d0 sample was also used.  Levels 
of mRNA (panel A) and protein (panel B) were examined using RT-PCR and 
western blot analysis.  Flow cytometry was performed (Panel C) to evaluate 
effects on cell cycle progression. 
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Figure 3.6.  Downstream targets of PI3K are phosphorylated and activated 
immediately following stimulation with MDI.  3T3-L1 cells were stimulated 
with MDI and proteins harvested at times indicated post-MDI. Antibodies 
recognizing total and phosphorylated forms of individual proteins were used to 
evaluate activation of the PI3K pathway. 
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Figure 3.7. Changes in Skp2 mRNA occur early and are not due to 
changes in mRNA stability.  A. Cultured preadipocytes were stimulated with 
MDI and RNA harvested along a short time course.  mRNA was isolated and 
evaluated by RT-PCR.  B. Cells were stimulated with FBS or FBS plus MDI. 
After 12 hours, 5µg/ml Actinomycin D was added to all plates and RNA 
harvested every hour for 5 hours.  Samples were analyzed by RT-PCR. 
 
109 
Figure 3.8. Skp2 promoter activity is increased following hormonal 
induction of adipogenesis.  3T3-L1 preadipocytes were transfected with 5.0 
µg pGL3-Skp2 (full length promoter construct), grown to 2 days post-
confluency, and stimulated with MDI, MDI + LY294002 (10µM), MDI + U0126 





Figure 3.9.  PI3K and MAPK responsive elements located within 500bp 
upstream of Skp2 gene.  A. Schematic depiction of pGL3-Skp2 promoter 
deletion constructs. B and C. Preadipocytes were cotransfected with 5.0 µg of 
either pGL3-Skp2 full length (2.4kb), 2.2kb, 1.5kb, 1.0kb, or 0.4kb insert plus 
20.0 ng renilla-SV40 as a transfection efficiency control.  Cells were grown to 2 
days post-confluency and stimulated with MDI, MDI + LY294002 (10µM), or 
MDI + U0126 (10µM). Luciferase activity was measured 12 hours post-
stimulation. 
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Figure 3.10. mTOR plays a role in regulating Skp2 protein expression 
during cell cycle progression.  Cultured preadipocytes were stimulated with 
MDI with or without 10µM Rapamycin. A. mRNA was isolated and gene specific 
primers for Skp2 were used along with 18S control primers in RT-PCR 
reactions. B. Whole cell lysates were collected at d0 and 20hr following 
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Helenalin is a biologically active, naturally-occurring compound contained in the 
Compositae family of plants.  It is known to have anti-inflammatory and anti-carcinogenic 
properties, yet mechanisms behind these actions are still being determined.  We have 
previously shown that the F-box protein Skp2 is highly regulated during preadipocyte 
proliferation.  Data presented here demonstrate that helenalin is a very potent inhibitor of 
Skp2 mRNA expression in 3T3-L1 preadipocytes when added with adipogenic media at 
day 0, before induction of Skp2.  Additionally, when helenalin is added to cells 6 hours 
post-MDI, established Skp2 mRNA levels are reduced significantly.  We have 
determined Skp2 mRNA to have a relatively short half-life (i.e., 5.5 hours), suggesting a 
rapid effect of helenalin.  Further studies demonstrate helenalin’s ability to completely 
block the increase in Skp2 promoter activity that occurs following MDI stimulation. The 
effect of helenalin on Skp2 expression occurs very early, within 3 hours following 
stimulation, and can be seen with changes in proliferation media alone.  An examination 
of signaling events previously shown, by our lab, to be important for Skp2 upregulation 
revealed impaired Akt phosphorylation in the presence of helenalin.  These studies are 
the first to show an effect of helenalin on Skp2 and growth factor receptor signaling 




The sesquiterpene lactone, helenalin, is a component found in the aerial portion 
of the flowering plant, arnica montana L.  Arnica is a native plant of mountainous regions 
in Europe, specifically Russia, and has long been used as an anti-inflammatory 
treatment for external wounds (e.g., bruises) and was approved by The European 
Scientific Cooperative on Phytotherapy (ESCOP) to be used as such.  One of the very 
early studies demonstrated that helenalin is an effective cardiotonic agent, improving 
cardiac strength in an in vivo animal model through increases in cyclic AMP (Itoigawa et 
al., 1987).  However, helenalin is primarily used in cellular studies as an inhibitor of 
NFκB p65, a function that is important for its known anti-inflammatory effects.  Hehner et 
al. suggests this occurs through inhibition of IKK activity and subsequent IκB 
degradation (Hehner et al., 1998;Hehner et al., 1998).  Others demonstrate helenalin’s 
ability to directly modify p65 via alkylation, thereby preventing p65 DNA-binding (Lyss et 
al., 1998).   
Recent attention has been focused on determining the mechanism(s) by which 
helenalin exerts anti-tumor effects. Helenalin induces apoptosis at 10-50 µM 
concentrations in leukemia Jurkat T cells (Dirsch et al., 2001a;Dirsch et al., 2001b), a 
highly desired outcome of chemotherapeutic treatments.  Interestingly, helenalin has 
also been shown to be a highly effective inhibitor of telomerase activity in cancer cells, 
primarily through alkylation and subsequent inactivation of the enzyme (Huang et al., 
2005).  In addition, several sesquiterpene lactones, including helenalin, possess 
powerful antioxidant activity, causing decreased lipid peroxidation (Jodynis-Liebert et al., 
1999;Jodynis-Liebert et al., 2000).   
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These and other studies provide clear evidence that helenalin has multiple 
modes of action within the cell, aside from its commonly cited ability to inhibit NFκB 
DNA-binding.  While helenalin is known to have anti-proliferative properties, a role in 
regulating cell cycle stage progression has yet to be investigated.  Skp2 is an important 
positive regulator of proliferation and is overexpressed in many types of cancers.  It 
functions as an F-box protein, the substrate recognition portion of the SCFSkp2 E3 Ligase. 
Skp2 is known to cause polyubiquitylation and subsequent degradation of negative cell 
cycle regulators p27 (Pagano et al., 1995;Carrano et al., 1999), p21 (Bornstein et al., 
2003;Wang et al., 2005), p57 (Kamura et al., 2003), and p130 (Tedesco et al., 2002).  
Our lab has recently shown Skp2 to also be expressed during early stages of adipocyte 
differentiation when cells enter a short synchronous period of replication.  Here, we 
demonstrate a very potent effect of helenalin on Skp2 expression and signaling events 
leading to induction of Skp2. 
 
MATERIALS AND METHODS 
 Materials - Dulbecco's Modified Eagle's Medium (DMEM) was purchased from 
Cellgro by Mediatech.  Bovine Serum, Fetal Bovine Serum (FBS), and Trypsin-EDTA 
were from Invitrogen Corporation. Propidium Iodide and RNase A was purchased from 
Sigma.  Chemical inhibitors were purchased from the following: Helenalin (Biomol) and 
Actinomycin D (Sigma). The following antibodies from Cell Signaling were used for 
western blot analysis: phospho-Akt (Ser473) and phospho-p44/42 (Thr202/Tyr204). 
Enhanced chemiluminescence (ECL) reagents were from PerkinElmer Life Sciences.  
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 Cell Culture and Differentiation - Murine 3T3-L1 preadipocytes were propagated 
in growth medium containing DMEM supplemented with 10% calf bovine serum as 
described previously (Morrison and Farmer, 1999).  By standard differentiation protocol, 
preadipocytes were propagated in growth medium until reaching a state of density arrest 
at 2 days post-confluence. Growth medium was replaced at density arrest with 
differentiation medium comprised of DMEM supplemented with 10% fetal bovine serum 
(FBS), 0.5 mM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, and 1.7 µM insulin 
(MDI).  The term "post-MDI" refers to the time elapsed since the addition of MDI to the 
culture medium. At 2 days post-MDI, medium was changed to DMEM supplemented with 
10% FBS and 0.4 µM insulin. From 4 days post-MDI until harvest, maintenance medium 
containing DMEM supplemented only with 10% FBS was changed every 48 hrs.  
Throughout the study, "time 0" refers to density arrested cells immediately before 
chemical induction of differentiation with the addition of MDI to the culture medium. 
Experiments described herein were conducted within the period of differentiation 
spanning from density arrest (0 hr) through 34 hrs post-MDI. All experiments were 
repeated three to five times to validate results and ensure reliability. 
 
 Protein Analysis - Cell monolayers were washed with PBS and scraped into ice 
cold lysis buffer containing 1.0 M Tris, pH 7.4, 150 mM NaCl, 1% Triton X, 0.5% Nonidet 
P-40, 1 mM EDTA, 1 mM EGTA, and 10 mM N-ethylmaleimide (NEM). Lysis buffer was 
freshly supplemented with phosphatase inhibitors; 20mM β-glycerophosphate, 10mM 
NaFl, and 2 µM sodium vanadate, as well as protease inhibitors; 0.3  µM aprotonin, 21 
µM leupeptin, E-64, 1 µM pepstatin, 50 µM phenanthroline, 0.5 µM phenylmethylsulfonyl 
fluoride. Cell lysates were clarified by centrifugation (13,000 x g, 10 min, 4°C) and 
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protein concentration was determined by BCA assay (Pierce). Lysates were 
resuspended in loading buffer containing 0.25 M Tris, pH 6.8, 4% SDS, 10% glycerol, 
10% dithiotreitol, 0.01% bromophenol blue, heated for 5 mins at 80°C, and placed on 
ice. Lysates were resolved on SDS-PAGE gels and transferred to polyvinylidene fluoride 
membranes (Millipore).  Following transfer, membranes were blocked with 4% milk and 
probed with indicated primary antibodies overnight at 4°C and horseradish peroxidase-
conjugated secondary antibodies for 1 hr at room temperature. Immunoblots were 
developed with ECL and visualized by autoradiography CL-XPosure film (Pierce). 
 
 RNA Isolation and Analysis - Total RNA was extracted using the RNeasy Mini Kit 
(QIAGEN) according to manufacturer’s instructions.  Total RNA (1µg) was subjected to 
Reverse-Transcriptase Polymerase Chain Reaction using One-Step RT-PCR kit 
(QIAGEN) according to manufacturer’s instruction.  Briefly, RT-PCR reactions were 
carried out in the presence of the supplied buffer, dNTPs (400 µM), enzyme mix (reverse 
transcriptases and DNA polymerase), and RNase inhibitor (10 U).  Gene specific primers 
were used at a final concentration of 0.6 µM and designed as follows: Skp2 forward, 5΄-
GGCAAAGGGAGTGACAAAGA-3΄; Skp2 reverse, 5΄-TCAAAGCACCAGGAGAGATT-3΄ 
(product size = 590 bp).  QuantamRNA Classic II 18S primer/competimers were used in 
the reactions as internal standards at a final concentration of 0.6µM.   
 
 Plasmids – Promega’s pGL3-basic vector was used to create mouse Skp2-pGL3 
constructs for luciferase assays.  Primers flanking the region of -2404 to +74 (2478bp) 
were used to amplify the murine Skp2 promoter from 3T3-L1 preadipocyte genomic 
DNA. Positive DNA fragments were gel purified.  Vector and isolated genomic DNA were 
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double-digested with Kpn I and Bgl II. The resulting DNA fragment was subcloned into 
the pGL3-basic vector. Nucleotide sequencing was conducted by SeqWright DNA 
Technology Services. This entire process was repeated twice to ensure reliability of 
results.   
 
  Luciferase Reporter Assays – 3T3-L1 preadipocytes (2.0 x 106 cells) were 
transiently transfected with 5 µg of firefly reporter plasmid using Amaxa’s Nucleofector 
(program T20) and incubated with pre-warmed proliferation media for no more than 10 
minutes at 37°C.  Cells were then replated at a confluent density, fresh media replaced 
24 hours post-transfection, and further cultured as indicated.  Firefly luciferase was 
measured using the Dual-Glo Luciferase Assay System (Promega) and reported as 
firefly luciferase counts. 
 
RESULTS 
A potential effect of helenalin on Skp2 expression was examined by treating 3T3-
L1 preadipocytes with 3, 5, or 8 µM helenalin at the time of adipogenic stimulation.  Our 
previous experiments show that the increase in Skp2 protein during preadipocyte 
proliferation is preceded by an early and dramatic increase in Skp2 mRNA (Chapter III).  
Therefore, RNA was collected at d0 (i.e., 2 days post-confluency) when cells are 
density-arrested and then 12 hours with or without varying concentrations of helenalin.  
As shown in Figure 4.1, Helenalin decreases Skp2 mRNA at 12 hours and this effect is 
dose-dependent.  A significant decrease can be seen with as little as 3 µM and because 
this compound is known to exhibit cytotoxic effects, all subsequent studies were carried 
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out using this lower concentration.  It is important to note that this concentration is also 
below the IC50 which has been determined to be 6µM (Dirsch et al., 2001a).   
Skp2 mRNA begins to increase by 4 hours following stimulation and is highly 
expressed at 12 hours (Figure 4.2A).  Figure 4.1 shows an effect of helenalin when 
added before Skp2 mRNA increases (i.e., at time of stimulation).  Helenalin was added 
at 6 hours post-stimulation to determine if increased levels of Skp2 mRNA could be 
reduced as well.  3T3-L1 cells were stimulated with MDI and helenalin added at that time 
or 6 hours post-stimulation.  RNA was harvested 12 hours after the initial time of 
stimulation.  We found that adding helenalin 6 hours after stimulation, a time at which 
Skp2 mRNA levels have already significantly increased, results in the same degree of 
inhibition as adding it with the stimulation media (Figure 4.2B).  These findings suggest 
several possibilities.  First, helenalin could be inhibiting something that occurs after 6 
hours, therefore, when adding helenalin at stimulation, Skp2 mRNA would still increase 
until 6 hours but would then be prevented from any further increase after that.  In this 
case, a long mRNA half-life would explain how adding helenalin at these two times 
would produce similar results.  Another possibility is that the effect of helenalin occurs 
earlier than 6 hours post-MDI and Skp2 mRNA has a short half-life.  Actinomycin D, a 
potent inhibitor of RNA synthesis, was used to determine Skp2 mRNA half-life.  The 
results of these studies indicated Skp2 mRNA half-life to be approximately 5.5 hours 
(Chapter III).  This is a relatively short half-life and is less than the amount of time cells 
were exposed to helenalin after adding it 6 hours post-MDI.  Thus, it appears that 
helenalin may have a quick effect and Skp2 mRNA turnover is rapid enough to cause 
such decreased levels under these conditions.  
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 To gain insight into how helenalin decreases Skp2, we determined the timeframe 
in which this effect occurs by examining mRNA levels at earlier time points following 
treatment.  3T3-L1 cells were stimulated plus or minus helenalin and RNA was collected 
at 3, 6, and 12 hours.  As shown in Figure 4.3, we found that when added with the 
stimulation cocktail, helenalin blocks the induction of Skp2 mRNA by 6 hours and as 
early as 3 hours.  Under normal conditions, Skp2 mRNA levels are slightly increased by 
3 hours and this induction is completely inhibited by helenalin.  These findings suggest 
helenalin blocks a very early step in the process of Skp2 gene expression.  
 Our lab has shown that during initial stages of 3T3-L1 preadipocyte 
differentiation, Skp2 protein expression is primarily driven by increases in promoter 
activity (Chapter III).  Therefore, preadipocytes were transfected with a Skp2 promoter 
(2.4kb) luciferase reporter construct and grown to 2 days post-confluency.  The resulting 
population of cells was stimulated with or without helenalin and Skp2 promoter activity 
was measured 12 hours after stimulation.  As shown in Figure 4.4, helenalin completely 
blocks the induction of Skp2 promoter activity, as luciferase activity at 12 hours is no 
different from d0.  Taken together, these data show that helenalin prevents the increase 
in Skp2 promoter activity and resulting mRNA expression.   
 We have formerly observed an increase in Skp2 promoter activity with a change 
in normal proliferation media (unpublished observations).  While this is not sufficient to 
produce a subsequent increase in protein (Chapter III - Figure 3.4), we examined 
whether an increase in Skp2 mRNA occurs under the same conditions and if so, whether 
helenalin is also capable of blocking that increase.  At d0, 3T3-L1 cells were exposed to 
a media change with calf serum (proliferation media) with or without helenalin, and RNA 
samples collected after 6 and 12 hours.  As seen in Figure 4.5, a change in media did 
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result in elevated levels of Skp2 mRNA, although not to the degree seen with MDI 
stimulation (Figure 4.2A).  Helenalin was indeed able to completely block this increase, 
suggesting its target is an intermediate step common to changes in proliferation and 
stimulation media. 
 Serum (calf and fetal bovine) can activate different signaling cascades through 
growth factor receptors, although not to the degree seen with insulin stimulation. Our lab 
previously demonstrated that the PI3K and MAPK pathways are required for Skp2 
expression, with PI3K playing the predominant role.  Therefore, cells were stimulated 
plus or minus helenalin and immunoblotting used to examine the phosphorylation state 
of Akt and ERK, important downstream targets of PI3K and MAPKK respectively.  Under 
normal conditions, Akt is phosphorylated by 15 minutes after stimulation with MDI and 
can still be seen as late as 12 hours (Figure 4.6).  ERK is also phosphorylated within 15 
minutes of stimulation, a pattern that persists through at least 6 hours.  We found that 
while helenalin had no effect on phospho-ERK, dramatic changes were seen in the 
phosphorylation of Akt on a residue critical for activity (Ser473).  A decrease in Akt 
phosphorylation was observed as early as 3 hours, and this inhibition was further 
amplified by 6 and 12 hours.  These data suggest a potent effect of helenalin on Akt 
signaling.   
 
DISCUSSION 
Dirsch et al. (Dirsch et al., 2001b) report a lag time of approximately 16 hours 
before signs of apoptosis appear in Jurkat T cells after treatment with helenalin, while 
others report neuronal death with 30 µM helenalin after only 6 hours (Chiarugi, 2002).  
The length of exposure in the studies presented in this paper was 12 hours and no 
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visible signs of toxicity were seen with 3 µM.  However, we have seen very apparent 
signs of toxicity using 10 µM concentrations of helenalin in less than 12 hours 
(unpublished observations).  It is important to note that the concentration at which we 
used helenalin is significantly lower than the IC50 (6 µM).  Interestingly, healthy PHA-
stimulated PBMC cells are resistant to the apoptotic effects of helenalin, at 
concentrations as much as 50 µM (Dirsch et al., 2001b), suggesting a cell-type specific 
and dose-dependent effect of helenalin on apoptotic signaling. 
 Skp2 promotes cell cycle progression during neoplastic growth and can be 
regulated by transcriptional and post-translational mechanisms.  We have previously 
reported transient expression of Skp2 during mitotic clonal expansion of adipocyte 
differentiation, primarily due to promoter activation.  Reduction of Skp2 levels with siRNA 
revealed a role for Skp2 in the degradation of p27 during proliferation, providing insight 
into the function of Skp2 in preadipocytes.  Discerning mechanisms regulating 
preadipocyte replication such as this is essential for understanding the etiology of 
hyperplastic obesity.  In results reported here, we show a very strong effect of helenalin 
on Skp2 expression.  Helenalin is not only able to completely block the induction of Skp2 
mRNA but prevents Skp2 promoter activity during early stages of adipocyte 
differentiation. While this regulation may also be mediated by changes in NFκB activity, 
we show that Akt signaling is impaired as helenalin almost completely blocks Akt 
phosphorylation following adipogenic stimulation.  Previous work by our lab has shown 
that Skp2 expression during preadipocyte proliferation is dependent on activation of the 
PI3K pathway, suggesting the effect of helenalin on Skp2 expression is through changes 
in Akt signaling.  Further studies are needed to discern whether helenalin is having a 
direct effect on Akt or whether the block in NFκB DNA-binding is somehow responsible.  
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We hypothesize that there is a direct effect of helenalin on Akt, or upstream kinases, due 
to the very rapid ability of helenalin to block Akt phosphorylation.  As well, Akt is 
traditionally thought to be upstream of NFκB activation and a reversal in this process 
would certainly be novel and unexpected. 
 The cytotoxic effect of helenalin on tumor cells has been well-documented but 
how this happens is still under investigation.  Data presented here suggest a block in 
growth factor receptor signaling due to the very early effect of helenalin and helenalin’s 
ability to block the effects of serum on Skp2 mRNA expression.  The PI3K/Akt pathway 
activates pro-mitotic survival signals following serum stimulation.  The ability of this 
pathway to inhibit apoptosis is dependent on Akt phosphorylation and subsequent 
activation (Kennedy et al., 1997).  Kennedy et al. showed that Akt blocks apoptosis by 
inhibiting Ced3/ICE-like activity, more commonly referred to as caspase activity 
(Kennedy et al., 1997).  Interestingly, the broad-spectrum caspase inhibitor zVAD-fmk is 
able to abolish helenalin’s ability to induce apoptosis in human leukemia Jurkat T cells 
(Dirsch et al., 2001b).  Specifically, caspases 3 and 8 were shown to be involved in the 
process.  We show that helenalin is an extremely potent inhibitor of Akt phosphorylation.  
This is a very specific effect as the phosphorylation of ERK remains unchanged.  These 
findings suggest that inactivation of Akt signaling is the upstream event regulating 
helenalin’s anti-mitotic caspase-dependent actions.  In contrast to helenalin’s early 
reduction of Akt phosphorylation, another sesquiterpene lactone, parthenolide, causes a 
dramatic increase in Akt phosphorylation following two to three hours of exposure 
(Chiarugi, 2002).  Longer periods of exposure to parthenolide cause a decrease in Akt 
phosphorylation, similar to helenalin’s early effect on Akt phosphorylation in 3T3-L1 
reported here.  Future studies are needed to evaluate helenalin’s effect on events 
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upstream of Akt.  However, it is very clear that helenalin’s potent effects can be 
attributed to its ability to affect survival signals within the cell at many different levels 
(e.g., impaired Akt signaling, reduced p65 DNA-binding, and inhibition of telomerase 
activity). 
Future studies are needed to examine the effect of helenalin on adipocyte 
differentiation.  One might hypothesize a negative effect of helenalin on processes 
involved in adipocyte differentiation as it is known to block p65 DNA-binding and now 
shown to inhibit Akt phosphorylation.  This line of investigation is also quite interesting 
knowing helenalin’s most cited role as an anti-inflammatory agent.  Obesity has recently 
been regarded as a chronic state of low-level inflammation, as adipocytes secrete pro-
inflammatory cytokines such as TNFα (Hotamisligil et al., 1993;Hotamisligil et al., 1995) 
and IL-6 (Mohamed-Ali et al., 1998).  Moreover, NFκB activity is highest during late 
stages of adipogenesis (Berg et al., 2004) and has been implicated in the release of 
cytokines from adipocytes (Skurk et al., 2004).  We show that helenalin inhibits a key cell 
cycle regulator during preadipocyte hyperplasia, but perhaps this potent sesquiterpene 





Figure 4.1. Helenalin decreases Skp2 mRNA expression in a dose-
dependent manner.  3T3-L1 preadipocytes were grown to 2 days post-
confluency and stimulated with 3, 5, or 8 µM helenalin.  Total RNA was 
collected after 12 hours of stimulation.  RNA was isolated and subjected to RT-
PCR using gene-specific primers targeting Skp2. 18S primer/competimer 
technology was used as a control. 
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Figure 4.2.  Helenalin is able to block the increase in Skp2 even after Skp2 
has begun to be expressed.  A. 3T3-L1 cells were stimulated with adipogenic 
media and RNA collected every 2 hours through 12 hours and then again at 34 
hours.  B. 3T3-L1 preadipocytes were stimulated and 3 µM helenalin added at 
time of stimulation or after 6 hours.  Samples were collected 12 hours post-
stimulation and Skp2 mRNA expression examined using RT-PCR. 
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Figure 4.3.  The decrease in Skp2 mRNA caused by helenalin occurs early.
Preadipocytes were stimulated in the presence of 3 µM helenalin and RNA 




Figure 4.4. Helenalin prevents Skp2 promoter activity during preadipocyte 
hyperplasia.  3T3-L1 preadipocytes were transiently transfected with 5 µg of a 
pGL3-Skp2 promoter hybrid luciferase vector.  Cells were stimulated with MDI 




Figure 4.5.  Skp2 mRNA increases with a change in proliferation media 
and helenalin is able to block this increase.  A day 0 sample with no media 
change was collected as a control for Skp2 basal levels.  Subsequently, cells 
received a media change with 10% calf serum in DMEM (proliferation media) 




Figure 4.6. Helenalin blocks the phosphorylation of Akt but not ERK.
Preadipocytes were stimulated with MDI plus or minus 3 µM helenalin and total 
cellular protein was harvested after 15 minutes, 3, 6, and 12 hours.  An 
unstimulated d0 sample was also collected.  Protein expression was examined 
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Data presented in the previous chapters, along with other findings made by our 
lab, have opened many avenues of questioning.  The importance of Skp2 in cancerous 
and non-cancerous cell proliferation, as well as disease states, provides a strong basis 
for research focusing on this cell cycle regulator.  Preliminary data and potential areas of 
focus will be discussed here. 
 Our studies have revealed PI3K-dependent regulation of Skp2 during adipocyte 
hyperplasia.  However, the inhibitor we used targets PI3K, thereby preventing activity of 
all downstream targets.  The canonical method by which PI3K signaling is transduced is 
through phosphorylation and activation of PDK1 and Akt.  A very interesting and 
important addition to this story would be to test the effect of specific PDK1 and Akt 
inhibitors on Skp2 because of the many targets and parallel pathways downstream of 
PI3K.    PI3K has downstream targets besides PDK1 and these additional studies would 
determine the extent to which PDK1 is required.  While PDK1 directly phosphorylates 
Akt, it has other substrates as well.  Expanding our knowledge about essential players 
within this pathway will help guide future experiments about the regulation of Skp2. 
 We have seen a dramatic decrease in Skp2 mRNA and protein in the presence 
of potent 26S proteasome inhibitors, epoxomicin and lactacystin.  We have also seen a 
block in Skp2 promoter activity by epoxomicin.  In previous work, we demonstrated that 
PI3K plays an essential role in Skp2 expression.  Taken together, these two separate 
findings implicate a PI3K, proteasome-dependent mechanism. NFκB p65 is a
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downstream target of both PI3K and MAPK signaling (Sizemore et al., 1999;Park and 
Levitt, 1993) that requires proteasomal degradation for activation (Palombella et 
al.1994).  We have found that treating 3T3-L1 preadipocytes with the potent p65 DNA-
binding inhibitor, helenalin, at stimulation completely blocks the increase in Skp2 
(Chapter IV).  While we have also shown that helenalin is a potent inhibitor of Akt 
signaling, its effect on NFκB is direct and the potential for NFκB to regulate Skp2 cannot 
be ignored as NFκB p65 is known to play an important role in cell cycle progression.  It 
is interesting to note that while not an exact match, we have found three potential NFκB 
binding sites within the Skp2 promoter.  Studies should not be limited to p65 or to the 
traditional NFκB transcription-activating complexes.  The reasoning for this is that in 
2001, Kurland et al. found that p50 homodimers, primarily thought to be repressors of 
transcription, bound to and activated transcription of the proto-oncogene bcl-2 in murine 
B-cell lymphoma cells (Kurland et al., 2001).  Furthermore, the effect of p65 on gene 
expression can depend on association with other key factors.  This was clearly 
demonstrated by Ashburner et al. when they showed a direct interaction between p65 
and HDAC proteins resulting in repression of NFκB target genes (Ashburner et al., 
2001).  Thus, the potential involvement of all NFκB family members should be 
evaluated.   
We have also identified several putative C/EBPβ binding sites within the Skp2 
promoter of preadipocytes, however, the role of C/EBPβ in Skp2 expression has never 
been examined.  C/EBPβ is known to be essential for clonal expansion and while protein 
levels are upregulated very early after MDI stimulation, DNA-binding is not present until 
cells have entered G1 phase.  This would suggest that if C/EBPβ plays a role in Skp2 
expression, it would enhance transcription rather than initiate it.  In line with this theory, 
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is our finding that while insulin is the primary component responsible for the increase in 
Skp2 during clonal expansion, there is enhanced expression when all components are 
combined.  MIX and dexamethasone are known to exert effects on C/EBPs, which could 
explain their ability to increase Skp2 expression above that seen with insulin alone.  To 
investigate whether C/EBPβ aids in or is required for Skp2 expression, experiments 
preventing DNA-protein interactions would be appropriate.  Several techniques that 
could be employed include using C/EBPβ siRNA during early stages of differentiation, 
deleting regions of the Skp2 promoter containing C/EBPβ binding sites, or inhibiting 
C/EBPβ nuclear localization or DNA-binding (e.g., expressing C/EBPβ with sequence 
mutations). Further studies would involve determining a direct interaction between 
C/EBPβ and the Skp2 promoter in 3T3-L1 preadipocytes. 
Our finding that Rapamycin blocks Skp2 protein, but not mRNA, expression at 20 
hours post-MDI stimulation suggests translational control may play a role in Skp2 
expression at this time.  Rapamycin is a potent inhibitor of mTOR and downstream 
translational control (Oshiro et al., 2004).  It is known that Skp2 protein can be regulated 
post-translationally by the ubiquitin/ proteasome system, however, translational control 
of Skp2 has not been studied.  We have found no change in Skp2 mRNA stability during 
clonal expansion (Chapter III), which rules out direct regulation by proteins such as HuR, 
an important regulator of mRNA stability throughout adipogenesis (Gantt et al., 2005).  
Regulation of Skp2 protein expression at the level of translation initiation would be a very 
novel finding.   
 The importance of identifying factors that decrease Skp2 cannot be overstated as 
Skp2 is overexpressed in many cancers and has now been shown to be highly regulated 
during adipocyte hyperplasia.  Our initial finding that re-stimulation of mature adipocytes 
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with MDI is not able to cause an increase in Skp2 protein, as it does in preadipocytes, 
suggests the importance of differentiation-specific factors in maintaining low levels of 
Skp2 during this time.  Koga et al. have shown that treatment of human hepatoma cells 
with the synthetic PPARγ ligand troglitazone causes significant decreases in Skp2 
mRNA and protein (Koga et al., 2003).  PPARγ is one of two master regulators of 
adipocyte differentiation and has been shown to be anti-mitotic, therefore, it is highly 
possible that PPARγ plays a role in regulating Skp2 in 3T3-L1 cells.  To test this 
hypothesis, Skp2 gene expression should be examined under the same re-stimulation 
conditions discussed earlier.  This would provide insight as to whether low levels of Skp2 
are primarily regulated at the level of gene or protein expression.  While there may be an 
increase in Skp2 gene expression with re-stimulation, we expect no change due to the 
fact that these cells are terminally growth-arrested, a feature which is critically important 
for differentiation to occur (Shao and Lazar, 1997). 
 PPARγ is a nuclear hormone receptor that heterodimerizes with the retinoid-X 
receptor (RXR) to regulate transcription of many genes during adipogenesis.  We have 
identified a putative PPAR/RXR binding site within the Skp2 promoter of 3T3-L1 cells.  
Taken together, a direct inhibition of Skp2 promoter activity by PPAR/RXR binding may 
be possible.  There are several studies that would address this question.  First, Skp2 
expression at all levels should be examined in the presence of siRNA targeting PPARγ 
under re-stimulation conditions.  It may also prove advantageous to include C/EBPα 
siRNA alone and in combination with PPARγ siRNA to see if the synergy between these 
two transcription factors plays a role in low levels of Skp2.  If PPARγ does indeed 
regulate Skp2 expression, one might expect to see increases in Skp2 promoter activity 
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following re-stimulation with PPARγ siRNA, however, because regulation by other factors 
and at other levels is likely, an increase in Skp2 protein may not be seen. 
 We show the importance of PI3K signaling for the expression of Skp2 and know 
from many previously published studies that Akt signaling is still intact and plays a 
critical role during adipocyte differentiation, a time when Skp2 expression is at its lowest.  
Therefore, it seems likely that decreased Skp2 gene expression during late stages of 
adipogenesis is not only due to the absence of transcriptional activators, but the 
presence of repressors as well.  While direct transcriptional inhibition by PPARγ has not 
been published, one cannot rule out this possibility.  Therefore it may be prudent to 
consider whether PPARγ plays a role in repressing Skp2 promoter activity.  Interestingly, 
all-trans retinoic acid is able to block Skp2 expression in human neuroblastoma cells 
(Nakamura et al., 2003).  All-trans retinoic acid (RA) binds to its receptor, RAR, which 
heterodimerizes with RXR to regulate transcription.  The common element in these two 
stories is RXR and perhaps ectopic expression of PPARγ in neuroblastoma cells would 
have the same effect on Skp2 as RA treatment.  These questions warrant further 
investigation.  In 1997, Schwarz et al. showed retinoic acid inhibits adipocyte 
differentiation by preventing C/EBPβ-mediated transcription (Schwarz et al., 1997).  The 
link between this and RA’s effect on Skp2 expression provides further support for an 
effect of C/EBPβ on Skp2 as discussed above. 
 In addition to studying the regulation of Skp2, it will also be important to examine 
other potential targets of Skp2 during adipocyte hyperplasia.  The ability to achieve very 
specific and potent knockdown of Skp2 using siRNA in these cells will help tremendously 
in doing this.  A substrate that has particular relevance to adipogenesis is the 
retinoblastoma protein p130.  Skp2 has been shown to target p130 for ubiquitylation and 
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degradation in human fibroblasts (Tedesco et al., 2002).  There is a very dramatic 
decrease in p130 protein at day 1 of adipocyte differentiation, with no change in mRNA 
levels (Richon et al., 1997).  Furthermore, the kinetics of p130 expression during clonal 
expansion are the exact inverse of Skp2 protein expression, suggesting a role for Skp2. 
 Our lab has also made a very novel discovery regarding histone deacetylase 
activity and Skp2 expression.  Chromatin modifications play an essential role in 
regulating eukaryotic gene expression and include phosphorylation, methylation, 
sumoylation, and acetylation. Histone acetylation and deacetylation play a significant 
role in regulating gene expression and cellular processes such as cell cycle, 
differentiation, and apoptosis. Histone deacetylases (HDACs) remove acetyl groups from 
histones resulting in more tightly wound nucleosomes and decreased transcription.  
There are four classes of HDACs: Class I (HDAC1, 2, 3, and 8); Class II (HDAC 4, 5, 6, 
7, 9, and 10); Class III (Sirtuins); and maize HD2.  The antifungal antibiotic, Trichostatin 
A (TSA), inhibits Class I and II HDACs and causes cell cycle arrest in both G1 and G2 
phases (Yoshida and Beppu, 1988).  We have seen opposing effects of TSA on Skp2 
expression in 3T3-L1 cells.  In density-arrested cells, Skp2 mRNA and protein levels are 
low.  We have found that TSA causes a significant increase in mRNA but not protein at 
this time.  This increase is not seen in fully differentiated cells suggesting a more 
dominant mechanism by which Skp2 gene expression is suppressed in fully mature 
adipocytes.  These data indicate that HDACs play a role in maintaining low levels of 
Skp2 at this time.  Conversely, during G2 phase when Skp2 levels are maximal, TSA 
almost completely blocks induction of both mRNA and protein.  This demonstrates a 
requirement of HDAC activity for Skp2 expression.  The amount of inhibition seen is 
directly proportional to the amount of time cells were exposed to TSA following MDI 
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stimulation, which suggests HDACs are functioning early in the process of Skp2 
upregulation. 
 There are no published papers to date studying acetylation of the Skp2 promoter, 
making these very novel findings.  The effect of TSA during density-arrest implies a 
direct effect of HDAC inhibition.  We have also treated cells with two other HDAC 
inhibitors, sodium butyrate and Nicotinamide, to narrow involvement of specific classes 
of HDACs.  Sodium butyrate (NaB), like TSA, targets Classes I and II, while 
Nicotinamide blocks activity of the third class (i.e., Sirtuins).  Skp2 mRNA is increased at 
day 0 with TSA and sodium butyrate but not Nicotinamide, establishing a functional role 
of Class I and/or Class II HDACs.  Further studies are needed to examine whether 
regions of the Skp2 promoter are indeed deacetylated at this time and to determine the 
specific HDAC(s) involved.  
 We have also seen an effect of TSA and NaB, but not NAM, on Skp2 expression 
during clonal expansion suggesting an early and indirect role of Class I and II HDACs.  
Interestingly, TSA and NaB have the ability to block proteasome activity by down-
regulating the expression of several critical subunits (Place et al., 2005).  As mentioned 
previously, we have seen a dramatic decrease in Skp2 mRNA and protein expression 
with specific inhibitors of the 26S proteasome.  It is entirely possible that the mechanism 
by which TSA affects Skp2 expression during the G2 phase of adipocyte hyperplasia is 
through blocking the activity of the 26S proteasome.  The ramifications for this indirect 
action are great, as 26S proteasome activity is critical for the expression and activity of 
many endogenous proteins.  NFκB inactivation is one example of an indirect effect of 
TSA inhibiting the 26S proteasome and gene expression (Place et al., 2005).  This, in 
combination with the effect of helenalin on Skp2 expression, provides one line of 
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research to examine the ability of TSA to decrease Skp2 expression during early stages 
of adipogenesis.   
 The data presented in Chapters II through IV have added significantly to the 
limited body of knowledge on the regulation of adipocyte hyperplasia.  The discovery of 
Skp2 expression in 3T3-L1 cells and the synchronized period of growth in which these 
studies were conducted provide a wonderful model for studying this cell cycle regulator.  
These findings have also provided ample preliminary data for potential lines of research 
on this topic.  The benefit of future studies on Skp2 regulation will not only aid in the 
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